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Abstract 
Chemotherapy today is often accompanied by major side effects due to delivery of 
toxic drugs to healthy tissue in addition to diseased cells. Targeted drug delivery offers the 
possibility of minimizing these side effects by specific delivery to cancer cells using 
targeted nanocarriers that enhance drug accumulation in tumors and facilitate target-
specific cellular uptake. Polymersomes, vesicles self-assembled from polymeric 
amphiphiles, are an attractive targeted vehicle, as they are capable of encapsulating both 
hydrophobic and hydrophilic drugs, have lengthy circulation times in vivo, and can employ 
degradable functionality for triggered release of payload and clearance from the body. 
This thesis reports on efforts to enhance the capabilities of degradable 
polymersomes for targeted delivery. First, targeting functionality is incorporated into 
polymersomes of the block copolymer poly(ethylene oxide)-b-poly(γ-methyl-ε-
caprolactone) by incorporating the reactive vinyl sulfone group into the amphiphile’s 
hydrophilic terminus, allowing site-selective reaction with cysteine-functionalized 
targeting peptides following self-assembly. The performance of targeted delivery using this 
polymersome is then evaluated in vitro. Binding and delivery to model cell lines for 
targeted and bystander cells is tracked using nontargeted polymersomes and compared to 
that for polymersomes using a high- or low-affinity ligand. Polymer degradation is also 
tracked both in simple media and during cellular delivery. Finally, a new monomer is 
developed incorporating acid-labile acetal functionality into a cyclic polyester. The 
polymerization of this monomer to two distinct polymers is also characterized and the 
degradation behavior of both polymers evaluated. 
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Targeted Drug Delivery 
Modern medicine has developed a plethora of compounds to kill cancerous cells. 
Many of these drugs offer high lethality to cancer cells using a minimal amount of drug, 
yet when taken from the lab to the clinic, many have significant drawbacks, including 
toxicity to healthy cells, major side effects that limit the amount of drug that can be used, 
and insufficient concentration of drug in the tumor itself for effective treatment. Tragically, 
though chemotherapeutics developed to date are often quite efficient for killing cancer cells 
in Petri dishes, they are often much less effective in the clinic due to the vicissitudes of the 
environment inside a living creature. This problem has been central to developing effective 
treatment strategies. 
Ideally, drugs would segregate directly to the diseased site and have no interaction 
with healthy tissue elsewhere in the body. This idea is not new; over a century ago it was 
proposed as the ‘magic bullet’ by Paul Ehrlich.1,2 The goal has been pursued by researchers 
and clinicians ever since, leading to the development of a wide variety of drug delivery 
systems leveraging many disparate approaches to bring treatment ever closer to Ehrlich’s 
vision. 
Current Clinical Cancer Treatment 
Before discussing the specifics of targeted drug delivery, it is instructive to briefly 
review current cancer treatment options to better understand targeted delivery systems and 
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the ways they promise to change the field. Cancer therapies today are based upon stages of 
the disease, a systematic description of the state of the disease in a patient. A common 
approach is the ‘TNM’ system, which describes a case as ranging from local tumor invasion 
(T), to lymph node involvement (N), to metastasis (M), when the cancer has spread widely 
throughout the body.3,4 It is on the basis of this staging system that current clinical treatment 
plans are often planned.5 
As an example, colorectal cancer is typically detected in the early stages of the 
disease, at which point the clinical standard is surgical removal of the tumor followed by 
adjuvant treatment (chemotherapy) to destroy any remaining undetected or unremoved 
malignancy. By combining presurgical (neoadjuvant), surgical, and adjuvant care 
clinicians have the best chance to eradicate the cancer before it becomes widespread. With 
the addition of radiation therapy, they also can avoid many of the post-surgical recurrences 
that account for a significant portion of long-term morbidity. Today, this approach results 
in five year survival rates of 60-85% for colorectal cancer.3,6,7  
The chemotherapy drugs used in these treatments using a range of approaches. 
Examples include antimetabolite pyrimidines,8 DNA crosslinking cisplatin,9–12 DNA 
intercalating doxorubicin, mitosis inhibiting paclitaxel, and gene damage promoting 
irinotecan.13–15 New treatment plans utilizing combinations of these chemotherapeutics 
have produced dramatic gains in survival. In some cases, synergistic effects between drugs 
have been observed, suggesting that simultaneous delivery of multiple drugs may help 
overcome some forms of drug resistance.16–20 
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These results are heartening, yet many of these chemotherapeutics have significant 
side effects and inefficiencies that are a direct result of inadequately tumor-specific 
delivery. Due to interaction with healthy cells in addition to cancer cells, major side effects 
occur, particularly to faster-reproducing cells. The symptoms of nonspecific delivery of 
these toxic drugs include systemic toxicity, neutropenia (low white blood cell count), 
diarrhea, liver impairment, hypertension, bleeding, lack of wound healing, proteinuria due 
to kidney damage, arterial thrombosis, decreased liver regeneration, and neurotoxicity, 
among others.21 Other commonly used drugs have been shown to clear completely from 
the bloodstream in a matter of hours, resulting in waste of drug and necessitating higher 
doses and repeated treatments.22 
As a result of these limitations, chemotherapy is simultaneously less effective than 
it might be at fighting malignancy and more damaging to a patient’s quality of life. The 
researcher’s goals, therefore, are quite challenging: to increase the concentration of drug 
in the tumor while decreasing it everywhere else in the body. 
Approaches to Drug Delivery Systems 
Many systems have been devised to more efficiently deliver therapeutic agents to 
tumor sites while minimizing interactions with surrounding tissue. In general, they take 
advantage of one or more of the following approaches.23,24 
1. Direct application: Rather than accumulating drug at the tumor following systemic 
injection, the drug is physically applied directly to the desired site. 
2. Passive targeting: The drug is modified or encapsulated in a carrier with a size 
appropriate for preferential accumulation at the tumor site rather than in other 
tissue. Attached groups for active targeting may or may not be present. 
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3. Actively targeted delivery: Certain cell types, including cancers, express high levels 
of molecular markers which are rare elsewhere in the body. One or more targeting 
moieties for a cell type-specific marker are tethered to the delivery vehicle. By 
binding preferentially to cells with high expression, drug is taken up preferentially 
by the desired cell type. 
4. External stimulus response: The carrier circulates until triggered to release its 
payload. Concentration of carriers at tumor sites via passive targeting is possible, 
but the release stimulus is from an external source. Examples of external stimuli 
include ultrasound, thermal cues, light, or magnetic fields. 
5. Environmental stimulus response: the delivery vehicle circulates without releasing 
drug until triggered by some feature of the delivery site. Passive targeting may be 
used to concentrate the vehicle at the tumor and active targeting groups may be 
present. Common triggers include pH and temperature. 
Some of these approaches have significant drawbacks. In many cases, the direct 
application of drug to tumor sites is of limited utility due to the difficulty of precisely 
injecting small tumors and a high degree of invasiveness for accessing certain areas of the 
body. In addition, an inability to locate all tumor sites, limited drug lifetimes following 
administration, and leakage into surrounding tissue. Similarly, problems arise when using 
external stimuli. In order to know where to aim the ‘gun’ providing the stimulus, the target 
must first be located and certain stimuli (e.g. temperature or light) can be difficult to target 
to deeper tissues. Both approaches rely on a time- and labor-intensive cycle of imaging, 
expert analysis, and repeated treatments due to the growth of previously unidentified sites. 
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A more desirable option, approaching the ‘magic bullet’ ideal would combine 
passive, active, and environmental targeting. This system would protect the drug while in 
circulation, passively localize to the tumor site, be taken up only by targeted cells, and 
release the drug only inside targeted cells. This project will pursue such a system to deliver 
the encapsulated drug in an efficient and highly specific manner. 
1.2 General Concepts in Delivery 
Passive Targeting 
The enhanced permeation and retention (EPR) effect has proven to be a great boon 
for delivery of drugs to tumors via the bloodstream. The phenomenon, first reported by in 
1986 by Maeda and coworkers,22,25 relies upon the fact that a tumors’ rapid, uncontrolled 
growth leads to vasculature (the blood vessel network) that is quite ‘leaky’ compared to 
that of healthy tissue. This network is rife with nanoscale fenestrations that allow 
nanoparticles to leave circulation for the tumors’ interstitial space by diffusion through 
these pores. Given sufficient time for diffusion from the bloodstream into tumors, the 
results of the EPR effect can be dramatic, and intratumoral drug concentrations can 
increase by a factor of 10 to 100 relative to systemically-injected free drug.24,26  
In order to take advantage of this effect, particles must be of the proper size to most 
effectively diffuse through pores in tumor vasculature while avoiding elimination 
elsewhere in the body. Many studies have addressed this issue, attempting to establish a 
cutoff for leveraging the EPR effect. Numerous optimum particle sizes have been reported, 
ranging from 200 to 600 nm.27,28 Direct observations of extravasating, fluorescent 
nanoparticles from 60 to 400 nm in diameter found that intratumoral accumulation was 
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most effective for particles in the range of 100-200 nm.29 This optimum size must be kept 
in mind when designing nanoparticles to most effectively leave circulation at the desired 
location. It is critical to note that the EPR effect is only used to concentrate nanoparticles 
in the tumor interstitial space. The internalization of these particles into the cell, essential 
for many drugs to function, must be achieved by some other means. This distinction, and 
how to get nanoparticles into the desired cells, will be discussed below. 
 
Figure 1-1: Source of the EPR effect. Scanning electron micrograph of A) normal rat colon 
with phenotypically healthy repeating honeycomb structure centered about the opening of 
mucosal glands and B) cancerous rat colon lacking honeycomb structure with poor 
uniformity in vessel walls. Scale bars 100 µm and 50 µm, respectively. C) Schematic 
illustration of the EPR effect. Appropriately-sized particles pass by healthy tissue due to 
well-formed vasculature but extravasate at the tumor site, increasing local concentration 
within the tumor interstitial space. From Skinner and Ganta.24,30 
 
Size Effects 
An unavoidable characteristic of the EPR effect is that it is slow. That is to say, the 
rate of accumulation of nanoparticles after distant administration is estimated to take place 
over the course of hours. As a result, prolonged systemic circulation is a necessity for 
effective intratumoral accumulation, with circulation half-lives (τ1/2) in excess of roughly 
six hours required.31 Just as important as knowing how long the carrier is in circulation is 
understanding how it leaves the body. Excretion in the urine, for example, leads to 
decreased drug concentrations but little else in the way of adverse effects.  
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Additionally, nanoscale porosity is by no means a feature unique to tumors. A 
number of other organs and tissues in the body possess fenestrations that can allow 
extravasation of nanoparticles. In some cases, the removal of nanoparticles is a result of 
the body’s natural filtration mechanisms. For example, particles of diameter 20-30 nm are 
eliminated by the kidney and excreted in the urine, while particles 150-300 nm in diameter 
tend to be accumulated in the organs of the reticuloendothelial (RES) system, which 
includes the liver and spleen, and are subsequently attacked by resident macrophages.32–36 
Nanoscale porosity can also lead to accumulation in healthy tissues and organs such as the 
bone marrow, heart, kidney, stomach, lung, cartilage, and muscle.37–45 Inflamed tissues can 
also accumulate particles due to fenestrations on the nano- to microscale.46 These size 
regimes offer opportunities for treatment in areas outside of cancer, as seen in studies 
leveraging size effects for delivery of therapeutic or imaging agents to noncancer targets 
such as cartilage and bone marrow, broadening the scope for passive targeting beyond 
chemotherapy.44 However, they also underscore the need to create nanoparticles intended 
for chemotherapy with a precise size lest they be lost to diffusion through fenestrations 
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Figure 1-2: Size effects are essential for accumulation of nanoparticles in the tumor by 
passive targeting. Here the effect of size is explored for sterically stabilized lipid vesicles. 
A) Accumulation in the RES as determined by dose accumulated in the liver (∆) and spleen 
() as a function of particle diameter. Diameters below 100 nm and above 200 nm both 
result in substantial accumulation in these organs, preventing them from reaching the 
tumor. B) By creating particles with diameters of 100-200 nm accumulation in the tumor 
is maximized. From Liu.45  
 
Clearly, there are sizes that must be avoided to prolong circulation and enable 
maximum extravasation at the tumor site. Creating a particle larger than the size of the 
fenestrations of the tumor vasculature would be ineffective, since passage of such a particle 
into the tumor interstitial space is physically limited. Similarly, creating a very small 
particle in an effort to easily pass through the endothelial wall at the tumor site would also 
tend to enhance accumulation in a variety of other tissues. Such a small particle would tend 
to have a low circulation time, deliver potentially toxic drugs to sensitive and essential 
areas such as the liver and bone marrow, and achieve only middling concentrations of drug 
in the tumor itself. The general consensus is that the ‘ideal’ particle for cancer treatment is 
in the size range of 100-200 nm, as shown in Figure 1-2.29,47,48 
Particle Shielding 
Even in this ‘ideal’ size range, the particle will still be subject to removal from 
circulation by the RES via the liver and spleen. Without a means to avoid filtration and 
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removal by these organs a nanoparticle delivery system will not be effective. Upon 
injection into the bloodstream, the particle is immediately exposed to a multitude of 
proteins capable of adsorption. Gradually, the particle is covered in a proteinaceous mix 
rich in immunoglobulins and the blood serum proteins fibrinogen and albumin49. 
Opsonization, the term for this process, can result in a particle with a different size, surface 
charge, and binding profile than the originally injected particle. Size plays a role in this 
process as well, as the high surface curvature present at the surface of sub-200 nm particles 
has been shown to decrease the efficiency of the opsonization process.50,51 Each of these 
opsonization-induced changes carries significant implications for the intended activity of 
the carrier in the body. The process of recognition, envelopment and destruction of foreign 
objects by scavenger macrophages is believed to be preceded by adsorption of opsonins 
that promote recognition by these specialized cells.52  
The most important factors affecting circulation time are recognition by the 
immune system, hydrophilicity, and surface charge.53 Immune system recognition can be 
triggered in many ways, including presentation of recognized binding sites, binding of 
antibodies, recognition by macrophages, and binding to receptors on scavenger cells. While 
in many cases this simply leads to inefficient delivery, also possible is a cascade of immune 
responses that enhances B cell activity, promotes the activation of dendritic cells and T 
cells and results in an intense allergic reaction and even anaphylactic shock.54,55 Such 
responses must be avoided if there is to be any therapeutic value from the delivery system. 
A number of studies have explored the effects of surface charge for purposes of 
delivery in the body. In general, a charged particle surface tends to have decreased 
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circulation time relative to one that is neutrally charged.56–58 Opsonization of charged 
particles occurs due to Coulombic interactions of serum proteins with the exposed ionic 
groups present on many proteins.59,60 In general, negatively charged surfaces result in 
greater activation of the immune system than positively charged particles, though the latter 
has been shown to activate the complement system as well.61 In any case, it is typically 
desirable to target a neutral, or at least modestly cationic, surface layer to most effectively 
avoid clearance and maximize circulation time.62–64 
 
Figure 1-3: Repeat unit of poly(ethylene oxide) (PEO), the hydrophilic polymer most often 
used to shield particles from opsonization in vivo. 
Intuition suggests a hydrophilic particle surface should result in greater particle 
compatibility with the aqueous milieu in vivo. Indeed, a more hydrophobic particle will 
tend to be rapidly cleared from the body due to increased opsonization resulting from 
hydrophobic interactions between proteins and the surface.65,66 Polymeric modification of 
the surface to impart hydrophilic character, most often by the polyether poly(ethylene 
oxide) (PEO, Figure 1-3), has been shown to greatly reduce protein adsorption compared 
to an unmodified surface.67 PEO has been incorporated by a variety of means, including 
physisorption of copolymer to a solid particle, covalent attachment to the particle surface, 
modification of a bilayer-forming amphiphile, or as an integral part of an amphiphilic self-
assembled polymeric system. Such surface modification has led to substantially increased 
circulation times and less particle accumulation in the spleen and liver.52,68,69 In one 
illustrative example, a ‘bare’ particle was 95% cleared from the bloodstream within 2 
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hours, while an otherwise similar particle shielded with PEO still had 10% of the injected 
dose in circulation after 24 hours.70,71 In another study, a PEO coating was shown to reduce 
activation of the immune system and reduce uptake by macrophages.72,73 Why is PEO such 
an effective shielding molecule? As Allen observed, ‘if you want to be invisible, look like 
water.’74 The ether oxygen has been suggested as a key factor in promoting hydrogen 
bonding between the water surrounding the particle and the exterior layer of PEO, resulting 
in a highly hydrated boundary layer with hydrogen bonding characteristics similar to that 
of water itself. As a result, PEO chains are sheathed with solvent molecules and effectively 
‘camouflaged,’ hiding the entire particle from opsonins.66 
While hydrophilicity decreases hydrophobic opsonization, steric repulsion is also 
crucial for deterring protein adsorption to the delivery vehicle. Attaching a shielding 
polymer to the exterior of a nanoparticle, whatever the means, not only blocks attractive 
interactions with opsonins by separating protein from the particle surface, the shield layer 
also provides a mechanical impetus to repel proteins. A force is developed when a protein 
impinges upon a shielding chain extended from the particle surface. Prior to impingement, 
the chain is at its most high-entropy state and able to adopt a variety of conformations. In 
the presence of a nearby protein, the number of conformations is limited by the constrained 
chain and entropy is decreased. By creating a sufficiently dense layer of such shielding 
chains, protein repulsion is sufficiently energetically favorable that protein adsorption can 
be avoided.75 
In summary, by combining careful control over particle size and surface chemistry 
it is possible to leverage passive targeting via the EPR effect in order to concentrate drug 
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carriers at the tumor site. This process is an important first step in targeting, allowing more 
chemotherapeutics to be administered with decreased side effects compared to the free 
drugs that would distribute throughout the body and negatively affect healthy tissues as 
well as those afflicted with disease. However, this is only a first step, because in order to 
be effective, drugs must also be delivered to the interior of cancer cells and released. These 
considerations are addressed in the following sections. 
1.3 Active Targeting 
Delivery: The Final Step 
Particle size and stealthiness are vital for enabling passage through the appropriate 
pores and the longevity in circulation to accumulate at the tumor site. However, the EPR 
effect is only effective in localizing the delivery system to the tumor interstitium, not for 
achieving internalization into the cell. Additionally, the fact that a nanoparticle is 
sufficiently stealthy to have evaded clearance and accumulate in the tumor interstitium 
does not bode well for efficient uptake into the desired cells via nonspecific interactions. 
Internalization is a crucial requirement, as many drugs function by interfering with 
intracellular processes. It is important to remember that active targeting groups do not 
enhance localization to the tumor, but do enhance internalization into targeted cells.76  
Thus a final hurdle to improved treatment remains: attaining efficient, specific 
uptake of the delivery vehicle into the target cells. While many small molecules are capable 
of passive diffusion through the cell membrane, this can be a slow process that requires a 
high concentration gradient across the membrane, presupposes free drug is present in the 
extracellular environment (note that some drugs are hydrophobic or prone to degradation), 
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and lacks target selectivity. It is therefore necessary to take advantage of the cell’s existing 
uptake pathways for the most efficient delivery, an approach that may offer the additional 
advantage of circumventing some modes of drug resistance.12,77–85 
 
Figure 1-4: Endocytic modes of entry into mammalian cells. Phagocytosis is not observed 
in cancerous cells. Pinocytosis depicted here occurs in healthy and cancerous cells by at 
least the distinct four methods depicted here. The modes are distinguished by endocytic 
vesicle size, the nature of their cargo, and the means of vesicle formation. From Conner.86  
 
Endocytosis 
Cells take in material from the surrounding environment in several ways. 
Collectively referred to as endocytosis, these processes are essential for the transport of 
essential molecules into the cell via envelopment and internalization of the cargo in a lipid 
vesicle. Endocytosis as a whole is divided into two categories, phagocytosis (‘cell eating’) 
and pinocytosis (‘cell drinking’) as shown in Figure 1-4. Each of the possible modes of 
endocytosis are distinguished by cargo, receptor type and mechanism of internalization. 
Most of these avenues of endocytosis are poorly suited for drug delivery. 
Phagocytosis is only observed in cells specialized for removal of large pathogens and 
debris and is therefore not present in cancer. Macropinocytosis is a mode of pinocytosis 
that does not invaginate around a particular cargo, but instead forms from ripples in the 
cell membrane that then encapsulate a large sample of the medium outside the cell, a 
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process not well suited to targeted delivery as concentrations may be low in this medium 
and specific targeting would be challenging. Caveolin-mediated endocytosis is very 
common in endothelial cells, but has small vesicle sizes (~60 nm) and a slow internalization 
time (τ1/2 > 20 min). Additionally, its regulation is not as well-understood as that for other 
modes of endocytosis, hindering development of targeting groups.86 Finally, clathrin- and 
caveolin-independent endocytosis are both modes encompassing a wide range of 
endocytosis routes that are not as well understood as the other modes of endocytosis and 
thus are very challenging to exploit for targeted delivery. 
The remaining mode is clathrin-mediated endocytosis (CME), also known as 
receptor-mediated endocytosis, though this latter designation has fallen out of favor due to 
the discovery of receptor-mediated interactions in other modes of endocytosis. CME is 
essential for the uptake of nutrients, signal transduction, cellular development, and 
maintenance of homeostasis throughout the life of a cell. This mode of uptake is attractive 
for the internalization of drug delivery vehicles due to its mediation by ligand binding to 
specific, high-affinity receptors on the cell surface, and the size of vesicles created during 
CME are on the order of 120 nm, which is an excellent match for passively targeted 
nanoparticles.87 
Generally speaking, CME occurs via the concentration of transmembrane proteins 
and their bound ligands into a clathrin-coated pit. The pit invaginates and pinches off to 
form a clathrin-coated vesicle. This coating is quickly removed and the vesicle rapidly 
matures to a late endosome, which can then fuse with other late endosomes or lysosomes. 
During this process, the receptor is released and recycled to the cell surface.88 As 
   15 
 
endosomes mature, the pH drops from the ‘normal’ extracellular pH of 7.4 (somewhat 
lower in tumors) to 5.0-6.5 in endosomes and 4.5 in lysozomes.89 By taking advantage of 
this internalization mechanism, it is possible to increase intracellular concentrations of 
payload dramatically, by as much as three orders of magnitude.90,91 
The decreasing pH following CME raises critical concerns for successful delivery 
of payload to the cellular cytosol. Some drugs are relatively fragile and may not survive 
the strongly acidic environment in the late endosomes or lysosome. Therefore, ensuring 
endosomal escape of payloads prior to maturation of endocytic vesicles and subsequent 
degradation of the drug is extremely important lest drug be destroyed at this late stage. This 
issue will be addressed below in the discussion of particular delivery systems. 
Active Targeting 
A major advantage of utilizing CME is it not only internalizes a particle, but it can 
do so in a highly specific manner. While receptors capable of activating endocytosis are 
ubiquitous in the body, the variety and quantity of receptors are heterogeneous between 
cell types. Further, they can be highly specific with regard to what ligand they will bind. 
This combination of heterogeneity between tissues and high specificity for a ligand is a 
boon to those seeking to specifically target cancer, as the particular overexpression patterns 
of many markers has been well studied for many forms of the disease. As a result, it is 
possible to tether targeting groups to a delivery vehicle that are appropriate for receptors 
overexpressed on the targeted cell, affording a route for selective internalization.92 
It is important to choose a target receptor that is both plentiful (there are many on 
the target cell), and specific (it is rare elsewhere in the body). In this way, a targeting ligand 
will be functionally inert except when it encounters its target, whereupon it will bind tightly 
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and, along with its payload, undergo CME. Fortunately, there are a variety of such targets. 
In most cases the targeted feature is not wholly absent from ‘normal’ cells but is highly 
upregulated in cancerous cells. Examples from the literature utilized for this purpose 
include: the vascular endothelial growth factor (VEGF) receptor, the epidermal growth 
factor receptor, certain integrins, the transferrin receptor, matrix metalloproteinases, and 
various chemokines.93,94 
Targeting Ligands 
A variety of kinds of targeting ligands have been employed to specifically bind 
overexpressed cell surface markers. Monoclonal antibodies are perhaps the most 
established and well-studied, with a history of use in biology due to their specific, high 
affinity binding with diverse targets under biological conditions.95,96 Because of this, they 
were among the first targeting groups employed. However, their large size (tens to 
hundreds of kg mol-1) and nonhuman origin caused short circulation times which were 
insufficient for efficient accumulation in tumors, issues that also persisted for chimeric 
antibodies with sequences from multiple species.97 Even when lower molar mass antibody 
fragments were created using only the active portion of the molecule, immunogenicity was 
still significant. Site-specific conjugation of antibody-based targeting groups to 
nanocarriers has proven difficult in practice, with poor control of ligand orientation 
resulting in less effective binding than predicted.98,99 Nonetheless, the high binding 
affinities and proven capabilities of antibodies have set them apart as the ‘gold standard’ 
against which all other systems are judged. 
Targeting using proteins bound to the nanocarrier is often accomplished by 
tethering directly to the ligand for a given receptor overexpressed on the target cell. For 
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example, the VEGF receptor is often targeted by conjugates to vascular endothelial growth 
factor itself. Typical targeting proteins tend to be far smaller than antibodies (EGF is 
approximately 6 kg mol-1), yet some of the same limitations apply. These include a lack of 
overall particle stealthiness due to a bulky targeting group, difficulty in achieving the most 
effective orientation of binding sites on the protein and improper secondary structure due 
to misfolding caused by conjugation techniques used to couple the protein to the carrier.100–
102 Further, some conjugates have unexpectedly acted as superagonists, activating signaling 
cascades resulting in cell proliferation.103 
Design of Targeting Peptides 
In many cases, only a small region of the many amino acid residues present in a 
ligand protein are active in binding. While the remainder of the protein may be 
physiologically relevant, due to the decreased stealthiness of a large ligand and low areal 
density of active binding site, it is often not advantageous to utilize the entirety of even a 
highly active natural ligand. Peptide-based targeting groups pare unnecessary portions of 
the larger protein away, leaving only a minimal, highly effective sequence of amino acids. 
These peptide systems lack the immunogenicity of antibodies due to their synthetic origin 
and are a fraction of the size of antibody at only hundreds to low thousands of g mol-1. In 
addition, the use of iterative and often automated solid phase synthesis techniques allows 
construction of peptides residue by residue and addition of useful functionality to the N-
terminus.104,105 These techniques allow fine control of molecular structure, allowing exact 
sequences to be used with precise control of orientation and connectivity. 
One approach to development of targeting peptides is to screen libraries of 
candidates against a target. A number of methods exist for this approach, including phage 
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display, combinatorial libraries, affinity selection, and peptide nucleic acid 
microarrays.106,107 Fundamentally, each approach relies on screening a large number of 
candidates for binding against the target and selecting the most effective. This has proven 
to be a useful approach to peptide design as it allows selection of novel sequences as well 
as, in some techniques, the introduction of non-natural amino acids and functional groups. 
This approach is especially applicable to targeting novel cellular features that lack the 
‘infrastructure’ in the literature necessary to select, characterize and optimize a natural 
ligand.108 
Integrin Targeting and Peptide Design 
In contrast to library-based approaches, a ‘rational design’ approach to peptide 
selection modifies existing natural protein ligands to maximize activity while minimizing 
regions superfluous to binding. By this method it is possible to take advantage of the 
interactions already ‘tested’ by nature while omitting nonessential complexity.109–111 An 
especially relevant example of rational design is the development of the fibronectin-
mimetic peptide PR_b for bioactive surface modification and cell-specific targeting to 
integrins. These proteins are two part transmembrane receptors composed of one α and one 
β subunit that mediate cell adhesion to the extracellular matrix or other cells. Integrins have 
been implicated in a variety of processes from the essential, such as homeostasis and cell 
adhesion, to the harmful, such as autoimmune diseases and cancers of the skin, lung, 
prostate, colon and breast, among others.112,113 In the body, these integrins function by 
binding extracellular matrix proteins such as fibronectin, fibrinogen or vitronectin to 
trigger a signal cascade promoting cell adhesion and spreading. Alternatively, the ligand 
for the integrin receptors and its coupled particle can be internalized via CME.114 
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The most ubiquitous integrin-targeting peptide in the literature today is the RGD 
sequence.115–118 Derived from the 10th type III repeat of fibronectin, this sequence is 
composed of an arginine, a glycine, and an aspartic acid in series.119,120 This ligand is 
capable of binding to certain activated receptors, allowing carriers bearing RGD sequences 
to be targeted towards the αV-containing receptors, especially αVβ3, though RGD can also 
be recognized by αVβ5, αVβ6, αIIbβ3, α1β5 and α5β1.121  
Specific Targeting of Integrin α5β1 
The last of these receptors, α5β1, is a particularly attractive target due to its 
overexpression on tumor vasculature both in clinical cancer and in experimentally-induced 
models.122 Highly expressed in embryos but only minimally expressed in healthy adult 
vasculature,123 specific targeting of the α5β1 integrin has been promising due to the 
integrin’s overexpression in cancers of the breast, prostate, colon, skin, lung and rectum 
and low levels of expression elsewhere.124–132 While the RGD sequence has proven quite 
effective in enhancing delivery to integrin α5β1, it has the potential to bind a variety of 
integrins, hindering delivery specificity. To address this concern, past efforts have targeted 
the α5β1 integrin specifically. As a result, specific targeting to this integrin using a high-
affinity ligand has the potential to enhance treatment outcomes by binding specifically to 
diseased cells. In this manner, nonspecific delivery to ‘bystander’ cells can be minimized, 
reducing side effects due to off-target effects of toxic drugs. 
To promote adhesion to this integrin, a variety of peptides have been synthesized 
incorporating both the PHSRN and RGD domains present on the integrin’s native ligand, 
fibronectin. Maintaining the proper distance between PHSRN and RGD, 30-40 Å in 
fibronectin, has been shown to be essential for proper binding after a number of studies 
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were undertaken to design peptides using no linker, linkers of glycine amino acids or a 
PEO linker.133–137 However, none managed to match the effectiveness of fibronectin alone. 
In contrast, the matching of both length and hydrophilicity of the region between RGD and 
PHSRN was shown to yield a peptide capable of encouraging cell spreading levels 
comparable to and even superior to fibronectin (sequence: 
KSSPHSRNSGSGSGSGSGRGDSP). This enhanced cell function was attributed to 
effective miming of fibronectin’s engagement of both PHSRN synergy and RGD binding 
sites combined with the greater areal density achievable with a peptide than the much larger 
protein.17 Named PR_b, the hydrophilically-matched spacer hypothesis was confirmed by 
systematic comparison to peptides incorporating hydrophobic or hydrophilic linkers.16 
Blocking experiments with antibodies have demonstrated that PR_b is a specific ligand for 
the α5β1 integrin138,139 and has a dissociation constant of 76.3 ± 6.3 nM,140 recommending 
PR_b for enhancement binding and payload delivery when tethered to a delivery 
vehicle.141–148 The development of such a specific and high-affinity ligand suggests a role 
for a versatile carrier capable of enhanced tumor accumulation via the EPR effect, specific 
internalization to the interior of cancer cells via binding between PR_b and the α5β1 integrin 
and a clear means of release from nanoparticles. The range of such particles and their 
suitability for such a strategy is discussed in the next section. 
1.4 Drug Delivery Vehicles 
Types of Delivery Vehicles 
The choice of the delivery system is critical, as it dictates characteristic advantages 
and drawbacks throughout the entire drug delivery process from initial injection to final 
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release. Many drug delivery approaches have been investigated. Some of the most common 
are depicted below in Figure 1-5.24,85,94,149,150 
 
Figure 1-5: Delivery systems of current interest in the literature. From Pangburn.149 
 
Perhaps the most classic nanoparticle is the simple one composed of a solid 
precipitate in which the payload is dissolved. These can be created using organic polymers, 
ceramics, proteins, carbon nanotubes, silica, gold or other inorganics, among 
others.52,94,151,152 Such a particle is ‘frozen,’ trapped in a state wherein the constituent 
molecules are immobile. In comparison to the systems discussed below, the external 
chemical functionality of the particle can be difficult to control, making addition of 
shielding groups such as PEO or targeting moieties difficult to achieve with the level of 
control possible in other systems. 
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Dendrimers, in contrast, are exquisitely well controlled chemically. As a result, it 
is possible to create nearly monodisperse particle sizes with identical molecular 
architecture. However, there are inherent limits to this approach. First, as a result of 
molecular crowding, particle sizes are limited, keeping the ultimate size of typical 
dendrimers well below the 100-200 nm window desired to effectively leverage the EPR 
effect. In addition, payload can only be encapsulated in the interior space, which is 
composed of a single chemical environment. Thus it is necessary to tailor the dendrimer in 
such a way to encapsulate only a single class of payload (i.e. hydrophobes) at the expense 
of the other (i.e. hydrophiles). Finally, such particles are quite labor intensive to create due 
to the iterative nature of the synthesis process.153–156 
Self-assembled amphiphilic systems have the potential to address some of these 
limitations of simple nanoparticles and dendrimers. Composed of many aggregated 
amphiphiles - molecules that possess distinct areas of hydrophilic and hydrophobic 
character on the same molecule - these systems are capable of self-assembly in water into 
various aggregates on the nano- to micro-scale. If carefully formulated, these systems can 
encapsulate both hydrophobic and hydrophilic cargo in a robust, chemically tailorable 
nanoparticle that is in many cases amenable to size adjustment by mechanical methods 
such as extrusion. Prior to discussing specific examples it is useful to review the concepts 
underlying amphiphilic self-assembly. 
Amphiphiles and Self-Assembly 
The current understanding of self-assembly in polymeric systems is greatly 
informed by systems composed of small molecule amphiphiles. In general, the structure of 
these lipidic amphiphiles is of the form RX, where R is a hydrophobic tail and X is a 
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hydrophilic head group. These groups can take a variety of chemical forms. For R groups, 
hydrocarbon chains are quite common, but unsaturation, branching, or aromatic rings are 
also possible. Hydrophilic head groups can be polar -sulfate, sulfonate, carboxylate and 
quaternary ammonium groups are common– or nonpolar, in which case a short chain of 
PEO is commonly employed. Under normal conditions, a familiar example being oil and 
water, close association of polar and nonpolar groups would be quite unfavorable; 
however, by chemically tethering these groups to one another interesting and useful phase 
behavior is possible.157 
The energetically unfavorable association of hydrophobic regions with water is 
mitigated by micellization. During this process, amphiphiles that exist as unimers in dilute 
solution reach a sufficiently high concentration to form aggregates. This concentration is 
referred to as the critical micelle concentration (CMC) or critical aggregation concentration 
(CAC), and is accompanied by sharp transitions in phenomena such as conductivity, 
osmotic pressure and turbidity.158 In water, this transition reflects a reordering of the 
surfactants in such a way as to concentrate hydrophobic tails ‘inward’ to form the core of 
the aggregate and hydrophilic groups ‘outward’ towards the solvent environment, resulting 
a global decrease in free energy relative to free unimers. 
The driving force behind micellization was originally attributed to favorable 
enthalpic interactions between hydrophobic groups,159 but this interaction has since been 
shown to make only a small contribution to the overall free energy decrease at the CMC.160 
Far more important is the entropic contribution from the solvent. Attractive forces between 
molecules of water are quite strong and tend to favor water interacting with itself. In order 
   24 
 
to accommodate a nonpolar chain, it is necessary for water to adopt a highly ordered, 
cagelike conformation, which severely constrains the number of states that the solvent can 
explore. In contrast, the interactions between water and the head groups can be quite 
favorable. The tipping point comes at the CMC, when the global free energy becomes 
lower for clustering hydrophobic portions of surfactants together in aggregates rather than 
for forming solvent cages to accommodate free unimers. This phenomenon is known as the 
‘hydrophobic effect.’ 
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Figure 1-6: The packing parameter of surfactants dictates the shape of self-assembled 
aggregates. From Israelachvili.161  
The shape adopted by this aggregate is dictated by geometrical packing 
considerations as shown in Figure 1-6. This is quantified by the ‘packing parameter,’ which 
is defined as the ratio of the volume of the tail to the product of the liquid-state length of 
the tail and the area of the head group. By changing this parameter (for example, increasing 
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the tail volume by including two tails rather than one), it is possible to access the canonical 
series of aggregate morphologies depicted in Figure 1-6.157,158 
Small molecule aggregates have played a pivotal role in the current understanding 
of targeted and stealthy drug delivery. Liposomes – lipid vesicles – have been investigated 
extensively to ascertain the effects of both targeting and shielding specifically for 
application to chemotherapy.162 These nanocontainers have proven versatile as they permit 
delivery of both hydrophilic and limited quantities of hydrophobic drugs through loading 
of the aqueous core and hydrophobic shell, respectively. Reactive functionality on lipid 
head groups allows the installation of a wide variety of targeting moieties including 
antibodies,98 antibody fragments,99 peptides,142,149 proteins,100,101 and aptamers.83,163–166 
This same chemical functionality has allowed steric shielding by tethering PEO, resulting 
in circulation half-lives of 15 hours, a vast improvement over the 2 hour circulation times 
for unshielded liposomes.167,168 Work on liposomes led to clinical treatment of cancer using 
sterically stabilized ‘stealth’ liposomes under the trade name Doxil for delivery of 
doxorubicin.71,169 Due to this versatility and proven record, liposomes are the system to 
which all others are compared. 
Macromolecular Self-Assembly.  
Polymeric amphiphiles are composed of covalently connected macromolecular 
blocks of different chemical composition. These blocks are selected such that each has a 
different affinity for a selective solvent, i.e. a solvent that preferentially solvates one block 
and not the other. This term is more general than the more specific 
hydrophilic/hydrophobic terminology and can therefore encompass a variety of 
nonaqueous solvent systems, including other polymers. With that in mind, the solvent 
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system being considered here is aqueous due its intended biological application, and the 
terms ‘hydrophobic’ and ‘hydrophilic’ will be used for the sake of clarity. 
Many of the same fundamental principles for small-molecule surfactants also apply 
for polymers, and above their CMC polymeric amphiphiles often adopt one of the 
‘standard’ morphologies depicted in Figure 1-6. However, the much longer chain lengths 
employed in polymeric systems can yield extreme hydrophobicity. As a result, in addition 
to the canonical sphere-cylinder-bilayer continuum, many nonequilibrium structures have 
been observed that are kinetically ‘trapped’ and thus unable to alter their morphology.170 
Further, polymers need not be simple diblocks, and creative syntheses have yielded 
polymers composed that are triblocks, tetrablocks or more in a single chain and various 
branched configurations. 171–173 Aggregates composed of these newer architectures have 
been observed to self-assemble into a variety of exotic structures.174–179 
Theoretical and experimental work to understand the routes by which these 
structures are generated has been extensive. While the arguments regarding self-assembly 
driven by global free energy minimization apply for both large and small molecules, the 
contribution from the stretching macromolecular amphiphiles’ much longer chains plays a 
very significant role that cannot be excluded from the analysis. The balance of 
contributions to free energy are often quantified as: core chain stretching, corona chain 
repulsion and interfacial tension between core blocks and solvent.180–182 
It is common to establish extrema for relative block lengths in self-assembled 
systems,183,184 with ‘starlike’ or ‘hairy’ aggregates at one extreme and ‘crew-cut’ 
aggregates at the other. In starlike systems, corona chains are large relative to the core 
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blocks. The resulting crowding at the particle surface prevents polymers from developing 
their unperturbed conformation by ‘squeezing’ coronal chains outward radially. As a result, 
the contribution to the overall free energy from core chain stretching is comparatively small 
and aggregate behavior is dominated by coronal repulsion and core surface energy. 
Consequently, geometric constraints result in low aggregation numbers and predominantly, 
if not exclusively, spherical morphology.185–188 It is in the crew-cut regime where the most 
variety is typically encountered in morphologies, including spheres, cylinders, bilayers, 
and a variety of more intricate structures. In these systems, the corona-forming block is 
small relative to the size of the core block. In contrast to starlike systems, the constraints 
imposed upon the corona blocks are small, resulting in a high surface area per corona chain, 
even to the extent of corona chains spreading across the core-solvent interface.188 As a 
result of this lack of crowding, the corona stretching term no longer predominates and all 
three of energies must be considered, especially that of core chain stretching.189 
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Figure 1-7: Observed morphologies following dispersal of different relative block sizes of 
PEO-b-poly(1,2-butadiene) (PB) copolymers in water. Vertical axis is degree of 
polymerization for PB. Horizontal axis is weight fraction of PEO in the diblocks 
copolymer. B = bilayer, C = cylindrical micelle, N = network, S = Sphere. From Jain.190 
 
Crew-cut aggregates are of particular interest due to their adjustability, allowing 
straightforward experimental access to a variety of morphologies. The free energy 
parameters can be modified by a variety of means, including choice of polymer blocks, 
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solvent, temperature, additives, polydispersity, or relative length of each block.191–193 This 
last consideration is particularly useful, as it allows targeting of self-assembled structures 
via well-understood synthetic means. An informative experiment holds the molar mass of 
one block constant while altering the molar mass of the other (see Figure 1-7). By these 
means it is possible to chart a transition from spheres to cylinders to bilayers as the ratio of 
soluble to insoluble blocks decreases.190,194,195 Such free energy transitions can be 
understood intuitively by the same geometric packing arguments used above for small 
surfactants.  
Morphology and Metastability 
While appealing for charting transitions, plotting morphological phase diagrams for 
dispersed amphiphiles is quite challenging. In order to achieve the thermodynamic 
equilibrium implied by a phase diagram, substantial kinetic barriers to rearrangement must 
be overcome. In small molecule surfactants, this is typically achieved through means such 
as exchange of unimers or micellar fusion and fission.196,197 In polymeric systems, 
however, the extremely low to immeasurably small CMC resulting from lengthy 
hydrophobic chains makes these processes extremely slow to nonexistent. In addition, the 
steric boundary of hydrophilic layers can have a strong repulsive effect and long core 
chains have been observed to relax in a way indicative of entanglements, further slowing 
equilibration.198,199 Chain exchange dynamics have been estimated to proceed at nine to 
eleven orders of magnitude more slowly in polymeric systems than for small molecule 
surfactants. When compared via neutron scattering, little significant chain exchange was 
observed even over the course of weeks.200,201 
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Direct observation of dispersed solutions via cryogenic transmission electron 
microscopy (cryo-TEM) has revealed the coexistence of multiple morphologies, implying 
that a global energy minimum has not been achieved.170,202 Polydispersity may play a role 
in these coexisting structures, but many studies report coexisting morphologies even in 
nearly monodisperse systems, suggesting that polydispersity-driven effects are not 
sufficient explanation.203 Clearly, kinetics must play a role in the formation and coexistence 
of these metastable states, blurring the lines of morphological transition that are often quite 
sharp for small molecule surfactants. These coexisting systems can be quite stable, and 
dilute suspensions are often observed to be little changed following months at room 
temperature.204,205 
In studies of phase behavior, it is common to use ‘liquid-like’ polymers with low 
glass transition temperatures for the core block. These allow dispersion and study of the 
transitions between morphologies due simply to changes in block length at room 
temperature without the need for cosolvents or high temperature as well as diffusional 
rearrangement within a given aggregate. These rearrangements are believed to result in a 
more thermodynamically favorable conformation and can result in the formation of a 
variety of highly curved surfaces without necessitating chain pullout. In this way it is 
believed that the energy penalty inherent in constraining the core block is minimized by 
allowing post-assembly assumption of conformations with high surface curvature.190 
Though rearrangement is often not immediate and the structures are not at a global 
thermodynamic energy minimum, the possibility for attaining curvature without 
overcoming the substantial kinetic barriers necessary for global energy minimization create 
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highly metastable structures. Such rearrangements have been reported to be sufficiently 
effective that core blocks are capable of adopting their unperturbed conformations.199 Post-
aggregation relaxation emphasizes the energetic benefits gained by rearrangements and has 
been observed in spherical, cylindrical, networked and bilayered aggregates.206,207 
1.5 Polymeric Delivery Vehicles  
Aggregate Morphologies 
When compared to existing small molecule-based carriers such as liposomes, 
macromolecular systems can be much more physically robust. Further, these particles are 
fully synthetic and not limited to the natural chemical palette, affording great flexibility to 
tailor chemical and physical architectures. The morphologies discussed above – sphere, 
cylinder and vesicle – have all been investigated for delivery of drug and imaging agents.208 
Spherical micelles are attractive for solubilizing and protecting hydrophobic agents 
in their central core.209 These aggregates have been made from a very wide variety of 
polymers and have been shown to effectively deliver many agents to tumor sites. However, 
they inherently lack versatility due to an inability to natively encapsulate hydrophilic 
agents and are difficult to easily synthesize in the 100 – 200 nm diameter size range. 
Nonetheless, they enjoy the same variety of chemical compositions that any polymeric 
system can possess, and have been modified with a wealth of chemical functionalities 
including surface coatings, internal crosslinking, and targeting groups.175,210–214 
Cylindrical micelles, also referred to as wormlike micelles or filomicelles, have 
recently been touted as drug delivery agents with unique advantages. These aggregates 
have been used as targetable vehicles for delivery of hydrophobic drugs.215 They have also 
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been shown to exhibit a very high degree of stealthiness and biodegradability when 
formulated using PCL-b-PEO or poly(lactide)-b-PEO (PLA-b-PEO).207,215–217 While these 
characteristics are shared by spherical systems, the high aspect ratio of these particles 
results in a variety of unusual and potentially useful phenomena. For example, filomicelles 
may be able to penetrate through the bulk of a porous tissue via reptation through its small 
pores, a route inaccessible to spheres with a similar radius of gyration.217 In addition, 
hydrodynamic effects lead to greater drag along the length of the cylinder yielding longer 
circulation times. This longer circulation time has also been attributed to an inability for 
macrophages to take up more than a small section of a given filomicelle in a single 
phagocytic event.218 While these advantages are compelling, like spherical micelles, 
wormlike micelles are also inherently limited in versatility due to the lack of a hydrophilic 
pocket. Nonetheless, they may prove to be highly effective carriers for hydrophobes and 










Figure 1-8: Cryogenic transmission electron micrographs of A) liposomes and B) 
polymersomes. Note the much thicker shell layers in polymersomes due to higher 
molecular weight hydrophobic blocks than the lipid tails in liposomes. Scale bars 100 nm. 
Liposomes were prepared by Maroof Adil and the image collected by Todd Pangburn 
(unpublished work) while polymersomes are from Demirgӧz.141 
Polymersomes 
Of the morphologies that can be adopted by polymeric amphiphiles, vesicular 
structures are particularly compelling for medical imaging or drug delivery. These 
structures have come to be known as polymersomes by analogy with their lipid-based 
counterparts, liposomes (Figure 1-8).219 Both are composed of a bilayer of amphiphiles and 
are capable of carrying both hydrophobic and hydrophilic payloads via their shell and core 
regions, respectively.220 As a result, a single carrier system can be used for a wide variety 
of payloads. This may also have ramifications beyond the obvious, as synergistic effects 
have been observed during simultaneous dosing of complimentary drugs.16–20 
Conveniently, similar processing techniques to adjust size and purify unencapsulated drug 
can be used for both liposomes and polymersomes and the desired size of 100-200 nm is 
easily obtained via sonication, freeze-thaw cycling and extrusion through appropriately 
sized membranes.141,143,221,222 
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A number of advantages of polymersomes over existing systems have been reported 
that make them particularly attractive for use in the body. Perhaps the most immediately 
apparent advantage is the shielding layer. Typically liposomes are formulated with 
approximately 5-10 mol% of lipids derivatized with sterically stabilizing PEO.74,223 
However, the protective layer in the final liposome is often considerably sparser due to 
micellization of PEO-containing lipids that dissociate from the liposome to create more 
highly curved and energetically favorable spherical (starlike) micelles.224,225 In 
comparison, there is complete coverage of the polymersome surface with PEO by the very 
nature of the constituent amphiphiles. The resulting shielding effect has been shown to be 
extremely effective, as injections of PEO-containing polymersomes remain in circulation 
twice as long as sterically shielded liposomes (polymersome τ1/2 > 24 h) as a result of 
decreased clearance due to the lack of a ‘handle’ for opsonization.226 It must be noted, 
however, that while substantially decreased, opsonization is still active for any particle due 
to the impossibility of wholly eliminating nonspecific interactions. 
The chemical versatility of polymersomes is considerable. As a result of their fully 
synthetic nature, it is theoretically possible to ‘build in’ nearly any desired chemical 
functionality. This is especially relevant when attachment of targeting groups is desired. 
By creating end-functional polymers, it is possible to tether a wide variety of targeting 
moieties to the exterior of the vesicle by a variety of chemistries. Prominent examples 
include carbodiimide-mediated couplings, Michael additions, and the copper-catalyzed 
azide-alkyne ‘click’ reaction.227–231 Reactive functionality can also be included with 
relative ease in the polymer backbone or at the hydrophobic terminus. By reacting these 
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groups, it is possible to introduce crosslinks within the bilayer itself to create a tough, 
rubbery particle, a process that would result in destruction of lipid bilayers.232 Similarly, 
photo-induced crosslinking of core chain termini has been shown to increase stability of 
biodegradable polymersomes.233 
Most striking, however, are the properties derived from the bilayer. Owing to the 
large molecules involved, the core layer of polymersomes are quite substantial, 8-21 nm, 
far thicker than the 3-5 nm typically observed in lipids.199,200,234 This thickness has 
implications for the therapeutic versatility of polymersomes, particularly due to the 
increased volume available for hydrophobic shell loading as well as decreased ‘leakiness’ 
from the hydrophobic core via permeation of the membrane.219 
To illustrate this point, solubilization of the hydrophobic chemotherapy drug 
paclitaxel in the shell layer is a necessary step for its successful delivery and for decreasing 
its side effects such as neurotoxicity; however, loading paclitaxel tends to destabilize 
liposomes.235–237 In contrast, polymersomes have been demonstrated to successfully 
solubilize up to 10 mol/wt% of a series of large (1.4 - 5.4 nm at 700 - 5400 g mol-1) 
fluorophores without a significant decrease in toughness. In contrast, liposomes could only 
load 1 mol/wt% of the smallest of these fluorophores prior to losing stability.205 Similarly, 
it was possible to encapsulate both the dye Nile Red and quantum dots in a single PEO-PB 
vesicle with no appreciable change in mechanical or morphological properties.221 
The strong driving force towards minimization of core block exposure to solvent 
also has mechanical benefits. Membranes, while not as stiff as lipid membranes, are much 
tougher. Using micropipette aspiration, polymersomal areal strains (ΔA/Ao) were shown 
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to approach 50% prior to rupture, in stark contrast to the 5% rupture observed in lipid 
systems over a range of compositions.199 Interestingly, relaxation was slow following 
aspiration, particularly as molar mass increased, consistent with frictive and entangling 
effects between chains.206 These mechanical features may be quite useful in the challenging 
and often hostile environment in vivo. 
Biodegradable Polymersomes 
The polymers discussed thus far have largely been inert, typically a hydrophilic 
block of PEO and a hydrophobic block of biologically inert polymers. These polymers are 
well suited to uncovering the physics of aggregation, as they are not easily degraded and 
are typically made to narrow molar mass distributions.238 However, if one is more 
concerned with medical therapies than with morphological theory, the very features that 
make these polymersomes so attractive, notably high resistance to breach of the vesicle 
wall, act in opposition to therapeutic goals. While a robust vesicle is extremely useful for 
getting the polymersome to the tumor site intact, it presents a problem following 
internalization. To wit, the payload generally must escape both the carrier and the 
endosome and then reach the cytoplasm, none of which is possible if the drug is trapped in 
an inert container. Thus delivery with polymers created to address questions of theory are 
inherently limited at the final stage by the very feature set that made them attractive 
theoretical systems. 
Degradable polymersomes are a solution to problem. By including degradable 
linkages in the core block, it is possible to create a system that is responsive to its 
environment. These carriers offer the potential to behave much like inert systems prior to 
internalization – maintaining the advantageous features of stealth and tough membranes 
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capable of solubilizing a variety of payloads – while degrading and releasing their payloads 
following internalization. Early biodegradable polymersomes were composed of PEO 
hydrophilic blocks coupled to hydrophobic blocks of either polylactide (PLA), poly(ε-
caprolactone) (PCL), or poly(trimethylene carbonate).239 Later studies incorporated blends 
of these polymers and inert PEO-PB diblocks to reduce hydrolysis.240 In recent years 
vesicles, composed solely of PEO-PCL have become more common in the literature due 
to advantages of this polymer in comparison to other polyesters including a lack of pH 
changes upon degradation, compatibility with other polymers, and slow degradation 
compared to PLA, poly(glycolic acid) and poly(lactic-co-glycolic acid).241,242 
Degradation-induced effects also make polymersomes useful. In the Discher model 
for degradation, hydrolysis gradually results in a decrease in hydrophobic block length, 
with a resulting increase mass fraction of the hydrophilic portion of the molecule.234 Using 
the arguments made above regarding surfactant self-assembly, this would favor the 
formation of highly curved surfaces such as spherical micelles. While this pathway is 
kinetically tractable and experimentally observable in wormlike micelles, which pinching 
off spheres, the same process is not possible in vesicles and results in energetically 
unfavorable stretching of core blocks.243 This unfavorable energetic state is ameliorated by 
the gradual accumulation of short-tail polymers to create highly curved pores in the vesicle 
wall, allowing release of the hydrophilic payload encapsulated in the aqueous lumen.240 
Poration is also a promising route for endosomal escape, a critical limitation of many 
systems. Following endocytosis there is a large nanoparticle concentration in the 
endosome. As pH drops, vesicles degrade, creating a high concentration of copolymers 
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with a shortened hydrophobic block. In these high-concentration situations, it is possible 
for the diblock to interact with endosomal lipids and accumulate in the endosomal wall. As 
in the vesicle poration case, these amphiphiles favor high-curvature conformations, 
resulting in the formation of holes in the endosomal wall, allowing release of drug into the 
cytoplasm.244 The end result is a vehicle capable of selectively releasing its payload 
following endocytosis, resulting in more effective treatment of tumors than that observed 
using inert polymersomes.245,246 
Dispersal and Biocompatibility 
Self-assembled aggregates are often formed by dispersing the copolymer into the 
aqueous phase from a good organic solvent for both blocks. Following dispersal, this 
solvent is removed by dialysis, evaporation or other means to leave behind polymersomes 
or other self-assembled aggregates.247,248 While this is a rapid approach suitable for some 
laboratory studies, in systems intended for dispersal in the human body, the inherent 
uncertainty concerning complete removal of hazardous solvents make such an approach 
unsuitable. Further, the use of high temperatures for dispersal of polymers excludes 
promising therapeutics due to conditions unsuitable for encapsulation of sensitive 
molecules.249  
It is therefore essential that systems intended for human use be able to self-assemble 
in water without the use of organic solvents. Candidate techniques include direct 
dissolution or thin film hydration, each of which requires a polymer that is liquid-like at 
room temperature. For studies of phase behavior systems such as PEO-b-poly(ethyl 
ethylene), PEO-b-PB, and PEO-b-poly(isoprene) have all been investigated as amphiphile 
capable of self-assembly under these conditions.141,202,205,250 However, these polymers are 
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biologically inert and incapable of the pH sensitivity desired in a responsive system and 
polymers must be capable of both organic solvent-free dispersal at ambient temperature 
and pH-sensitive degradation. 
 
Figure 1-9: Diblock copolymer poly(ethylene oxide)-b-poly(γ-methyl-ε-caprolactone) 
used to form self-assembled aggregates, including polymersomes,194 by thin film hydration 
at room temperature. 
Systems using polyester hydrophobic blocks have been proven in numerous studies 
to be extremely effective and versatile delivery systems for a variety of applications. 
Unfortunately, FDA-approved PCL is semicrystalline, with a Tm ≈ 60 °C, making room 
temperature dispersal in water impossible without the aid of organic cosolvents or high 
temperature. Another approach, and one that is explored in this thesis, is the use of a 
modified PCL that eliminates crystallinity, making it compatible with bio-friendly 
dispersion techniques. Work by Trollsas and coworkers provided a route to modify the CL 
monomer by substitution of a methyl group in the γ position of the caprolactone ring to 
create γ-methyl-ε-caprolactone (MCL).251 This modification disrupts chain packing, 
resulting in an amorphous polymer with a glass transition temperature of -60 ºC. This 
monomer has since been utilized to create PEO-b-poly(γ-methyl-ε-caprolactone) diblock 
copolymers (Figure 1-9) that are dispersable by simple thin-film hydration247,252 and form 
the full range of canonical aggregates in water at room temperature in a manner comparable 
to PCL.194,249 This system has also been investigated for deep-tissue imaging, 
encapsulating fluorescent agents for diagnosis.253,254 By utilizing PEO-PMCL it is possible 
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to obtain highly stable nanoparticles that behave much like known systems yet are 
dispersible by bio-friendly techniques. 
1.6 Summary 
Cancer remains one of the greatest challenges in modern medicine, proving capable 
of withstanding the extremely diverse treatment strategies currently employed. 
Chemotherapy is among the most widely used treatment options, but a hallmark of 
chemotherapy is the infliction of a wide range of side effects that negatively affect a 
patient’s quality of life and often dictate the tolerable dosages that can be administered, 
limiting therapeutic efficacy. Many approaches have been investigated to decrease these 
side effects while preserving the therapeutic effects of chemotherapy drugs. A promising 
avenue has been the development of nanoparticle systems that take advantage of the leaky 
blood vessel network often present in the vicinity of fast-growing tumors to preferentially 
accumulate nanoparticles carrying drug at the tumor site for eventual release of a toxic 
drug. 
Liposomes are the most common of these nanoparticle carriers and have been 
modified to include targeting functionalities that greatly enhance uptake into target cells 
that overexpress specific cell-surface receptors. These carriers, however, tend to have 
limited circulation times due to their limited steric repulsion layer and while effective at 
encapsulating hydrophilic drugs, have limited capacity for loading of hydrophobes. 
Polymersomes, the macromolecular analogs of liposomes, have the potential to increase 
treatment efficacy by enhancing intratumoral accumulation due to the extended circulation 
time afforded by their dense hydrophilic brush layer, encapsulation of both hydrophilic and 
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hydrophobic payloads, tough shell layer, and synthetic flexibility. However, most 
polymersomes have been composed of nondegradable polymers that slow release and 
eventual clearance from the body, or have lacked targeting functionality, hindering binding 
and uptake into targeted cells. 
The primary purpose of this work was to develop polymersomes combining 
degradable, polymersome-forming amphiphiles with functionality for site-specifically 
tethering a targeting peptide to enable specific binding to targeted cells. The goal is to 
enhance the specificity of delivery of chemotherapeutic drugs and consequently incur 
fewer negative side effects during chemotherapy. Towards this end, methods were 
developed to synthesize well-defined polymersome-forming amphiphiles capable of rapid 
reaction with cancer-targeting peptides while preserving peptide orientation. The behavior 
of these targeting polymersomes was then investigated both in simple solution and in vitro 
in the presence of targeted and untargeted cells. Following these investigations, a novel 
polymer system was designed to integrate an acid-labile moiety into the polymer backbone. 
By this means it is hoped that it will be possible in the future to create polymers with more 
rapid degradation and release when subjected to the lower pH present in the vicinity of 
tumors and following uptake into targeted cells and enhance the specificity of delivery and 
minimize the deleterious side effects of chemotherapy. 
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2 Synthesis and Characterization of Reactive PEO-PMCL 
Polymersomes* 
2.1 Introduction 
This chapter describes the synthesis and molecular characterization of a 
polymersome-forming block copolymer of poly(ethylene oxide) (PEO), a hydrophilic 
polymer, and poly(γ-methyl-ε-caprolactone (PMCL), a hydrophobic polymer, that 
integrates chemistry such that following self-assembly site-specific tethering of a targeting 
peptide is possible. In addition, this chapter includes verification of the self-assembly of 
the PEO-PMCL amphiphiles, characterization of the solution morphology of the 
aggregates, both before and after tethering of a targeting peptide, and characterization of 
the extent of the conjugate addition of the model targeting peptide. 
This work was motivated by a desire to combine the potential advances in payload 
diversity, circulation time, and synthetic flexibility afforded by use of polymersomes 
compared to other delivery mechanisms with the need to integrate a means of tethering a 
targeting peptide capable of binding to receptors overexpressed on targeted cancer cells. 
By doing so it is hoped that the specificity of delivery can be enhanced. To maintain 
vesicular morphology independent of the peptide used for targeting, it is essential that the 
chemistry used to tether the targeting peptide be capable of reacting relatively rapidly and 
in high yield after the self-assembly of polymersomes. While examples exist of 
                                                 
* Reproduced in part from Petersen, M.A., Yin, L., Kokkoli, E., Polymer Chemistry 1, 1281-1290. Copyright 
2010 Royal Society of Chemistry. 
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polymersome morphology being maintained when peptides are attached prior to self-
assembly141, the potential for the emergence of novel, highly-complex morphologies has 
also been demonstrated255 and complicates the prospect of developing a versatile, modular 
drug delivery vehicle that are best avoided. A vinyl sulfone group is particularly attractive 
for this approach, as it will react selectively with thiols (easily introduced into peptides by 
addition of a cysteine residue) via conjugate addition in mild aqueous conditions and is 
relatively stable with regards to hydrolysis. The alkyne-azide ‘click’ reaction has also been 
used for a similar purpose,139,147 but has the drawback of requiring a potentially toxic 
copper catalyst for the reaction to proceed in most conventional formulations.256,257 
While polymersomes have previously been formed using PEO-PMCL,194 they have 
lacked suitable reactivity on the PEO block to enable tethering of a targeting peptide. 
Similarly, while self-assembling amphiphiles have been synthesized that were capable of 
tethering a targeting peptide (while maintaining peptide orientation), these have been in 
nondegradable systems. In these cases the chemically robust polymers used allowed for 
relatively harsh reaction conditions without the risk of undesired side reactions (e.g. 
transesterification, backbiting reactions, etc.) that affect the integrity of the polymer chain, 
alter molar mass distributions, and impact the final morphology adopted by aggregates of 
these polymers.139,147,255 Examples of such systems are shown in Figure 2-1. 
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Figure 2-1: Several polymer systems have been developed en route to degradable targeted 
polymersomes. All have factored significantly in this work. Early efforts predominantly 
used PEO-PB.141,219,222 PEO-PMCL was developed as a degradable system also capable of 
adopting the range of canonical aggregates.194,247,252 PEO-PB was later modified with either 
azide139,147 or vinyl sulfone255 functionality using synthesis techniques not readily 
amenable to use with a degradable block suck as PMCL to enable the tethering of targeting 
peptides functionalized with alkynes or thiols, respectively. The current work develops a 
method to integrate the vinyl sulfone reactive end group into PEO-PMCL. 
Due to the need for installation of a reactive group onto a degradable chain that 
could be substantially degraded by exposure to harsh conditions, it was necessary to 
develop a route to install a reactive group prior to polymerization of the degradable PMCL 
block. To achieve this goal, a related procedure by Bae et al. was initially followed to 
preferentially modify one end of PEO diol with divinyl sulfone (VS).37 This could then be 
used to initiate polymerization of PMCL from the remaining hydroxyl groups. This resulted 
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in a mixture of VS-PEO-VS homopolymer, VS-PEO-PMCL diblock copolymer, and 
PMCL-PEO-PMCL triblock copolymer, from which the desired diblock could be isolated. 
Following isolation of the desired end-functional diblock copolymer (VS-PEO-PMCL), 
the polymer self-assembled in aqueous solution to form polymersomes analogous to those 
observed in unfunctionalized PEO-PMCL systems. These polymersomes were modified 
after self-assembly with thiol-containing peptides by site-specific attachment to the vinyl 
sulfone groups in the vesicle corona. Following peptide attachment the vesicle morphology 
was unchanged. 
2.2  Experimental 
Materials 
All chemicals were obtained from Sigma-Aldrich (St. Louis, MO) and used as 
received unless otherwise noted. Water was obtained from a Milli-Q water system purified 
to a resistivity of 18.2 MΩ cm. Peptides were synthesized by the Oligonucleotide and 
Peptide Synthesis Facility at the University of Minnesota and their molar masses were 
confirmed by Matrix Assisted Laser Desorption Ionization Mass Spectrometry (MALDI-
MS). 1H NMR spectra were acquired using a Varian VAC-300 spectrometer at room 
temperature, all polymer samples were dissolved in CDCl3 at approximately 1 wt/vol % 
and chemical shifts were referenced to tetramethylsilane and integrations reported relative 
to 2.0 kg mol-1 PEO (180 methylene protons per chain). Size exclusion chromatography 
(GPC) was performed and polydispersity indices (Ð) were determined using a Hewlett-
Packard series 1100 liquid chromatography system equipped with a Hewlett-Packard 
1047A RI detector and three PLgel 5 μm MIXED-C columns (Polymer Laboratories) with 
   47 
 
chloroform as the mobile phase (35 °C, 1 mL/min) and calibrated using polystyrene 
standards (Polymer Laboratories). All phosphate buffered saline (PBS) was 100 mM and 
pH 7.5 with 5 mM ethylenediaminetetraacetic acid (EDTA). Dialysis bags were 
regenerated cellulose and purchased from Spectrum Labs. Fluorescence readings were 
acquired using a Varian Cary Eclipse fluorescence spectrophotometer. 
Mass Spectrometry 
Electrospray Ionization Mass Spectrometry (ESI-MS) samples were dissolved at 
approximately 1 w/v% in 50:50 MeOH:H2O doped with approximately 0.1 w/v% KCl and 
measurements obtained using a Bruker Biotof II instrument in reflectron mode. MALDI-
MS samples were dissolved at approximately 1 w/v% in THF containing 10 w/v% 2-(4-
hydroxyphenyl-azo)-benzoic acid (HABA) and 1 w/v% NaCl as a cationizing agent 
followed by spotting of 0.7 μL of the solution on a MALDI target. Measurements were 
acquired using a Bruker Reflex III instrument in reflectron mode. Analysis and predictions 
for all mass spectrometry data was performed using Bruker DataAnalysis software.  
 
Figure 2-2: 1H NMR spectrum and assignments for nonreactive PEO-PMCL. 
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Figure 2-3: GPC trace for nonreactive PEO-PMCL. 
Synthesis of Non-Reactive PEO-PMCL 
MCL was prepared by Baeyer-Villiger oxidation of 4-methyl cyclohexanone using 
m-chloroperoxybenzoic acid (mCPBA) and 4-methyl cyclohexanone as described 
elsewhere.24-25, 41 PEO-PMCL was synthesized by tin octoate-catalyzed ring opening 
polymerization of MCL from a 2.0 kg mol-1 PEO methyl ether (MePEO) macroinitiator. In 
a sample reaction, MePEO (550 mg, 0.28 mmol) and a Teflon-coated stir bar were added 
to a previously flame-dried reaction vessel, heated under vacuum to 110 °C for 2 h, sealed 
and cooled to room temperature. In a dry box under inert atmosphere MCL (3.0 g, 23 
mmol) and SnOct2 (12 μL, 37 μmol) were added to the reaction vessel. It was sealed, 
transferred to an oil bath and allowed to react at 110 °C for 1.5 h under mixing. The vessel, 
now containing a clear, viscous liquid, was cooled to room temperature. The mixture was 
dissolved in CH2Cl2 and precipitated twice into hexanes. 
1H NMR (CDCl3): δ 4.10 (m, 
142H, -C(O)-O-CH2-), 3.65 (s, 180H, -O-CH2-CH2-O-), 3.38 (s, 3H, CH3-O-), 2.30 (m, 
142H, -CH2-C(O)-O-), 1.75-1.35 (m, 355H, -CH2-CH(CH3)-CH2-, -CH2-CH(CH3)-CH2-, 
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and –CH2-CH(CH3)-CH2-), 0.92 (d, 213H, -CH2-CH(CH3)-CH3-). Mn 24.0 kg/mol, Ð 1.19 
(GPC). 
Synthesis of VS-PEO-PMCL 
VS-PEO-PMCL synthesis was based on that of Bae.37 We have made significant 
modifications to enhance yields and provide precision characterization of the 
intermediates. The details are described below. 
 
Figure 2-4: MALDI-MS of unmodified PEO. Here HABA was used as a matrix and NaCl 
dopant as a cationizing agent. This mass spectrum was used to aid comparison to unknown 
mixtures of polymers synthesized en route to VS-PEO-PMCL. 
(a) Tosylation of PEO: In a representative reaction, bis(hydroxyl) terminated PEO 
































































































































































































0_E13\1: +MS, Baseline subtracted(0.80), Smoothed (0.19,1,GA), Baseline subtracted(0.80)
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chilled to 0 °C. Ag2O (1.75 g, 7.5 mmol) was synthesized from aqueous NaOH and 
AgNO3
42 and added to the chilled PEO under vigorous stirring followed by KI (0.6 g, 
3.6mmol) and p-toluenesulfonyl chloride (1.5 g, 7.8 mmol). The reaction mixture was 
stirred rapidly for 2 h at 0 °C, filtered over Celite, and reduced under vacuum to a white 
solid. The solid was then dissolved in 75 mL H2O, filtered, extracted into 3 x 50 mL 
CH2Cl2, dried over MgSO4, and precipitated into ice-cold diethyl ether. Residual solvent 
was removed from the resulting white solid under vacuum. Yield 95%, 85% tosylation by 
integration of methylene protons at 4.16 ppm and comparison to the PEO backbone peak 
at 3.65 ppm; 1H NMR (CDCl3): δ 7.80 (d, 1.7H, Ar), 7.35 (d, 1.7H, Ar), 4.16 (t, 1.7H, TsO-
CH2-), 3.65 (b, 180H, -O-CH2-CH2-O-), 2.45 (s, 2.6H, -Ar-CH3); ESI-MS (Figure 2-5 and 
Figure 2-6): m/z unmodified PEO [M+K+] calculated 2126.207 observed 2126.114, Ts-
PEO [M+K+] calculated 2148.137 observed 2148.141, Ts-PEO-Ts [M+K+] calculated 
2126.041 observed 2126.114. Mn 3.86 kg/mol, Ð 1.05 (GPC). In order to ease 
characterization of mixed intermediates prepared above, bis(tosyl) PEO was also prepared 
wherein all hydroxyl groups were reacted with tosyl chloride, allowing direct comparison 
between known bis(tosyl) PEO and unknown intermediates. To prepare bis(tosyl) PEO, 
approximately 5 g of polymer was dissolved in approximately 100 mL of CH2Cl2. 
Approximately 1 mL triethylamine was added followed by a 1.1 molar excess of tosyl 
chloride with respect to polymer. The solution was allowed to react under stirring for 18 h 
and polymer isolated by multiple precipitations into ice-cold diethyl ether followed by 
drying under vacuum. The expanded mass spectrum of the product of this reaction can be 
seen in Figure 2-5. 
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Figure 2-5: Expanded view of MALDI-MS of tosylated PEO. Here MALDI-MS was used 
for initial characterization but ESI-MS (detail in Figure 2-6) was used for detailed analysis 
















































































































































































































































































0_E17\1: +MS, Smoothed (0.19,1,GA), Baseline subtracted(0.80)
   52 
 
 
Figure 2-6: Detail of ESI-MS characterization data for PEO tosylated using Ag2O. ESI-MS 
was used to minimize potential loss of tosyl substituents during ionization. Predicted data 
are depicted in (a)-(c) while (d) shows experimental mass spectrum. While Ts-PEO is 
clearly distinguishable, masses corresponding to Ts-PEO-Ts and unmodified PEO overlap 
and cannot be distinguished. 
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Figure 2-7: MALDI-MS of bis(tosyl) PEO prepared in analysis of mixed tosylates used in 
synthesis of VS-PEO-PMCL. 
(b) Displacement with thioacetate: Potassium thioacetate (5.1 g, 50 mmol) was 
dissolved in 125 mL of dry N,N-dimethylformamide (DMF) and the mixture was added to 
the mixed PEO tosylates from the previous reaction (9.5 g, 4.75 mmol) and stirred until no 
solids were visible. The mixture was degassed by three freeze-pump-thaw cycles, 
backfilled with nitrogen, and allowed to react under stirring for three days at 35 °C. DMF 
was removed by vacuum distillation. The solid was dissolved in 200 mL of H2O, filtered, 
extracted with 3 x 60 mL CH2Cl2 and then dried over MgSO4. Volume was reduced under 
vacuum and the polymer precipitated into ice cold diethyl ether followed by solvent 







































































































































































































































0_E20\1: +MS, Smoothed (0.19,1,GA), Baseline subtracted(0.80)
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by integration of methylene protons at 3.09 ppm and comparison to the PEO backbone 
peak at 3.65 ppm. 1H NMR (CDCl3): δ 3.65 (b, 180H, -O-CH2-CH2-O-), 3.09 (t, 1.7H, -S-
CH2-CH2-), 2.34 (s, 2.6H, -S-C(O)-CH3); MALDI-MS (Figure 2-8 and Figure 2-9): m/z 
unmodified PEO [M+Na+] calculated 2110.23 observed 2110.13, [M+K+] calculated 
2126.21 observed 2126.20, AcS-PEO [M+Na+] calculated 2124.20 observed 2124.13, 
[M+K+] calculated 2140.17 observed 2140.10, AcS-PEO-AcS [M+Na+] calculated 
2138.16 observed 2138.11, [M+K+] calculated 2110.10 observed 2110.13. Mn 3.23 kg/mol, 
Ð 1.07 (GPC).  
It should be noted that use of a wash bottle of bleach on all surfaces in contact with 
thioacetate and derivatives as well as proper personal protective equipment is highly 
recommended due to their strong odors. 
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0_E22\1: +MS, Smoothed (0.19,1,GA), Baseline subtracted(0.80)
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Figure 2-9: Detail view of MALDI-MS data for a combination of unmodified PEO, AcS-
PEO and AcS-PEO-AcS. Predicted peaks are depicted in (a)-(c) and experimental data in 
(d). Observations in experimental measurements were consistent with a mixture of these 
three forms of PEO. 
 
(c) Deprotection to thiol: PEO thioacetate (8.5 g, 4.25 mmol) was dissolved in 150 
mL methanol containing 150 mM potassium methoxide and stirred at room temperature 
for 1.5 h. The mixture was subsequently neutralized with HCl, filtered, and solvent 
removed under vacuum. To reduce disulfide bonds, the solid was dissolved in 300 mL 0.1 
M aqueous sodium bicarbonate to which was then slowly added sodium borohydride to 0.1 
M (1.13 g, 29 mmol) followed by stirring under a nitrogen atmosphere.43 The solution was 
acidified to pH 3 by dropwise addition of HCl, extracted into 3 x 50 mL CH2Cl2, dried over 
MgSO4, volume reduced under vacuum, and finally precipitated into ice cold diethyl ether. 
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The reduction-precipitation step was performed twice to yield a light-yellow solid. Yield 
75%, 85% thiol modification as calculated by integration of methylene protons at 2.70 ppm 
and comparison to the PEO backbone peak at 3.65 ppm. 1H NMR (CDCl3): δ 3.65 (b, 180H, 
-O-CH2-CH2-O-), 2.70 (q, 1.7H, -CH2-S-), 1.60 (t, 0.85H, -SH); MALDI-MS (Figure 2-10 
and Figure 2-11): m/z unmodified PEO [M+Na+] calculated 2110.23 observed 2110.18, 
[M+K+] calculated 2126.21 observed 2126.23, HS-PEO [M+Na+] calculated 2126.21 
observed 2126.23, [M+K+] calculated 2142.18 observed 2142.11, HS-PEO-SH [M+Na+] 
calculated 2142.19 observed 2142.11, [M+K+] calculated 2114.14 observed 2114.19. Mn 
3.43 kg/mol, Ð 1.08 (GPC). 
 
Figure 2-10: Expanded view of MALDI-MS data used to characterize mixed PEO thiolates 
































































































































































































































































































































































0_G13\1: +MS, Smoothed (0.19,1,GA), Baseline subtracted(0.80)
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Figure 2-11: Detail view of MALDI-MS characterization data for thiol-modified PEO. 
Predicted data are depicted in (a)-(c) while (d) shows experimental mass spectra. 
(d) Divinyl sulfone attachment: Thiol-terminated PEO (2.0 g, 1 mmol) was 
dissolved in 50 mL tetrahydrofuran (THF) containing triethylamine (700 μL, 5 mmol) and 
degassed by three freeze-pump-thaw cycles. A small amount of dithiothreitol (DTT) (38 
mg, 0.25 mmol) was added under nitrogen atmosphere to reduce any residual disulfide 
bonds and the reaction was allowed to stir for 1 h. Divinyl sulfone (DVS) (5 mL, 50 mmol) 
was rapidly added under vigorous stirring. The reaction vessel was capped and allowed to 
react for 18 h at room temperature. The solution was reduced in volume under vacuum, 
precipitated three times into ice-cold diethyl ether and remaining solvent removed under 
vacuum. Yield 80%, 85% DVS modification was calculated by integration of methylene 
protons at 2.94 ppm and comparison to the PEO backbone peak at 3.65 ppm. 1H NMR 
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(CDCl3): δ 6.71 (dd, 0.85H, CH2=CH-SO2-), 6.46 (d, 0.85H, CH2=CH-SO2-), 6.22 (d, 
0.85H, CH2=CH-SO2-), 3.65 (b, 180H, -O-CH2-CH2-O-), 3.31 (m, 1.7H, -SO2-CH2-CH2-
S-), 2.94 (m, 1.7H, -S-CH2-CH2-O-), 2.74 (t, 1.7H, -SO2-CH2-), 2.53 (bs, 1.3H, -OH); 
MALDI-MS (Figure 2-12 and Figure 2-13): m/z unmodified PEO [M+Na+] calculated 
2110.23 observed 2110.24, [M+K+] calculated 2126.21 observed 2126.22, VS-PEO 
[M+Na+] calculated 2112.14 observed 2112.18, [M+K+] calculated 2128.11 observed 
2128.08, VS-PEO-VS [M+Na+] calculated 2114.05 observed 2114.04, [M+K+] calculated 
2130.02 observed 2130.02. Mn 4.05 kg/mol, Ð 1.13 (GPC).  
To aid in characterization of mixed intermediates, bis(vinyl sulfone) PEO was 
prepared. To synthesize bis(vinyl sulfone) PEO, a similar procedure was followed to that 
employed by Zupancich using PEO-PB.255 In short, approximately 5 g of PEO diol 
homopolymer was added to a pressure vessel with a side-mounted stopcock. Sufficient 
toluene (~25 mL) was added to fully dissolve the polymer. This solution was then frozen 
in liquid nitrogen and vacuum applied until all toluene had been removed. The polymer 
was dissolved in ~30 mL dry CH2Cl2. Under nitrogen, a 10-fold excess of sodium hydride 
was added, followed by a 25-fold excess of divinyl sulfone with respect to the hydroxyl 
groups. The vessel was sealed and allowed to react at 40 °C for 3.5 days. Sodium hydride 
was neutralized by dropwise addition of acetic acid. The resulting salts were then filtered 
and the polymer isolated by multiple precipitations into ice-cold diethyl ether. The final 
polymer was dried under vacuum and quantitative end-substitution with vinyl sulfone was 
verified by 1H NMR. MALDI-MS can be found in Figure 2-14. 
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Figure 2-12: Expanded view of MALDI-MS of VS-PEO product following reaction of 
































































































































































































































































































































































0_G13\1: +MS, Smoothed (0.19,1,GA), Baseline subtracted(0.80)
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Figure 2-13: MALDI-MS data for a combination of unmodified PEO, VS-PEO and VS-
PEO-VS. Predicted peaks are depicted in (a)-(c) and experimental peak in (d). The 
predicted peaks and those observed in experimental measurements are consistent with a 
mixture of these three forms of PEO.  
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Figure 2-14: MALDI-MS of bis(VS)-PEO used to verify m/z values for VS-PEO. The 
polymer was prepared by reacting unmodified PEO diol with vinyl sulfone.High m/z peaks 
are attributed to a minority of coupled polymer chains. 
(e) Polymerization of MCL: VS-PEO (1.5 g, 0.75 mmol) was added to a flame dried 
reaction vessel, dried under vacuum to baseline and back filled with argon. In a glove box, 
MCL (11.6 g, 91 mmol) and SnOct2 (30 μL, 92 μmol) were added and mixed thoroughly. 
The reaction vessel was sealed and heated to 110 °C for 1.5 h to yield a viscous liquid. The 
vessel was then cooled to room temperature, the product dissolved in CH2Cl2, and 
precipitated twice into hexanes followed by solvent removal under vacuum. 1H NMR 
(CDCl3): δ 6.71 (dd, 0.85H, CH2=CH-SO2-), 6.46 (d, 0.85H, CH2=CH-SO2-), 6.22 (d, 







































































































































































































































0_G16\1: +MS, Smoothed (0.19,1,GA), Baseline subtracted(0.80)
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3.31 (m, 1.7H, -SO2-CH2-CH2-S-), 2.94 (m, 1.7H, -S-CH2-CH2-O-), 2.74 (t, 1.7H, -SO2-
CH2-), 2.30 (m, 140H, -CH2-C(O)-O-), 1.75-1.35 (m, 350H, -CH2-CH(CH3)-CH2-, -CH2-
CH(CH3)-CH2-, and –CH2-CH(CH3)-CH2-), .92 (d, 210H, -CH2-CH(CH3)-CH3-). Mn 29.3 
kg/mol, Ð 1.35 (GPC). 
(f) Isolation of purified VS-PEO-PMCL: The product of the previous step was 
dissolved in 30 mL CH2Cl2 and transferred to glass centrifuge tubes. Methanol was added 
dropwise until a cloudy solution was observed. The mixture was then heated until clear, 
allowed to cool to room temperature, and centrifuged for 10 minutes at 1500g. The 
supernatant was carefully decanted into a fresh centrifuge tube and the pellet collected. The 
process was repeated until no triblock (PMCL-PEO-PMCL) peak was apparent in the 
supernatant GPC trace. Solvent was removed under vacuum and the viscous colorless 
liquid dissolved in 25 mL THF and added to 75 mL H2O. The resulting cloudy mixture 
was then transferred to a hydrated dialysis bag (MWCO 10 kDa), dialyzed against 10 two 
liter volumes of water over 7 days at room temperature and lyophilized. 1H NMR (CDCl3): 
δ 6.71 (dd, 0.8H, CH2=CH-SO2-), 6.46 (d, 0.8H, CH2=CH-SO2-), 6.22 (d, 0.8H, CH2=CH-
SO2-), 4.10 (m, 140H, -C(O)-O-CH2-), 3.65 (b, 180H, -O-CH2-CH2-O-), 3.31 (m, 2H, -
SO2-CH2-CH2-S-), 2.94 (m, 2H, -S-CH2-CH2-O-), 2.74 (t, 2H, -SO2-CH2-), 2.30 (m, 140H, 
-CH2-C(O)-O-), 1.75-1.35 (m, 350H, -CH2-CH(CH3)-CH2-, -CH2-CH(CH3)-CH2-, and –
CH2-CH(CH3)-CH2-), 0.92 (d, 210H, -CH2-CH(CH3)-CH3-, 210H). Mn 24.7 kg/mol, Ð 
1.11 (GPC). 
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Figure 2-15: GPC traces for each form of modified PEO. 
Preparation of Dispersions 
All dispersions were prepared by thin film hydration. Polymer was dissolved in 
CH2Cl2 and added to a vial of known mass. Solvent was evaporated under a nitrogen stream 
to create a thin film which was dried under vacuum overnight at 45 °C. PBS was then added 
to the sample to reach 1 wt/vol % polymer. A Teflon-coated stir bar was added, the vial 
sealed, and the solution stirred at room temperature for 1 week. 
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Peptide Attachment 
Dispersions used for peptide attachment assays were prepared as described above 
and extruded through polycarbonate membranes of first 400 nm then 200 nm. Peptides 
were prepared as a stock solution in PBS. 1100 µl of dispersed polymer was transferred to 
a vial containing a Teflon-coated stir bar. The desired amount of peptide was added from 
a stock solution followed by buffer to reach a total volume of 1300 µL. Samples were 
allowed to react at room temperature for 18 h while stirring. Unincorporated peptide was 
removed by dialysis against 3 x 3 liter volumes of PBS using dialysis membranes with a 
molecular weight cutoff (MWCO) of 3.5 kDa over 72 h. The amount of attached peptide 
was determined by rapid injection and immediate, vigorous mixing of 60 μL of 
fluorescamine (10 mg mL-1 in acetone) into each purified sample. Resulting fluorescence 
was measured using λex = 390 nm and λem = 500 nm at a 90° angle relative to the excitation 
signal and comparing data to a calibration curve of known peptide concentrations. Data 
collected for samples not reacted with peptide were used to determine background 
fluorescence and subtracted from peptide-containing samples. All reported fluorescence 
data is the average of ten measurements (n=10). Each experiment was performed in 
triplicate. 
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Figure 2-16: Calibration curve used to quantify attached peptide using fluorescamine. 
Microscopy 
Cryo-TEM imaging was performed by Ligeng Yin. Samples to be imaged by 
cryogenic transmission electron microscopy (cryo-TEM) were prepared using a home-built 
controlled environment vitrification system (CEVS) at room temperature.44 An aliquot of 
micelle solution (typically 8 μL) was loaded onto a lacey carbon support film (Ted Pella), 
which was held by a pair of tweezers in the water vapor saturated CEVS. Excess solution 
was blotted away using a piece of filter paper to form a thin film spanning the holes of 
lacey carbon with thickness of approximately 100–300 nm. About 15 seconds of waiting 
time was allowed to relax possible deformations formed during blotting. The grid was then 
quickly plunged into melting ethane (at ~90K) cooled by surrounding liquid nitrogen. The 
vitrified sample was transferred into a Gatan 626 cryogenic sample holder, and examined 
at about –177 °C in a JEOL 1210 TEM with accelerating voltage of 120 kV. Images were 
collected using a Gatan 724 multiscan CCD and processed with Digital Micrograph version 
3.3.1. Phase contrast was enhanced by utilizing a 3–20 μm underfocus. 
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2.3 Results and Discussion 
Modification of PEO 
Installation of a selectively reactive end group on the hydrophilic terminus of a 
diblock copolymer capable of forming polymersomes has been undertaken in the past using 
vinyl sulfone and azide groups. In these cases, the end group was installed after 
polymerization of both blocks was complete and under relatively harsh reaction 
conditions.139,147,255 However, the harsh reaction conditions employed to install the vinyl 
sulfone moiety are not applicable to PMCL systems due to the susceptibility of this 
aliphatic polyester to degradation and transesterification that would not be significant 
factors for nondegradable polymers. Due to this fact it was necessary to devise a synthetic 
route to install the vinyl sulfone moiety prior to polymerization of PMCL and verify that it 
was maintained following polymerization and purification. The key step of such a synthesis 
is selective end-modification of a precursor PEO diol to allow installation of vinyl sulfone 
on one end of the molecule while maintaining the hydroxyl group necessary to initiate ring-
opening polymerization of MCL. The synthetic route to vinyl-sulfone modified PEO is 
shown in Figure 2-17. 
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Figure 2-17: Synthetic route to vinyl-sulfone modified PEO (VS-PEO) from PEO diol. 
Alcohols were first tosylated in methylene chloride using Ag2O which was then displaced 
with sodium thioacetate in DMF to install a protected thiol functionality. Following 
isolation, thioacetates were cleaved in alkaline conditions to thiols which were reacted with 
an excess of divinyl sulfone. Following isolation, the remaining hydroxyl groups could be 
used to initiate polymerization of PMCL.  
Bouzide and Sauvé developed an approach using silver(I) oxide to selectively 
monotosylate a variety of diols, among them oligo(ethylene glycols).258 The authors 
reported 85% monotosylation of hexaethylene glycol in the presence of a stoichiometric 
amount of tosyl chloride. This is a far more selective result than that obtained using a 
simple base-catalyzed reaction with a stoichiometric amount of tosyl chloride, which 
would be expected to yield a statistical 1:2:1 mixture of unmodified diol, the desired 
monotosylate and the bistosylate, respectively. Bouzide and Sauvé noted that as the length 
of polymer chain between end groups increased the selectivity of monotosylation 
decreased.258 This method of selective end-modification has since been applied to PEO 
with as many as 80 repeat units (3.5 kg/mol),258,259yet no quantification was performed 
with regard to selectivity in such large molecules. 
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Figure 2-18: 1H NMR spectra (CDCl3) of PEO derivatives. (a) PEO tosylates (b) PEO 
thioacetates (c) PEO thiolates (d) PEO vinyl sulfonates (e) VS-PEO-PMCL.  
After silver(I) oxide-mediated tosylation of PEO, the resulting white solid was 
analyzed by 1H NMR spectroscopy, and it was determined that, on average, 85% of PEO 
chains had a tosyl group installed (Figure 2-18a). ESI-MS measurements (Figure 2-5 and 
Figure 2-6) were consistent with the presence of the desired monotosylate (Ts-PEO). 
Overlapping peaks for unmodified PEO and the bistosylate (Ts-PEO-Ts, Figure 2-7) 
confirmed that at least one was present but made it impossible to confirm the presence of 
both of these polymers. The entire mixture of tosylated polymers was reacted with an 
excess of potassium thioacetate in DMF to replace the tosyl groups with thioacetates. 1H 
NMR analysis confirmed that tosyl groups were displaced to form the thioacetate (Figure 
2-18b). MALDI-MS (Figure 2-8 and Figure 2-9) was used to confirm that this 
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transformation had taken place and comparison to predicted results indicated that all three 
expected forms of PEO were present (AcS-PEO-SAc, AcS-PEO-OH, and HO-PEO-OH). 
Molar masses and isotopic abundances were consistent with theoretical predictions, 
confirming the coexistence of these PEO derivatives along with the desired heterotelechelic 
form of the polymer (AcS-PEO-OH). 
The mixture of thioacetates was deprotected to the corresponding thiols by 
dissolution in methanol containing potassium methoxide. The GPC trace of the products 
was multimodal (Figure 2-19a) due to the formation of disulfide bonds between thiol-
functionalized chains. Two cycles of reduction with aqueous sodium borohydride43 
followed by extraction into an organic phase and precipitation into cold diethyl ether 
effectively reduced disulfide bonds, resulting in a nearly monomodal GPC trace (Figure 
2-19b). Following reduction, MALDI-MS was consistent with theoretical predictions for 
HS-PEO, PEO and the HS-PEO-SH, with distinct peaks apparent for each molecule (Figure 
2-10 and Figure 2-11), while 1H NMR spectroscopy confirmed complete conversion to the 
thiol (Figure 2-18c). Reoxidation was also reversible, as the multimodal GPC trace 
attributed to formation of disulfide bonds could be recovered by bubbling air through the 
sample (Figure 2-19c). 
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Figure 2-19: GPC traces of thiol-modified PEO demonstrating that this polymer is prone 
to oxidation to form disulfide bonds chains at thiol-modified end groups. Cleavage of these 
disulfide bonds is essential both for purification and to ensure thiols are available for 
reaction with divinyl sulfone. (a) Following cleavage of the thioacetate many PEO chains 
are linked via disulfide bonds, leading to a high Ð value. (b) Following reduction only 
minimal low elution volume peak is visible and the polydispersity index is much lower, 
consistent uncoupled free chains. (c) Disulfide bonds can be reintroduced by bubbling air 
through the sample. 
 
Divinyl sulfone was added to thiol-modified end groups by conjugate addition 
between thiols and vinyl sulfone. To minimize disulfide bond formation all solvent was 
thoroughly degassed and reactions were performed under nitrogen atmosphere. After 
dissolution of polymer, a small amount of dithiothreitol was added to reduce any 
fortuitously-formed disulfide bonds. In early experiments the commonly-used disulfide 
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reducing agent tris(2-carboxyethyl) phosphine (TCEP) was used, but use of this reagent 
was discontinued following very low yields due to apparent reaction with divinyl sulfone.  
Following reduction, divinyl sulfone was added rapidly under vigorous stirring at 
large excess to minimize chain-chain coupling. Following reaction, repeated precipitation 
into ice-cold diethyl ether yielded a white solid free of unattached divinyl sulfone with 
quantitative reaction of thiol groups as determined by 1H NMR spectroscopy (Figure 
2-18d). A small peak at low elution volume was detected by GPC and was unaffected by 
the addition of reductants, implying some divinyl sulfone mediated chain-chain coupling. 
Experimental MALDI-MS data was consistent with simulated predictions of VS-PEO, 
PEO, and VS-PEO-VS (Figure 2-12, Figure 2-13, and Figure 2-14). To verify that no 
reaction would occur between hydroxyl groups and vinyl sulfone, unmodified PEO was 
mixed with divinyl sulfone under identical conditions to those used to install vinyl sulfone 
on the thiol-terminated system. Following precipitation into cold diethyl ether, no evidence 
of divinyl sulfone was observed in the 1H NMR spectrum, confirming minimal reactivity 
with hydroxyl groups under these conditions. 
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Scheme 2-1: Polymerization of MCL from crude VS-PEO macroinitiator and purification 
used to isolate VS-PEO-PMCL diblock. 
Polymerization of MCL 
After installation of vinyl sulfone, the remaining hydroxyl end groups were used as 
initiation sites for polymerization of MCL. In past studies, PEO-PMCL has primarily been 
prepared in organic solvent using aluminum alkoxides and PEO monomethyl ether as the 
initiating system.23-25 Initial experiments using these conditions and vinyl-sulfone modified 
PEO (VS-PEO) resulted in loss of vinyl sulfone groups. To address this concern, SnOct2 
was employed as the catalyst and no solvent was used. No loss of vinyl sulfone was 
detectable by 1H NMR spectroscopy under these conditions. In all cases a diblock of 
approximately 11 kg/mol was targeted (i.e., PEO 2 kg/mol, PMCL 9 kg/mol), a molar mass 
similar to that shown to form vesicles in studies of unreactive PEO-PMCL.25  
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When PEO methyl ether was used to initiate polymerization it was possible to 
obtain the unreactive diblock polymer PEO-PMCL while maintaining Ð values below 1.2 
as long as the polymerizations were not allowed to proceed to full conversion. When vinyl-
sulfone modified PEO was used to initiate polymerization, polymerization proceeded from 
all available hydroxyl groups as shown in the GPC data presented in Figure 2-20. Based 
on these data we concluded that VS-PEO formed the desired vinyl sulfone-functionalized 
block polymer VS-PEO-PMCL. However, initiation also occurred at both ends of residual 
unmodified PEO to yield PMCL-PEO-PMCL (low elution volume). VS-PEO-VS remained 
as well (evident at high elution volumes). The agreement between predicted and 
experimental mass spectra for modified PEO above clearly suggested that a mixture of 
singly-, doubly- and unmodified PEO was present; however, quantification of the relative 
populations of each product by MALDI-MS is challenging47-49 and necessitated 
quantification by other means. Using 1H NMR data following polymerization of MCL 
supplemented by comparison of relative peak heights in the GPC trace of the combined 
polymers (Figure 2-20) we estimated that the mixture was composed of approximately 10 
mol% VS-PEO-VS (2270 g/mol), 70 mol% VS-PEO-PMCL (11 kg/mol) and 20 mol% 
PMCL-PEO-PMCL (ca. 20 kg/mol), demonstrating only mild selectivity compared to the 
stoichiometric mixture that would be expected for more conventional approaches to end-
modification. 
Following MCL polymerization, fractional precipitation was used to isolate the 
target VS-PEO-PMCL diblock, taking advantage of the relatively greater hydrophobicity 
of the triblock PMCL-PEO-PMCL. By slow addition of methanol to a dichloromethane 
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solution of the crude mixture until the point of cloudiness and centrifuging the mixture it 
was possible to gradually adjust solvent quality to be incompatible with triblock polymer 
while leaving most of the diblock and nearly all of the VS-PEO-VS in solution (Figure 
2-20b). By formulating similar arguments to those used in to estimate the quantity of each 
polymer following MCL polymerization it was possible to estimate that after fractional 
precipitation 60 mol% of the remaining mixture of VS-PEO-PMCL and VS-PEO-VS was 
comprised of the VS-PEO-PMCL diblock. Dialysis against water was used to remove 
residual VS-PEO-VS. Following dialysis and lyophilization no degradation of the polymer 
chain was detectable by GPC (Figure 2-20c) and only a small degree of vinyl sulfone loss 
was detectable by 1H NMR spectroscopy (~10%, Figure 2-18e), yielding the desired 
diblock as a viscous, transparent liquid. 
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Figure 2-20: GPC elugrams showing the purification of VS-PEO-PMCL diblock. (A) 
Polymerization initiated from hydroxyl groups on vinyl sulfone modified PEO. 
Unmodified PEO formed the triblock PMCL-PEO-PMCL at low elution volumes, VS-PEO 
formed the diblock VS-PEO-PMCL and comprises the middle peak and VS-PEO-VS 
initiated no polymerization of MCL and was eluted last. (B) Following precipitation from 
CH2Cl2 to remove PMCL-PEO-PMCL, the diblock VS-PEO-PMCL remained, as did VS-
PEO-VS. (C) After dialysis, only the desired VS-PEO-PMCL diblock remained. 
 
Aggregate Morphology and Peptide Attachment 
To verify that aggregate morphology was unaffected by vinyl sulfone groups and 
attached peptide, cryo-TEM was used to compare the solution morphology of VS-PEO-
PMCL without peptide (VS-0) and samples densely grafted with peptide (VS-100) to the 
control sample of unreactive PEO-PMCL. In the nonreactive system (Figure 2-21) vesicles 
were the primary morphology observed. Some wormlike micelles were also present, 
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consistent with coexisting morphologies observed in a number of self-assembled polymer 
systems, including PEO-PMCL.25, 50-51 When vinyl sulfone groups were present but no 
peptide had been conjugated to the reactive end groups (sample VS-0, Figure 2-21), there 
was little discernable difference in morphology from that expected in the absence of a 
reactive group and only vesicles were observed. 
  





Figure 2-21: Cryo-TEM of nonreactive PEO-PMCL diblock copolymer (sample O-0 in 
Table 2-1) following thin-film hydration. Vesicles were the predominant morphology with 
some coexisting wormlike micelles, consistent with prior studies of this system.194 Large 
black structures on the periphery of images are the lacey carbon used to suspend samples 
for vitrification. Images by Ligeng Yin. 
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Figure 2-22: Cryo-TEM of reactive VS-PEO-PMCL diblock copolymer without peptide 
(sample VS-0 in Table 2-1) following thin-film hydration. Vesicles were again the 
predominant morphology and the reactive group did not appear to have a significant effect 
on morphology. Large black structures on the periphery of images are the lacey carbon 
used to suspend samples for vitrification. Images by Ligeng Yin. 
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To probe the capacity of this vinyl-sulfone functional polymer to attach peptides, 
dispersions of either nonreactive PEO-PMCL (9100 g/mol PMCL, 18 wt% PEO, Ð 1.19) 
or reactive VS-PEO-PMCL (8900 g/mol PMCL, 18 wt% PEO, Ð 1.11) were formed at 1 
wt/vol% in PBS (pH 7.5). Following extrusion to 200 nm, the desired amount of peptide 
(CGRGDS or GRGDS) was added to the polymersome solution and allowed to react for 
18 hours. Then the solution was dialyzed against pure water to remove unreacted peptide. 
To determine the amount of peptide attached to polymersomes, the fluorescamine assay 
was used.52 A fluorescence-based assay was chosen due to the fact that the more common 
colorimetric assays rely on measures of absorbance to quantify peptide concentrations. In 
the case of polymersomes, solutions are not necessarily clear even prior to the addition of 
assay reagents and as a result, absorbance measurements are particularly susceptible to 
interference from the dispersion itself. The superior selectivity of the fluorescence-based 
assay (minimal fluorescence unless fluorescamine reacts with peptide amines) and 90° 
detection angle should decrease interference relative to absorbance-based assays even if 
the solution scatters light. In the present study, any interference from the solution would 
result in an underestimation of attached peptide, whereas an absorbance-based assay would 
overestimate this quantity. As a result, if the values reported here are inaccurate, it is more 
likely to be due to underestimation of peptide conjugation than overestimation. 
Fluorescence values obtained for VS-PEO-PMCL dispersions without peptide were 
used as a measure of background (sample VS-0) and peptide amounts determined by 
comparison to fluorescence of calibration curves containing known amounts of peptide 
(Figure 2-16). The results of this assay are presented in Table 2-1. When peptides contained 
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a thiol-bearing cysteine residue, even low concentrations of peptide were highly reactive, 
and nearly all of the peptide coupled to vinyl sulfone groups on the surface of vesicles. As 
the amount of peptide was increased relative to the total vinyl sulfone groups present on 
both the exterior and interior interface, the amount of coupled peptide increased then 
gradually plateaued at slightly over 40% of all vinyl sulfone groups. This is consistent with 
only outwardly-oriented vinyl sulfone groups being available for reaction with thiols, as 
approximately half of the polymer chains on a given aggregate are situated on the inner 
surface of the polymersome and thus inaccessible to peptides. As approximately 10% of 
the vinyl sulfone groups were hydrolyzed during dialysis purification, the measured level 
of peptide attachment is consistent with saturation or near-saturation of the remaining 
reactive sites. Any residual unreacted vinyl sulfones on the vesicle’s exterior interface in 
high peptide-concentration samples (VS-100 and VS-500) may be the result of dense 
crowding following peptide attachment resulting in steric restraints hindering the addition 
of further peptides. 
Table 2-1: Results of peptide attachment to polymersomes. All ‘VS-’ samples were 
composed of VS-PEO-PMCL while all ‘O-’ samples were composed of PEO-PMCL. 
Experiments were performed in triplicate and experimental uncertainty was calculated as 








VS-15 CGRGDS 15 14±2.1 
VS-40 CGRGDS 40 37±3.3 
VS-75 CGRGDS 75 38±7.5 
VS-100 CGRGDS 100 40±1.8 
VS-500 CGRGDS 500 42±3.7 
VS-100R GRGDS 100 .25±.45 
O-0 - 0 .04±.40 
O-100 CGRGDS 100 .25±.64 
aMole % versus polymer.  
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To ensure proper function of targeting groups it is essential that the attachment of 
ligands not only proceed to high reaction conversions but also be site-specific, as simply 
tethering a targeting group without regard for orientation will result in decreased ligand 
activity.260,261 Here, presentation of the peptide with a specific orientation is facilitated by 
attachment solely due to reaction between the thiol on a cysteine residue at the N-terminus 
of the peptide and a vinyl sulfone group in the vesicle corona. Of particular concern is that 
amines can act as donors in conjugate additions. To ensure that peptide attachment was not 
due to the reaction of amines GRGDS peptide, which lacks a cysteine residue but contains 
a terminal amine, was reacted with VS-PEO-PMCL vesicles. Following dialysis only a 
small amount of peptide was detected (0.25 mol% ± 0.45%), suggesting that if peptide 
amines do react with vinyl sulfone groups, this reaction occurs much less readily than is 
the case for thiols, a finding consistent with prior reports about the relative reactivity of 
each functional group in conjugate addition.55 When cysteine-containing peptides were 
mixed with polymersomes lacking the vinyl sulfone groups (O-100) minimal peptide was 
detected (0.25 mol% ± 0.64%), implying that both a vinyl sulfone group and a thiol are 
required for peptide attachment. These results suggest that site selective attachment of 
targeting groups is indeed possible in this system, as the vast majority of attachment will 
occur between a vinyl sulfone group in the polymersome corona and a peptide’s N-terminal 
thiol. No change in morphology was observed following the near-saturation of the vesicle 
surface with peptide (sample VS-100, Figure 2-23). 





Figure 2-23: Cryo-TEM of peptide-saturated VS-PEO-PMCL diblock copolymer (sample 
VS-100 in Table 2-1) following thin-film hydration and then peptide conjugation. Here 
approximately 40 mol% of all vinyl sulfone groups (both exterior- and interior-facing) are 
tethered to the thiol-bearing peptide CGRGDS. This limited reaction is likely due to near-
saturation of exterior reactive groups only, since interior-facing groups are not accessible 
to the peptide. No apparent change in morphology is observed upon tethering of this nearly 
600 g/mol targeting moiety. Large black structures on the periphery of images are the lacey 
carbon used to suspend samples for vitrification. Images by Ligeng Yin. 
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2.4  Conclusions 
To develop a degradable, targeted drug delivery system the vesicle-forming block 
polymer VS-PEO-PMCL was developed. This amphiphile self-assembled in water to form 
vesicles with reactive vinyl sulfone groups at the terminus of the corona-forming PEO 
block. These groups were capable of tethering high concentrations of a thiol-containing 
targeting peptide after self-assembly of vesicles in mild conditions without the need for 
catalyst. Attachment of thiol-containing targeting peptides proceeded to high conversion 
while maintaining the orientation of the peptide (CGRGDS) while peptides lacking a thiol 
group (GRGDS) underwent minimal attachment.  
Following targeting peptide attachment, no change was observed in aggregate 
morphology. In biological systems, even low concentrations of surface-bound ligand 
dramatically enhance binding and endocytosis in cells overexpressing targeted receptors.38, 
56-57 Given the structural similarity between PEO-PMCL and VS-PEO-PMCL, by blending 
the reactive polymer as the minority component prior to self-assembly it should be possible 
to simultaneously take advantage of both the shielding capacity of the PEO corona and the 
enhanced targeting due to bound ligands on the exterior of the vesicles. This system should 
serve as a versatile platform for specific delivery of a variety of therapeutic payloads and 
capable of utilizing a wide range of targeting moieties. These applications as well as 
polymer degradation behavior will be further explored in the following chapter. 
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3 Bioresorbable Polymersomes for Targeted Delivery of 
Cisplatin† 
3.1  Introduction 
The previous chapter addressed the synthesis and molecular characterization of the reactive 
amphiphilic diblock copolymer vinyl sulfone-poly(ethylene oxide)-block-poly(γ-methyl-
ε-caprolactone) (VS-PEO-PMCL) as well as comparison to its nonreactive analog PEO-
PMCL (Figure 3-1). This chapter describes efforts to apply these polymers to biological 
systems for targeted delivery of the anticancer drug cisplatin. 
 
Figure 3-1: Molecular structure of the block copolymers PEO-PMCL and VS-PEO-PMCL 
used in this work. These polymers self-assemble in water, forming polymersomes capable 
of encapsulating both hydrophilic and hydrophobic payloads. The vinyl sulfone moiety 
allows selective conjugation, after self-assembly, to thiol-containing targeting ligands.  
 
Many approaches to delivering cisplatin been investigated to diminish the side 
effects associated with nonspecific delivery of cisplatin.262,263 One of the most promising, 
cisplatin encapsulated in liposomes, increased the amount of the drug that could be 
administered without major side effects and significantly increased platinum concentration 
                                                 
† Reproduced in part from Petersen, M.A., Hillmyer, M.A., Kokkoli, E., Bioconjugate Chemistry, ASAP 
(2013). Copyright 2013 American Chemical Society. 
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in the tumor.264–267 Despite these promising inroads, therapy using the liposomal system 
proved to be ineffective due to the lack of a route for drug to reach the interior of target 
cells. Though liposomes and encapsulated drug had accumulated in the vicinity of cancer 
cells, there was no way for the drug to be delivered to the interior of cells, a crucial final 
step for administered drug to be effective.268–272  
In this chapter the role of the targeting ligand was investigated, comparing binding 
and specificity between the cysteine-functionalized forms of the simple RGD and the PR_b 
peptide. The latter peptide enhanced binding to α5β1-overexpressing cancer cells, such as 
DLD-1, with little or no binding to CACO-2, an intestinal epithelial cell line that expresses 
low levels of the α5β1 integrin.139,273–278 Release of a model drug from these peptide-
functionalized polymersomes was tracked and release profiles were compared between 
simple buffered solutions and after binding and internalization into cells, exploring the 
effects of hydrolases on intracellular release. Intracellular trafficking and release of a model 
drug from polymersomes in live cells was observed via confocal microscopy to 
quantitatively and qualitatively study payload colocalization with intracellular 
organelles.279 Finally, treatment efficacy of the chemotherapy drug cisplatin was compared 
between when it is free in solution and when it is encapsulated in polymersomes to 
determine the effect of targeting. The results indicated that targeted delivery using PR_b 
dramatically enhanced specific delivery of cisplatin to α5β1-overexpressing DLD-1 human 
colon cancer cells but not to nontargeted CACO-2 cells relative to nontargeted 
formulations. 




All chemicals were obtained from Sigma-Aldrich (St. Louis, MO) and used as 
received unless otherwise noted. Polymers were synthesized according to previously 
described procedures and were composed of a PEO block with a number average molar 
mass of 2 kg mol-1 and a PMCL block with a number average molar mass of 9 kg mol-1 for 
both the nonreactive polymer PEO-PMCL and the vinyl-sulfone modified reactive polymer 
VS-PEO-PMCL.194,252,280 Water was obtained from a Milli-Q water system purified to a 
resistivity of 18.2 MΩ cm. Unless otherwise specified, all phosphate buffered saline (PBS) 
was 100 mM and pH 7.4. Phosphate-citrate buffers were prepared using appropriate 
combinations of dibasic sodium phosphate and citric acid for the desired pH and ionic 
strength was adjusted to match the polymersome interior using sodium chloride. Peptides 
cPR_b (CKSSPHSRNSGSGSGSGSGRGDSP) and cGRGDSP (CGRGDSP) were 
synthesized by the Oligonucleotide and Peptide Synthesis Facility at the University of 
Minnesota. Antibodies were purchased from Millipore (Billerica, MA). Fluorescence 
readings were acquired using a Beckman Coulter DTX 880 spectrophotometer. Hoechst 
33342 nucleic acid stain, CellLights Early Endosome-GFP (Rab5-GFP), and CellLights 
Lysosome-RFP (LAMP1-RFP) were obtained from Invitrogen (Carlsbad, CA). Fetal 
bovine serum (FBS) was purchased from Atlas Biologicals (Fort Collins, CO). 
Polymersome Preparation 
Polymersomes were prepared at 1 wt/vol% of polymer in water using thin-film 
hydration followed by peptide conjugation as described previously.280 All targeting 
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polymersomes were formulated to incorporate 10 mol% VS-PEO-PMCL polymer and 90 
mol% of PEO-PMCL, resulting in a final peptide concentration of 9 mol% on the vesicle 
exterior. The disparity between incorporated reactive polymer and final peptide 
concentration was attributed primarily to vinyl sulfone hydrolysis during polymer 
purification and vesicle formation as described in the previous chapter. Cisplatin, 
sulforhodamine B, and calcein blue were encapsulated by dissolution at the desired 
concentration in the suspension media prior to polymersome formation. After a minimum 
of 7 d of stirring, samples were subjected to 10 freeze-thaw cycles using liquid nitrogen 
and a water bath at ~65 °C and unincorporated drug and peptide removed via filtration 
through a Sepharose CL-4B column using an Amersham Acta Fast Protein Liquid 
Chromatograph at 0.85 mL s-1. To ensure that the same amount of encapsulated payload 
was delivered in experiments testing binding, release, and toxicity, encapsulated dye was 
quantified by lysing a known volume of purified polymersomes and measuring 
fluorescence.  
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Figure 3-2: Example calibration curve used to determine concentrations of platinum 
concentration using the o-phenylenediamine assay. Similar curves were used for 
determining platinum concentrations in polymersomes and for cisplatin release 
experiments. Error bars are from three wells at identical nominal concentrations. 
Polymersome Characterization 
Cisplatin concentrations were determined using o-phenylenediamine, which 
chelates platinum to elicit a concentration-dependent change in absorbance at 703 nm. The 
magnitude of this color change was used to determine concentration by comparison to a 
calibration curve of known platinum concentrations (Figure 3-2).281 Encapsulation 
efficiency for cisplatin ranged from 3-5%, which is on the lower side of the efficiencies 
reported for other polymersomal systems222,282,283 and could likely be improved by 
increasing polymer concentration during hydration, though verification of the resulting 
morphology would be necessary upon altering this parameter. 
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Figure 3-3: The critical aggregation concentration (CAC) of the PEO-PMCL amphiphilic 
block polymer was determined using the Nile Red assay.284 To determine the CAC, data 
were linearized on a ln-ln plot and linear fits were made to the high- and low-slope data. 
The intersection of these lines was taken to be the CAC. Representative data from a single 
experiment are shown above. This experiment was repeated in quadruplicate 3 times (n=3) 
with an average CAC of 0.38 ± 0.06 µM. 
 
Critical Aggregation Concentration 
The critical aggregation concentration (CAC) was determined using a Nile Red 
assay and PEO-PMCL diblock copolymer. This dye has minimal fluorescence in aqueous 
environments, but in nonpolar environments (such as the interior of the polymersome shell 
layer) fluorescence increases dramatically.284–286 As such, upon reaching the CAC, 
fluorescence will increase. To determine the CAC, serial dilutions of PEO-PMCL 
dissolved in tetrahydrofuran (THF) were made into known volumes of pH 7.4 PBS with at 
least a 50-fold excess of buffer versus THF in a 96-well plate. 1 μL of Nile Red dissolved 
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in methanol at approximately 1 mg mL-1 was then added to each well to a total volume of 
150 μL per well. The plate was mixed on an orbital shaker for 0.5 h and fluorescence 
measured at λex/λem of 485/525 nm. As shown in Figure 3-3, by plotting the natural 
logarithm of fluorescence versus the natural logarithm of polymer concentration, it was 
possible to construct linear fits that met at 0.38 ± 0.06 µM. This concentration that was 
taken to be the CAC for PEO-PMCL. 
Table 3-1: Hydrodynamic diameter of the polymersomes as determined using NTA. The 
experiment was performed five times and the standard deviations were calculated using 
these data. Histograms are shown in Figure 3-4. 
Sample Size ± SD (Dh, nm) 
Nontargeted 217 ± 63 
cGRGDSP 214 ± 62 
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Figure 3-4: Pooled NTA experiments to measure particle size for each polymersome 
formulation. These histograms are the sum of the five individual histograms collected for 
each formulation and were analyzed to determine the mean particle size and standard 
deviation, which is reported in Table 3-1. To allow comparison of particle size 
distributions, peak heights have been normalized to the maximum peak height of each 
distribution. 
Particle Size 
The size of the nanoparticles was characterized by Nanoparticle Tracking Analysis 
(NTA) using a NanoSight LM10-HSBT14 Nanoparticle Characterization System with a 
640 nm laser and a high resolution CCD camera. Each of the three polymersome 
formulations used for the measurements was diluted approximately 1000-fold into pH 7.4 
phosphate buffered saline and injected using a clean 1 mL syringe into the sample flow cell 
maintained at 23.3 ºC using clean syringes. Measurements were performed for 60 seconds 
five times for each sample using a detection threshold of 5 and automatic shutter and gain 
adjustment. Size and standard deviation were determined from these pooled results 
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assuming that particles were spherical, performing the experiment five times per 
formulation. The results of this analysis are shown in Figure 3-4 and summarized in Table 
3-1. 
 
Figure 3-5: A dialysis technique was used to determine the release profile of cisplatin from 
polymersomes. Escape from a dialysis bag was compared between cisplatin encapsulated 
in polymersomes and the free drug. Free drug, which is much smaller than the dialysis bag 
pore size (50 kDa), rapidly equilibrated across the membrane, while drug encapsulated in 




To verify that cisplatin was not leaking from polymersomes prior to delivery, a 
dialysis experiment was used to measure release rates. Cisplatin was encapsulated into 
polymersomes and unencapsulated drug removed as described above. The purified 
polymersomes were then placed into a dialysis bag (regenerated cellulose, MWCO 50 kDa) 
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that was in turn placed into a tenfold excess of pH 7.4 PBS. In parallel, free drug (200 μg 
mL-1 in PBS) was placed into another dialysis bag and placed into another identical but 
separate volume of PBS. Both dialysis systems were then subjected to gentle magnetic 
stirring. An aliquot of the liquid from outside the dialysis bag was periodically removed 
and frozen at -20°C. At the end of the experiment, all samples were thawed, vortexed 
thoroughly, and the platinum concentrations determined with the o-phenylenediamine 
assay described above. The results of this release study are shown in Figure 3-5 and suggest 
that leakage of the drug from polymersomes was minimal over the time scale of the toxicity 
experiments.  
Cell Culture 
DLD-1 human colon cancer cells were grown in growth media (GM: RPMI 1640 
supplemented with 10% FBS and 1% penicillin/streptomycin) in an incubator maintained 
at 37 °C and 5% CO2. Cells were kept in T-75 flasks and fed every 2 d. When cells reached 
approximately 90% confluence, they were washed twice with PBS, trypsinized (1 mL of 
0.25% trypsin with 0.1% ethylenediaminetetraacetic acid), resuspended in GM and seeded 
at 106 cells per flask. For CACO-2 cells, the same procedure was used but with GM 
containing 20% FBS. 
Flow Cytometry 
DLD-1 cells were grown to 90% confluence, trypsinized, and 106 cells suspended 
in three microcentrifuge tubes each containing 1 mL of fluorescence buffer (FB: PBS with 
0.02% sodium azide and 2.5% FBS) at 0 °C. Mouse IgG was added to one tube for isotype 
control and mouse anti-human integrin α5β1was added to a second tube. All three tubes 
were placed on a rotary shaker for 35 minutes at 4 °C. All three were pelleted, washed 
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twice with FB and resuspended in 1 mL of FB. Secondary antibody (5 μL donkey anti-
mouse IgG-FITC) was added to the isotype control and α5β1 tubes and mixed by rotary 
shaker at 4 °C for an additional 40 minutes. All tubes were again washed twice in FB and 
resuspended in 1 mL of FB. Flow cytometry was performed using a FACSCalibur flow 
cytometer at the Flow Cytometry Core facility in the Cancer Research Center at the 
University of Minnesota. 1.5x104 cells were counted for each curve. 
  







Figure 3-6: Representative curves used to determine IC50 values for A) DLD-1 and B) 
CACO-2 cells. Data points are experimental measurements while dotted lines indicate 
fitting curves. To determine IC50 values, measurements were conducted using a range of 
platinum concentrations either as the free drug or encapsulated in polymersomes. Viability 
was assessed using the MTT viability assay and values were normalized to untreated cells. 
Curves were fit to the data and IC50 for a given experimental formulation was determined 
as the intersection of the fit curve with 50% cell viability. 
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Viability Assays 
Cells were seeded onto polystyrene plates at 2x105 cells per well and allowed to 
attach overnight in GM. The media was then removed, fresh GM added and polymersomes 
containing either PBS or cisplatin were added at the desired concentrations. Plates were 
returned to the incubator for 24 h. Following this incubation, the GM and polymersomes 
were removed, the plates were washed twice with warm PBS, fresh GM was added and the 
plates were returned to the incubator for 2 d. After 2 d, the MTT assay was performed 
according to the recommendations of the manufacturer (Sigma-Aldrich), with 
measurements of optical density taken using a Molecular Devices Spectramax Plus 384 
spectrophotometer. Viability curves were fit to a sigmoidal curve to determine 50% 
inhibition concentrations (IC50) using untreated cells to establish 0% inhibition. 
Representative curves can be found in Figure 3-6. 
Binding Assays 
Cells were plated at 106 cells per well in a white-bottomed 96-well plate and 
allowed to adhere for 18 h. The media was then exchanged for 100 μL of fresh GM. Free 
peptide was added at various concentrations and sufficient GM was added so all wells 
contained a total volume of 125 μL. 15 μL of polymersomes containing 2 mM 
sulforhodamine B was added and plates were returned to the incubator for 1 h. The 
polymersome solutions were diluted as necessary using isotonic PBS to ensure equal dye 
concentrations were delivered to all wells. Plates were washed 3 times with PBS to remove 
unbound polymersomes and 100 μL of fresh GM was added to each well. Fluorescence 
measurements were taken at 37 °C using an excitation wavelength of 535 nm and an 
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emission wavelength of 595 nm. Wells that contained approximately the same number of 
cells but to which no dye had been added were used to account for autofluorescence.  
Polymer Degradation 
To evaluate degradation of PEO-PMCL polymersomes, both molecular and 
morphological changes were tracked as a function of time. Phosphate-citrate buffers of 100 
mM were formulated at pH 7.4, 6.5, 5.5 and 4.5 with 0.02% NaN3 added to prevent 
bacterial growth. Polymersomes of PEO-PMCL with no targeting functionality were 
prepared in each of these buffers via thin film hydration at 1 wt/vol% and maintained at 37 
°C in an incubator. Samples of approximately 500 μL were occasionally withdrawn, frozen, 
lyophilized, dissolved in deuterated chloroform, filtered through a 0.2 μm PTFE membrane 
to remove insoluble salts, and subjected to 1H NMR and GPC. For 1H NMR, 
tetramethylsilane was used as a reference to establish a chemical shift of 0 ppm and molar 
masses were determined by comparison of the integration values of PMCL protons at 4.10 
ppm to the integration values of the PEO chain at 3.65 ppm. For GPC, apparent molar mass 
was determined versus a set of polystyrene standards. In parallel, aliquots of pH 7.4 and 
pH 4.5 samples were periodically withdrawn and cryo-TEM was performed by Ligeng Yin 
using techniques described in the prior chapter and elsewhere.280 
Solution Release 
To evaluate release as a function of pH, polymersomes containing 100 mM 
sulforhodamine B were formed and purified as described above. Phosphate-citrate buffer 
was formulated to pH 7.4, 6.5, 5.5 and 4.5 and 150 μL of these four buffers were added to 
separate wells in a 96 well plate. To these buffers, 1 μL of purified polymersome solution 
was added. Then fluorescence was measured over time. After 24 h, wells were frozen at -
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80 °C for 2 h, thawed at 37 °C for 2 h and final fluorescence was measured. Wells to which 
no polymersomes had been added gave background fluorescence measurements. 
 
Figure 3-7: An MTT viability assay was used to verify the concentrations of chloroquine 
used in experiments were not toxic to DLD-1 human colon cancer cells. Viability was 
determined using the same procedure described in the main text. Data are the mean ± 
standard error of 2 separate experiments (n=2), with each experiment performed in 
triplicate. 
Intracellular Release 
DLD-1 cells were plated at 106 per well in a 96-well plate and allowed to adhere 
for 18 h in GM. The media was then exchanged for 100 μL of fresh GM with or without 
500 μM of chloroquine. Polymersomes were immediately added, diluting as necessary to 
ensure equal dye concentrations, and after gentle shaking, plates were returned to the 
incubator for 30 minutes. Wells were then washed twice with warm GM and 150 μL of 
fresh GM was added to each well, with those wells previously containing chloroquine again 
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supplemented with the drug to 500 μM. Fluorescence was measured immediately and again 
at 2 h, 8 h, and 24 h, as described above. Plates were then placed in a -80 °C freezer for 2 
h, thawed for 2 h at 37 °C, and final fluorescence was measured. To control for 
autofluorescence, wells containing polymersomes without fluorescent dye were included. 
Nonspecific adhesion of polymersomes to the plate was not found to result in significant 
fluorescence. Chloroquine was verified to not affect cell viability in the concentration 
ranges used in this experiment (Figure 3-7). 
 
Figure 3-8: Fluorescence versus concentration for calcein blue dye. Calcein blue was 
diluted into PBS, pH 7.4, to verify quenching. Serial dilutions were made in a 96-well 
plate and fluorescence was measured at λex/λem of 340/430 nm. Error bars from five 
separate wells were smaller than the points on the graph. 
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Calcein Blue Fluorescence 
To determine the optimal concentration of calcein blue to use for microscopy, a 
solution of the dye was made at 100 mM in pH 7.4 PBS. Using a multipipettor and a 96-
well black polystyrene plate, serial dilutions were made into pH 7.4 PBS from 100 mM to 
0.01 mM. Fluorescence was then measured on a Beckman Coulter DTX 880 
spetrophotometer using λex/λem of 340/430 nm as shown in Figure 3-8. On the basis of 
this result, 5 mM and 100 mM calcein blue were selected for encapsulation into 
polymersomes for nonquenching and quenching concentrations, respectively. 
Confocal Microscopy 
DLD-1 cells were seeded onto a glass-bottomed 24-well plate at 5x104 cells per 
well in 200 μL of GM per well and allowed to attach overnight in an incubator. Media was 
then exchanged for 200 μL of fresh GM in each well. Wells to be used for imaging received 
2.5 μL of CellLights early endosomes-GFP and 7.5 μL of CellLights lysosome-RFP, the 
media was mixed and the cells returned to the incubator for 18 h. Following incubation, 25 
μL of purified cPR_b-functionalized polymersomes containing either nonquenching (5 
mM) or quenching (100 mM) concentrations of calcein blue were added. After 2 h of 
incubation at 37 ° C, media was removed and each well washed twice with warm GM. 2 h 
wells were immediately nuclear stained using Hoechst 33342 (see below) while 150 μL of 
GM was added to 24 h wells. Immediately prior to imaging, media was replaced with 100 
μL of warm GM containing diluted Hoechst 33342 at 1 μM, which was allowed to stain 
the nuclei for 5 minutes at 37 °C. These wells were washed twice with warm GM and 
finally filled with 150 μL of GM prior to imaging. 
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Imaging was performed on a Zeiss Cell Observer SD spinning disk confocal 
microscope at 37 °C and 5% CO2 at the University of Minnesota Biomedical Image 
Processing Lab. A 100x objective was used, and the green channel used for GFP-tagged 
early endosomes, the red channel used for RFP-tagged lysosomes and the blue channel 
used for both nuclei and calcein blue. Slices were taken every 0.25 μm from the bottom to 
the top of cells, collecting each channel in series for each slice. A slice at the center of the 
central cell was used for analysis. The Manders coefficients between the blue channel and 
the green channel as well as the blue channel and the red channel were determined, 
accounting for background fluorescence according to the Costes technique in NIH ImageJ 
and gating out nuclei so as to consider only polymersomes.287,288 
3.3 Results and Discussion 
Introduction 
Particle size and prolonged circulation are vital for enhancing the carrier concentration 
in tumors; however, the EPR effect is only effective for localizing the delivery vehicle to 
the tumor interstitium, not for achieving internalization into cells. This last step has proven 
to be a major stumbling block for past attempts to deliver cisplatin.268–272 In these cases, 
cisplatin loaded into liposomes was delivered systemically and, as desired, platinum 
concentrations in the tumor were enhanced and the tolerated dose increased significantly 
due to decreased side effects, presumably via the EPR effect and the drug being sequestered 
inside of the liposomes. However, treatment outcomes were not improved due to the 
limited uptake of cisplatin into the cancer cells. To achieve internalization, active targeting 
groups show great promise. Using ligands tethered to the delivery vehicle, the cell’s 
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existing uptake pathways and overexpression of certain cell-surface receptors can be used, 
affording a route for selective internalization. Such an approach may also allow some 
modes of resistance to cisplatin or other encapsulated drugs to be circumvented, as has 
been shown in studies demonstrating selective binding and uptake of nanoparticle-based 
cisplatin carriers.12,76–84 
Active targeting capability was incorporated into PEO-PMCL polymersomes using 
a vinyl sulfone moiety capable of site-specifically tethering a targeting peptide following 
self-assembly as discussed in the previous chapter. Due to compatibility between PEO-
PMCL and VS-PEO-PMCL and the high reactivity between vinyl sulfone and thiol-
containing peptides, the amount of targeting peptide incorporated into the corona could be 
easily controlled, here using either 0 or 9 mol% peptide by mixing appropriate ratios of the 
two polymers prior to self-assembly. 
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Figure 3-9: Toxicity of unloaded polymersomes to the DLD-1 human colon cancer cells. 
Toxicity was evaluated with an MTT viability assay after 24 h of incubation at 37 °C. 
While in the rest of this work polymer concentrations never exceeded 0.8 mg mL-1, no 
significant decrease in viability was observed even at much higher concentrations. Data is 
the mean ± standard error of 4 separate experiments (n=4), with each experiment performed 
in triplicate. 
 
Biocompatibility and Binding 
While the chemical similarity of PEO-PMCL to the more commonly studied and 
biocompatible PEO-poly(ε-caprolactone)289,290 suggested PEO-PMCL would also be 
nontoxic, the biocompatibility of this polymer had not yet been examined directly. The 
effect of both nontargeted and targeted PEO-PMCL polymersomes on the viability of 
DLD-1 human colon cancer cells was investigated. As shown in Figure 3-9, neither 
targeted nor nontargeted PEO-PMCL polymersomes impacted cell viability following a 24 
h incubation period of cells with unloaded polymersomes. High cell viability was observed 
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even at concentrations much greater than 0.8 mg mL-1, the maximum concentration of 
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Figure 3-10: Histograms from flow cytometry experiments used to determine the 
expression of α5β1 integrin, the target of cPR_b peptides. Experiments were performed 
using (A) DLD-1 and (B) CACO-2 cell lines. Untreated cells were used to measure cell 
autofluorescence and an isotype control was included to verify the binding was specific. 
The pronounced shift to higher fluorescence values in DLD-1 cells – but not in CACO-2 – 
following incubation with an antibody specific to α5β1 integrin is indicative of much higher 
expression of the integrin on DLD-1 cells. These data are from a single experiment but are 
representative of n = 2. 
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To evaluate binding specificity, it was necessary to first determine the expression 
levels of the target α5β1 integrin on DLD-1 and CACO-2 human colon cancer cells. To do 
this, both cells lines were evaluated via flow cytometry with an anti-human α5β1 antibody. 
While some expression was observed in CACO-2 (Figure 3-10B), the pronounced shift 
towards higher fluorescence in DLD-1 (Figure 3-10A) indicated α5β1 expression was much 
greater in this cell line. On the basis of these results, CACO-2 was adopted as a model for 
‘bystander’ tissue in the body, nontargeted cells that express low levels of integrin α5β1, 
which is the target of the cPR_b peptide, to which drug delivery is not desired due to the 
potential for deleterious side effects. 
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Figure 3-11. Specificity of targeting to the α5β1 integrin using several formulations of 
polymersomes was evaluated. Polymersomes were formulated to encapsulate 2 mM 
sulforhodamine B without a targeting group, with 9 mol% cGRGDSP, or with 9 mol% 
cPR_b incubated with either (A) high α5β1-expressing DLD-1 cells or (B) low α5β1-
expressing CACO-2 cells. Increasing concentrations of free cGRGDSP peptide were added 
prior to incubation to determine if binding between integrins and fluorescent polymersomes 
could be blocked. Following 1 h incubation at 37 °C, unbound polymersomes were washed 
away and the fluorescence of bound polymersomes was measured. Autofluorescence of 
cells was measured using untreated cells. Data are the mean ± standard error of 3 separate 
experiments (n=3), with each experiment performed in quadruplicate.  
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To minimize the negative side effects of chemotherapy it is essential that binding 
of the delivery vehicle occurs with high specificity for the target cells. To determine if 
employing a high-affinity targeting peptide such as cPR_b would yield improved binding 
to α5β1-overexpressing cancer cells, the effect of the targeting ligand on the binding of 
polymersomes to DLD-1 cells was evaluated (Figure 3-11A). Here minimal binding 
occurred in the absence of a targeting peptide, a pronounced increase when the cGRGDSP 
peptide was used, and a maximum effect using the cPR_b peptide. Further, this binding 
could be inhibited by including free cGRGDSP peptide in media, which hindered the 
interaction between the peptides and integrins. Across all experiments using nontargeted 
polymersomes, the peptide concentration of the free cGRGDSP in the media was not found 
to have a statistically significant effect on fluorescence.  
To determine if binding to cells with lower expression of α5β1 integrin would be 
significant, potentially resulting in nonspecific delivery, the same experiment was 
performed using low-α5β1-expressing CACO-2 cells, a cell line often used as a model of 
intestinal epithelia.139,273–278 Little or no binding enhancement was observed (Figure 
3-11B) using targeted polymersomes compared to nontargeted polymersomes regardless 
of the concentration of the blocking peptide. These results suggested that polymersomes 
functionalized with the cPR_b sequence could promote delivery to the cancer cells of 
interest that overexpress the α5β1 integrin with minimal delivery to bystander cells even if 
they express low levels of the integrin.  
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Figure 3-12. Release rates of PEO-PMCL polymersomes were first measured in simple 
buffered solution. To measure release, polymersomes were loaded with self-quenching 
(100 mM) concentrations of sulforhodamine B. Release was first evaluated in isotonic 
phosphate-citrate buffer at 37 °C with pH 7.4, typical of circulating blood, to 4.5, typical 
of lysosomes. No significant difference was observed in release rate at different pHs. Data 
is the mean ± standard error of 3 separate experiments (n=3), with each experiment 
performed in quadruplicate. 
 
Degradation and Release 
To evaluate the release properties of PEO-PMCL polymersomes and degradation 
of the polymer, studies were first conducted in simple buffered solution at pH values from 
7.4 to 4.5 (Figure 3-12), levels commonly used to simulate the decreasing pH level 
encountered by a drug delivery vehicle as it is trafficked from outside the cell to different 
organelles following endocytosis.291–294 Fluorescent sulforhodamine B was loaded into 
polymersomes at self-quenching (100 mM) concentrations, unencapsulated dye was 
removed, and fluorescence was tracked for 24 h by monitoring increasing fluorescence as 
dye escaped polymersomes. The remainder of the dye was then released to determine the 
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fluorescence corresponding to 100% escape. After 24 h, release was nearly complete in all 
cases, with no apparent effect of pH on release kinetics. The release profile was well-





Figure 3-13: To determine if degradation of PEO-PMCL polymer was occurring in 
buffered solution, polymer molar mass was tracked by (A) GPC and (B) 1H NMR. In both 
cases degradation appeared to be minimal over the time period of the experiment. 
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Consistent with previous reports295,296 little polymer degradation was observed 
spectroscopically or chromatographically over 50 days at pH 7.4, 6.5, 5.5, or 4.5 (Figure 
3-13), suggesting the release mechanism in this pH range is not polymer degradation and 
that dye release is likely due to diffusion of the dye through the polymersome membrane. 
In addition, cryo-TEM studies at pH 7.4 and 4.5 showed no major changes to polymersome 











Figure 3-14: Cryo-TEM of PEO-PMCL, Day 0, pH 7.4. Some coexisting phases, mainly 
wormlike micelles, are present, but the predominant morphology is vesicles. Here D) is a 
portion of C) collected at higher magnification. Cryo-TEM by Ligeng Yin. 
  












Figure 3-15: Cryo-TEM of PEO-PMCL, Day 0. pH 4.5. The predominant morphology 
appears to be polymersomes. Cryo-TEM by Ligeng Yin. 
  












Figure 3-16: Cryo-TEM of PEO-PMCL, Day 10, pH 7.4. As at earlier time points, 
polymersomes are the predominant morphology with minor coexistence of wormlike 
micelles and some complicated structures, particularly immediately adjacent to the lacey 
carbon. Cryo-TEM by Ligeng Yin. 
  











Figure 3-17: Cryo-TEM, Day 10, pH 4.5 of PEO-PMCL. Vesicles are again the 
predominant morphology, including some multilamellar structures as well as the 
complicated aggregates near the lacey carbon ‘struts’ observed at pH 4.5. White disruptions 
in A) are beam damage. Cryo-TEM by Ligeng Yin. 
  











Figure 3-18: Cryo-TEM of PEO-PMCL, Day 20. pH 7.4. As at earlier time points vesicles 
remain the predominant morphology observed, including some quite large vesicles of 
several μm diameter. Cryo-TEM by Ligeng Yin. 
  











Figure 3-19: Cryo-TEM of PEO-PMCL, Day 20, pH 4.5. As with pH 7.4, the predominant 
morphology observed here are vesicles, including multilamellar vesicular structures. The 
large vesicles observed at pH 7.4 are not seen here, but this may be due to the limited 
‘window’ afforded by the technique. Dark regions are likely ice crystals and white spots 
are beam damage. Cryo-TEM by Ligeng Yin. 
  











Figure 3-20: Cryo-TEM, Day 31 of PEO-PMCL, pH 7.4. After 31 days, vesicles remain 
the primary structure, albeit accompanied somewhat more by coexisting articulated and 
wormlike structures. Cryo-TEM by Ligeng Yin. 
  











Figure 3-21: Cryo-TEM of PEO-PMCL, Day 31, pH 4.5. As with the pH 7.4 sample above, 
here vesicles seem to be accompanied by somewhat more coexisting articulated structures 
and wormlike micelles. Despite this, vesicles remain the predominant morphology. Cryo-
TEM by Ligeng Yin. 
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Figure 3-22. Release rates of targeted PEO-PMCL polymersomes were measured in in the 
presence of DLD-1 cells. To determine if release rates changed following cell binding and 
uptake, polymersomes containing 100 mM sulforhodamine B were incubated for 1 h at 37 
°C with DLD-1 cells with or without chloroquine. Cells were washed with 37 °C PBS and 
sulforhodamine B release was monitored for up to 24 h. Release in the first 2 h was much 
faster than observed in solution release experiments (Figure 3-12) but could be inhibited 
by chloroquine. After 24 h nearly complete release of dye had occurred with or without 
chloroquine, consistent with results observed in simple buffered solutions (A). Total dye 
delivery was enhanced by the presence of targeting peptides, particularly cPR_b, and 
chloroquine had no significant effect on total dye delivered, as total fluorescence following 
lysis were not significantly different between untreated samples and those treated with 
chloroquine. Data is the mean ± standard error of 3 separate experiments (n=3), with each 
experiment performed in quadruplicate. *=statistically significant difference (p<0.02), 
†=no statistical significant difference (p>0.10) via paired t-test. 
 
Intracellular Release. While simple buffered solutions can simulate the pH 
encountered following uptake, the absence of digestive enzymes limits the conclusions that 
can be drawn.297–299 To address this limitation, release was monitored for 24 h from PEO-
PMCL polymersomes following binding to DLD-1 human colon cancer cells (Figure 3-22). 
As in binding studies (Figure 3-11), the total amount of delivered dye was enhanced with 
targeted polymersomes and cPR_b peptide outperformed cGRGDSP. After 24 h, most of 
the dye had been released, consistent with the solution release study (Figure 3-12). 
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However, in the absence of chloroquine, release in cells was much more rapid, with >75% 
of the dye released within 2 h.  
Dye release was also tracked in the presence of 500 μM chloroquine, a 
concentration verified to be nontoxic to DLD-1 cells (Figure 3-7). This small-molecule 
drug is membrane-permeable at neutral pH, yet upon entering an acidic cellular 
compartment is protonated, rendering it membrane-impermeable and resulting in rapid 
accumulation of drug. This protonation raises compartment pH, decreasing the activity of 
hydrolases in acidic organelles such as the late endosome and lysosome.300–303 As shown 
in Figure 3-22, if enzymes are not inhibited, release rates in the presence of cells were 
substantially faster than release rates observed in solution (Figure 3-12). For example, in 
the case of cPR_b-targeted polymersomes, after 2 h approximately 80% release had 
occurred in the presence of uninhibited (0 m chloroquine) DLD-1 cells while 
approximately 30% release had occurred in simple buffered solution. However, when 
digestive enzymes were inhibited (500 m chloroquine) during delivery of the same 
polymersome formulation to DLD-1 cells approximately 35% of dye had been released 
after 2 h, nearly recovering solution release rates. Similar trends in relative release rates 
between inhibited and uninhibited cells could also be observed for nontargeted and 
cGRGDSP-targeted polymersomes.  
The rapid dye release seen in uninhibited cells was dramatically slower upon 
inhibition, suggesting that acidic conditions are necessary but not sufficient for rapid 
release and that enzymatic hydrolases play a major role in compromising polymersomes to 
rapidly release the encapsulated dye. By hydrolyzing the labile ester linkages in the PMCL 
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block curvature is induced in the polymersome membrane resulting in pore formation and 
payload release. This is a phenomenon active in triggering payload release in other 
degradable polymersomal delivery systems subject to hydrolysis240,241,304 and potentially 
affords a route to release of drug from the endosomal-lysosomal pathway into the cytosol. 
 Confocal Microscopy 
To better understand the trafficking and release of dye from polymersomes live-
cell confocal microscopy was used to directly visualize trafficking and release in DLD-1 
cells transfected to express both Rab5-GFP and LAMP1-RFP, markers of early endosomes 
and lysosomes respectively. Labeling of organelles using these fusion proteins allowed 
more selective labeling of organelles than is possible using more conventional dyes that 
rely upon accumulation in acidic organelles. Polymersomes encapsulating 5 mM calcein 
blue were administered in growth media for 2 h, unbound polymersomes washed away 
with warm growth media and cells imaged either immediately or 22 h later. The rapid 
image collection allowed by spinning disc confocal microscopy allowed visualization of 
trafficking in live cells in real time, but for analysis of colocalization still frames were used. 
  
















Figure 3-23: Confocal microscopy was used to visualize trafficking of nonquenching 
targeted polymersomes (9 mol% cPR_b) in live DLD-1 cells. Results shown here are for 2 
h at 37 °C. Cells were transfected to express LAMP1-RFP (lysosome, red channel) and 
Rab5-GFP (early endosome, green channel). Polymersomes encapsulated 5 mM calcein 
blue and nuclei stained with Hoechst 33342 (both blue channel). Scale bars indicate 10 μm. 
  
















Figure 3-24: Confocal microscopy was used to visualize trafficking of nonquenching 
targeted polymersomes (9 mol% cPR_b) in live DLD-1 cells. Results shown here are for 2 
h at 37 °C. Cells were transfected to express LAMP1-RFP (lysosome, red channel) and 
Rab5-GFP (early endosome, green channel). Polymersomes encapsulated 5 mM calcein 
blue and nuclei stained with Hoechst 33342 (both blue channel). Scale bars indicate 10 μm. 
  














Figure 3-25: Confocal microscopy was used to visualize trafficking of nonquenching 
targeted polymersomes (9 mol% cPR_b) in live DLD-1 cells without nuclear stain. Results 
shown here are for 2 h at 37 °C. Cells were transfected to express LAMP1-RFP (lysosome, 
red channel) and Rab5-GFP (early endosome, green channel). Polymersomes encapsulated 
5 mM calcein blue (blue channel). Scale bars indicate 10 μm. 
  
















Figure 3-26: Confocal microscopy was used to visualize trafficking of quenching targeted 
polymersomes (9 mol% cPR_b) in live DLD-1 cells. Results shown here are for 2 h at 37 
°C. Cells were transfected to express LAMP1-RFP (lysosome, red channel) and Rab5-GFP 
(early endosome, green channel). Polymersomes encapsulated 100 mM calcein blue and 
nuclei stained with Hoechst 33342 (both blue channel). Scale bars indicate 10 μm. 
  
















Figure 3-27: Confocal microscopy was used to visualize trafficking of quenching targeted 
polymersomes (9 mol% cPR_b) in live DLD-1 cells. Results shown here are for 2 h at 37 
°C. Cells were transfected to express LAMP1-RFP (lysosome, red channel) and Rab5-GFP 
(early endosome, green channel). Polymersomes encapsulated 100 mM calcein blue and 
nuclei stained with Hoechst 33342 (both blue channel). Scale bars indicate 10 μm. 
  
















Figure 3-28: Confocal microscopy was used to visualize trafficking of quenching targeted 
polymersomes (9 mol% cPR_b) in live DLD-1 cells. Results shown here are for 22 h at 37 
°C. Cells were transfected to express LAMP1-RFP (lysosome, red channel) and Rab5-GFP 
(early endosome, green channel). Polymersomes encapsulated 5 mM calcein blue and 
nuclei stained with Hoechst 33342 (both blue channel). Scale bars indicate 10 μm. 
  















Figure 3-29: Confocal microscopy was used to visualize trafficking of quenching targeted 
polymersomes (9 mol% cPR_b) in live DLD-1 cells. Results shown here are for 22 h at 37 
°C. Cells were transfected to express LAMP1-RFP (lysosome, red channel) and Rab5-GFP 
(early endosome, green channel). Polymersomes encapsulated 5 mM calcein blue and 
nuclei stained with Hoechst 33342 (both blue channel). Scale bars indicate 10 μm. 
  














Figure 3-30: Confocal microscopy was used to visualize trafficking of quenching targeted 
polymersomes (9 mol% cPR_b) in live DLD-1 cells. Results shown here are for 22 h at 37 
°C. Cells were transfected to express LAMP1-RFP (lysosome, red channel) and Rab5-GFP 
(early endosome, green channel). Polymersomes encapsulated 100 mM calcein blue and 
nuclei stained with Hoechst 33342 (both blue channel. Scale bars indicate 10 μm. 
  














Figure 3-31: Confocal microscopy was used to visualize trafficking of quenching targeted 
polymersomes (9 mol% cPR_b) in live DLD-1 cells. Results shown here are for 22 h at 37 
°C. Cells were transfected to express LAMP1-RFP (lysosome, red channel) and Rab5-GFP 
(early endosome, green channel). Polymersomes encapsulated 100 mM calcein blue and 
nuclei stained with Hoechst 33342 (both blue channel). Scale bars indicate 10 μm. 
  















Figure 3-32: Confocal microscopy was used to visualize trafficking of quenching targeted 
polymersomes (9 mol% cPR_b) in live DLD-1 cells without nuclear stain. Results shown 
here are for 22 h at 37 °C. Cells were transfected to express LAMP1-RFP (lysosome, red 
channel) and Rab5-GFP (early endosome, green channel). Polymersomes encapsulated 100 
mM calcein blue (blue channel). Scale bars indicate 10 μm. 
  














Figure 3-33: Confocal microscopy was used to visualize trafficking of quenching targeted 
polymersomes (9 mol% cPR_b) in live DLD-1 cells without nuclear stain. Results shown 
here are for 22 h at 37 °C. Cells were transfected to express LAMP1-RFP (lysosome, red 
channel) and Rab5-GFP (early endosome, green channel) while polymersomes 
encapsulated 100 mM calcein blue (blue channel). Scale bars indicate 10 μm. 
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Table 3-2: Manders coefficients were determined for cPR_b-functionalized polymersomes 
delivered to DLD-1 cells. These data were used to quantitatively describe colocalization 
between the blue channel (polymersomes) and either the green (early endosomes) or red 
(lysosomes) channels after 2 h and 24 h.287,288 M1 describes the portion of the blue channel 
that overlaps with either the red or the green channel while M2 describes the portion of the 
red or green channel that overlaps with the blue channel. Nonquenching dye concentrations 
(5 mM) were used to study trafficking while quenching concentrations (100 mM) were 
used to determine the location of intracellular dye release. In all calculations nuclei were 
omitted. Nonquenching analysis used Figure 3-24 and Figure 3-28 for 2 h and 24 h, 
respectively. For analysis of quenching formulations Figure 3-26 and Figure 3-31 were 
used for 2 h and 24 h, respectively. 
 
Time Channel M1 M2 Dye  
2 h green 0.3792 0.0402 5 mM 
2 h red 0.6405 0.0719 5 mM 
24 h green 0.0455 0.0211 5 mM 
24 h red 0.8452 0.1948 5 mM 
2 h green 0.0824 0.0337 100 mM 
2 h red 0.8694 0.4686 100 mM 
24 h green 0.0186 0.0902 100 mM 
24 h red 0.9290 0.1886 100 mM 
 
To study trafficking, calcein blue was encapsulated at a nonquenching 
concentration (5 mM), allowing visualization of concentrated dye regardless of release. 
The Manders coefficients were calculated after 2 and 24 h (Table 3-2), allowing a 
quantitative evaluation of colocalization.287,288 Here M1 describes the portion of blue from 
dye delivered in polymersomes that overlaps with endosomes (green) or lysosomes (red) 
while M2 describes the portion of the green or red channels that overlaps with blue. The 
values shown in Table 3-2 indicate that at early time points polymersomes had been 
trafficked to both the endosomes and the lysosomes. However, after 24 h the dye was 
predominantly colocalized with lysosomes. This result is consistent with previous reports 
of intracellular trafficking following binding to the α5β1 integrin.139,293,294. To verify that 
blue fluorescence was not entirely due to the nuclear stain, images were collected with 
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nonquenching concentrations of calcein blue but without the nuclear stain. In this case, 
similar colocalization patterns emerged as when Hoechst was present, an example of which 
can be seen in Figure 3-25. 
By encapsulating a self-quenching concentration of calcein blue into polymersomes 
(100 mM) it was possible to track where the payload was released as the dye would only 
be visible when diluted by release from the polymersomes. As in trafficking studies, 
colocalization was quantitatively determined using the Manders coefficients at 2 and 24 h 
(Table 3-2). In contrast to the nonquenching experiment, where some colocalization was 
observed between the early endosomes and the dye at early time points, for the quenching 
concentrations most colocalization of the dye was observed in the lysosomes even at 2 h. 
This trend is especially pronounced after 24 h, with very little colocalization between the 
early endosomes and calcein blue and more pronounced accumulations of blue dye within 
lysosomes. This release in the lysosomes (and to a lesser extent in the early endosomes) 
after 2 h is in keeping with the release rates shown Figure 3-12 and further emphasize the 
key role that digestive enzymes play in release of encapsulated payloads from delivery 
vehicles. As with nonquenching concentrations, images collected in the absence of nuclear 
stain had similar colocalization patterns as when the Hoechst was present, examples of 
which can be seen in Figure 3-32 and Figure 3-33. 
The observed rapid release is in stark contrast to the much slower release rate 
observed at even low pH in simple buffered solution, underscoring the role of enzymatic 
activity on intracellular payload release. Further, the fact that not all blue fluorescence from 
polymersomes overlaps with endosomes or lysosomes, particularly at later time points, 
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suggests that the entire payload is not ultimately sequestered in these organelles. 
Nonetheless, given the low expected fluorescence of dye dispersed in the cytosol, 
definitively establishing escape from the endosomal-lysosomal degradation pathway on the 
basis of this analysis alone is challenging. This question was instead addressed by 
determining if a drug delivered in the polymersomes that requires delivery to the cytosol 
or nucleus inhibits cell growth, as only drug that is released from these organelles would 
inhibit growth and drug sequestered in the endosomes or lysosomes would not be expected 
to affect viability. 
  
   137 
 
 
Figure 3-34: The IC50 value for free cisplatin, nontargeted polymersomes, cGRGDSP-
functionalized polymersomes (9 mol% cGRGDSP), and cPR_b-functionalized 
polymersomes (9 mol% cPR_b) was determined for DLD-1 cells following incubation for 
24 h at 37 °C. Free cisplatin had the lowest IC50, followed closely by cisplatin encapsulated 
in targeted polymersomes using the cPR_b peptide. Significantly more drug was necessary 
to inhibit cell growth when encapsulated in cGRGDSP-functionalized polymersomes, 
while approximately three times more cisplatin was required to inhibit cell growth when 
encapsulated in nontargeted polymersomes compared to free drug. In contrast, delivery to 
the CACO-2 cell line showed no significant difference from the nontargeted polymersomes 
regardless of the targeting peptide. Results (mean ± standard error) for the DLD-1 are from 
four separate experiments (n=4) each conducted in triplicate and results for the CACO-2 
are from three separate experiments (n=3) each conducted in triplicate. * Statistically 
significant difference from free drug (p<0.05), † no statistical difference from free drug 
(p>0.10), § statistically significant difference from nontargeted polymersomes (p<0.05), ‡ 
no statistical difference from nontargeted polymersomes (p>0.10) via paired t-test. 
 
Cisplatin Delivery 
Cisplatin was encapsulated into polymersomes and delivered to DLD-1 cells to 
determine if the enhanced binding of targeted polymersomes observed in Figure 3-11 and 
Figure 3-22 would yield commensurate gains in treatment efficacy. Cisplatin interacts with 
nucleic acids of rapidly-dividing cancer cells to hinder their growth and is not expected to 
inhibit growth if wholly sequestered in lysosomes.305,306 The well-established MTT 
viability assay, which relies on cellular metabolism to convert yellow (3-(4,5-
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dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to its purple formazan 
derivative, was used to determine the IC50 of DLD-1 and CACO-2 cultures following 
treatment with free cisplatin or the drug encapsulated in non-, cGRGDSP-, or cPR_b-
targeted polymersomes (Figure 3-34). Prior to cell studies, polymersomes were verified to 
encapsulate cisplatin, with encapsulation efficiencies (3-5%) on the lower side of previous 
reports using polymersomes to encapsulate drugs not amenable to ‘active’ loading.222,282,283 
Following encapsulation, polymersomes were verified to release the drug quite slowly in 
simple buffered media (Figure 3-5). 
Free drug required the lowest dose to inhibit growth using both α5β1-overexpressing 
DLD-1 cells and low α5β1-expressing CACO-2 cells, which was attributed to the drug being 
free to interact with the cell without first releasing from a polymersome. In contrast, when 
encapsulated in nontargeted polymersomes significantly more drug was necessary to 
inhibit growth. Given the results of polymer toxicity studies (Figure 3-9) this low toxicity 
from the cisplatin encapsulated in the nontargeted formulations is probably the result of 
drug release following limited delivery via the same nonspecific uptake pathway that was 
responsible for fluorescence in nontargeted formulations in Figure 3-11A and Figure 3-22. 
When a targeting peptide was used, the enhancements to binding and payload delivery 
compared to the nontargeted formulations, also as observed in these experiments, resulted 
in decreased viability for α5β1-overexpressing DLD-1 cells while IC50 values were not 
significantly affected for CACO-2 cells. For DLD-1 cells, the cGRGDSP peptide was 
effective relative to nontargeted polymersomes while cPR_b reduced the amount of 
cisplatin required by more than 50% relative to the nontargeted formulation. Statistical 
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comparison indicated no significant difference between the amounts of drug needed using 
cPR_b-functionalized polymersomes and free drug in DLD-1 cells. Taken together with 
the binding experiments shown in Figure 3-11 it can be seen that targeting with the cPR_b 
peptide not only enhanced binding to α5β1-overexpressing cells and delivery of the 
encapsulated drug but it also left almost unaffected cells with low levels of the targeted 
α5β1 integrin receptor.  
A substantial difference is apparent between relative binding (Figure 3-11), and 
relative growth inhibition, as observed in the IC50 (Figure 3-34). This difference is 
consistent with microscopy, which indicated that a substantial fraction of the 
polymersomes’ payload was delivered to the lysosomes, where it is physically sequestered 
away from nuclear DNA to which it would otherwise bind to inhibit cellular function and 
growth.12,307–310 Nonetheless, the effectiveness of cisplatin delivery using targeted 
polymersomes suggests the lysosome is not the only site of their delivery and release, as 
sufficient quantities of the cisplatin drug must be escaping from polymersomes and 
lysosomes following their uptake in order to see the observed growth inhibition.  
3.4 Conclusions 
Cisplatin therapy is often limited by major side effects and resistance. By tethering 
the cPR_b targeting peptide to the outside of PEO-PMCL polymersomes it was possible to 
obtain specific binding and uptake into α5β1-overexpressing human colon cancer cells, 
greatly exceeding the amount of binding seen with a cGRGDSP ligand while maintaining 
minimal binding to cells with low levels of α5β1 expression. Intracellular release was 
tracked and imaged by a combination of fluorescent plate assays and live-cell confocal 
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microscopy. The effect of pH alone on polymer degradation and payload release rates was 
found to be minimal from pH 7.4 to 4.5. Release occurred much more rapidly following 
endocytosis and the slower solution release rates could be recovered by inhibiting enzymes 
in acidic organelles, implicating enzymatic hydrolysis as a key mode of release for PEO-
PMCL polymersomes. When cPR_b-functionalized polymersomes were used to 
encapsulate cisplatin, toxicity to α5β1-overexpressing cells outperformed nontargeted and 
cGRGDSP-functionalized polymersomes, with IC50 values on par with those of the free 
drug, while maintaining low levels of toxicity to cells expressing low levels of the integrin. 
PEO-PMCL polymersomes with cPR_b targeting appear to be promising carriers for 
minimizing side effects due to nonspecific delivery into α5β1-overexpressing cancer cells. 
Despite these encouraging results, the lack of degradability in simple buffered 
solutions, even those with quite acidic conditions, may hamper efforts towards the kind of 
responsive, triggered release of payload that remains a major goal in the drug delivery 
literature. The next chapter addresses efforts to develop new means to introduce acid-
sensitive functionality in the polymer chain make it more prone acidic degradation and 
enhance the triggered release capability of future drug delivery systems. 
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4 Controlled Polymerization of an Acetal-Containing 
Polyester for Hydrolysis in Acidic Conditions 
4.1 Introduction 
The previous chapters addressed the synthesis (Chapter 2) and application (Chapter 
3) of the amphiphilic diblock copolymer PEO-PMCL and its reactive analog VS-PEO-
PMCL. However, this polyester-based system proved slow to degrade in the acidic 
conditions experienced following endocytosis into target cells, hindering payload release. 
This chapter describes efforts to address these shortcomings by developing a polymer that 
integrates a more pH-sensitive functional group to enhance treatment efficacy by triggering 
polymer degradation and payload release under mildly acidic conditions. 
Environmentally-responsive polymers have proven to be an extremely rich area of 
research, opening new avenues to address longstanding needs unmet by conventional 
macromolecules. Contributions have been made to the fields of biomedicine, sensing, 
electronics, textiles, and filtration, among others.311–317 A major focus of interest has been 
on polymers that are sensitive to changes in pH for drug delivery vehicles which are 
capable of payload release near or inside of targeted cancer cells.85,149,318,319 This approach 
to delivery takes advantage of the fact that in comparison to physiological conditions in the 
bloodstream (pH 7.4), the environments in the vicinity of a tumor (pH 5.5-6.5) and in the 
endosome following uptake (pH 5.0–5.5) tend to be more acidic.320,321  
Polymers sensitive to changes in pH are generally of two main classes. The first 
class is composed of macromolecules that incorporate a protonatable moiety capable of a 
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reversible ionization state, generally resulting in a change to either solubility or 
conformation.322,323 The second class is comprised of polymers that undergo irreversible 
degradation.324 Simple polyesters, including those described in the previous chapters, are 
an example of this second class, and have been used extensively.280,325–328 However, to 
induce rapid degradation and payload release in physiologically-relevant pH ranges, more 
acid-labile degradable groups are required due to the slow hydrolysis rates of many 
polyesters at mildly-acidic pH values.  
 
Figure 4-1: Structure of acetals, the group used to enhance pH-responsive degradation. A) 
General structure of acetals and equilibria with acid-catalyzed hydrolysis to the aldehyde 
via the hemiacetal. B) Structure of a polymer with acetals in the backbone and structure 
after acid-catalyzed hydrolysis. In the case of ketals, the hydrogen in the aldehyde and 
derivatives is replaced by an arbitrary substituent. 
Acetals and ketals (Figure 4-1) are classes of functional group that have been 
investigated extensively for triggered degradation in acidic conditions. Interest has been 
particularly focused on drug delivery applications due to the groups’ relative resistance to 
hydrolysis at physiological pH (7.4) but rapid degradation in acidic conditions analogous 
to those of the endosomal compartment (pH 5.0-5.5) after endocytosis.24,320,329 The precise 
rate of degradation is affected by both the substituents present330,331 and the hydrophilicity 
of the polymer.332,333  
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Figure 4-2: Examples of approaches used to incorporate acid-labile acetal or ketal 
functionality into polymers, including A) in the polymer backbone following step-growth 
polymerizations,334,335 B) as pendant groups following step-growth336 or conventional 
radical333 polymerizations, and C) as part of the backbone following Ru-catalyzed 
methathesis337 or an analogous acid-catalyzed acetal exchange polymerization.338Many 
polymers incorporating acetal or ketal functional groups have been synthesized (some 
sample structures are shown in Figure 4-2), but often by means that complicate their use in 
drug delivery applications. Synthesis has generally been either by uncontrolled cationic339–
341 or step-growth334,335,342–346 polymerizations, which result in polydisperse systems that 
complicate achieving specific self-assembled morphologies, or as nondegradable polymers 
which incorporate acetal functionality only as pendant groups,336,347–349 potentially limiting 
post-delivery clearance of the polymer from the body. Interesting new approaches have 
also been investigated, including Ru-catalyzed metathesis337,350 and a metathesis analog 
using acid-catalyzed acetal exchange reactions.338 Such approaches may mitigate some of 
the disadvantages of existing synthetic methods while still incorporating a diverse range of 
acetals in the polymer backbone, but cannot be easily integrated into existing approaches 
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to synthesizing amphiphiles to target promising self-assembled nanocarrier morphologies 
such as polymersomes or wormlike micelles.207,219,234  
This chapter reports on efforts to develop 2-methyl-1,3-dioxan-4-one (MDO) as a 
cyclic ester monomer for ring-opening transesterification polymerization (ROTEP) to a 
polyester which contains acetals in the backbone for triggered degradation in low-pH 
conditions. The chapter includes structural and kinetic characterization of the 
polymerization of MDO into two distinct polymers, the nearly acetal-free poly(3-
hydroxypropionic acid) (P-3(HPA)) and the acetal-retaining poly(2-methyl-1,3-dioxan-4-
one) (PMDO). Thermodynamic parameters for polymerization of MDO to PMDO were 
measured from equilibrium monomer concentrations, and the degradation behavior of 
these polymers when exposed to physiologically-relevant pH conditions was investigated 
and compared. 
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4.2 Results and Discussion 
 
Figure 4-3: Scheme depicting the synthesis of MDO monomer and bulk polymerizations 
using diethylzinc to P(3-HPA) at higher catalyst loadings (with loss of acetal functionality) 
or to high-acetal PMDO at lower loadings of the catalyst. 
 
Figure 4-4: 1H NMR spectra and proton assignments for A) 2-methyltetrahydrofuran-3-
precursor and B) 2-methyl-1,3-dioxan-4-one (MDO) after Baeyer-Villiger oxidation and 
purification. 
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Figure 4-5: 13C NMR spectra and structural assignments for A) 2-methyltetrahydrofuran-
3-one starting material and B) MDO monomer after purification from Baeyer-Villiger 
oxidation of the furanone precursor. 
 
Figure 4-6: COSY spectrum of MDO monomer with proton assignments.  
   147 
 
Synthesis of 2-methyl-1,3-dioxan-4-one (MDO) 
MDO is a cyclic ester that incorporates acetal functionality and would be expected 
to decompose to 3-hydroxypropionic acid and acetaldehyde upon hydrolysis. To synthesize 
this monomer, racemic 2-methyltetrahydrofuran-3-one was treated with meta-
chloroperoxybenzoic acid (mCPBA), resulting in Baeyer-Villiger oxidation to obtain 
MDO following workup and distillation. The reaction is shown in Figure 4-5 and the 
monomer was characterized by several techniques, including 1H NMR spectroscopy 
(Figure 4-4), 13C NMR spectroscopy (Figure 4-5), and 2-D homonuclear correlation 
spectroscopy (COSY, Figure 4-6). To the best of our knowledge, this is a novel route to 
this molecule, which previously has been reported in the French and Japanese patent 
literature, but only as the product of a ring-closing reaction between 3-hydoxypropionic 
acid and acetaldehyde.351,352 
   148 
 
 
Figure 4-7: Bulk polymerization of MDO in the presence of PEO methyl ether (2 kg mol-
1) macroinitiator using tin octoate catalyst at 60 °C and 110 °C ([MDO]o/[PEO]o = 200, 
[SnOct2]o ≈ 10 mM). Some shift of the initiator peak occurred towards lower elution 
volumes, suggesting polymerization from PEO, but formation of oligomers was significant 
and molar mass distributions were very broad for all temperatures and polymerization 
times. 
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Figure 4-8: Solution polymerizations of MDO in the presence of PEO methyl ether (2 kg 
mol-1 ) macroinitiator using TEA catalyst ([MDO]o = 1.5 M, [PEO]o = 7.5 mM, Tpolym = 60 
°C, tpolym = 1 h) at two concentrations in CH2Cl2 ([TEA]o/[PEO]o = 1.1 and [TEA]o/[PEO]o 
= 2.2) as well as a reaction in THF ([TEA]o/[PEO]o = 1.1). Some shift of the initiator peak 
to lower elution volumes was accompanied by the formation of high molar mass molecules 
with very broad molar mass distributions.  
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Figure 4-9: Bulk polymerization of MDO using TBD catalyst at room temperature and 
PEO methyl ether as a macroinitiator ([TBD]o = 30 mM, [MDO]o/[PEO]o = 200). After an 
initial monomodal increase in molar mass, no further conversion occurred over multiple 
days until more TBD was added, which resulted in a rapid shift to lower elution volumes 
with some broadening of the molar mass distribution. 
 
Early Polymerization Efforts 
Polymerization of MDO was first attempted using PEO methyl ether (2 kg mol-1) 
as an initiator and several common catalyst systems: stannous octoate (SnOct2), triethyl 
aluminum (TEA) and triazabicyclodecene (TBD). These reactions were attempted either 
in the bulk (SnOct2, TBD), or in solution (TEA). In trial reactions using stannous octoate 
([SnOct2]o ≈ 10 mM, Tpolym = 110 °C and 60 °C), and triethyl aluminum ([MDO]o ≈ 1.5 M, 
[TEA]o = 8.25 mM or 16.5 mM, Tpolym = 60 °C in both THF and CH2Cl2), some higher 
molar mass species were observed in SEC elugrams, but monomer conversions were low 
   151 
 
and molar mass distributions were extremely broad (Ð > 3.0, Figure 4-7 and Figure 4-8). 
Due to the poor control over these polymerizations, both tin octoate and TEA were not 
pursued further for polymerization of MDO. In the case of the TBD-catalyzed bulk 
polymerization of MDO at room temperature ([TBD]o = 30 mM), only minimal monomer 
conversion occurred unless large amounts of catalyst were added (Figure 4-9). Due to the 
inefficiency of this approach, this route to MDO polymerization was also abandoned. More 
detailed information regarding these early efforts can be found in the Experimental section. 
Table 4-1: Several polymers were synthesized by diethylzinc-catalyzed bulk 
polymerization of 2-methyl-1,3-dioxan-4-one (MDO) monomer using benzyl alcohol as 
the initiator. At higher catalyst loadings, nearly all acetal groups were eliminated as 
acetaldehyde, resulting in P(3-HPA). The number average degree of polymerization (by 1H 

















HPA110 140 7.92 7.7* 1.14* 72.02 <1 -33.2 58.4 
HPA131 120 9.46 8.9* 1.22* 72.02 <1 -31.3 73.1 
HPA594 31 42.8 35.2* 1.23* 72.02 <1 -27.0 78.5 
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Figure 4-10: Representative A) 1H and B) 13C NMR spectra and structural assignments of 
P(3-HPA) samples synthesized by diethylzinc-catalyzed polymerization of MDO at higher 
(20 mM - 150 mM) catalyst concentrations. Spectra here are from sample HPA594 (42.8 
kg mol-1), where polymerization was conducted in the bulk at room temperature with 
[ZnEt2]o = 31 mM, [BnOH]o = 15.2 mM, and tpolym = 8 h. Characterization data for these 
polymers are summarized in Table 4-1 and NMR spectra for other molar masses of P(3-
HPA) can be found in Figure 4-24. 
Synthesis of Poly(3-hydroxypropionic acid) (P(3-HPA)) 
Diethylzinc (ZnEt2), a catalyst used in the past for polymerization of cyclic 
esters,353–355 was investigated for bulk polymerization of MDO using benzyl alcohol as the 
initiator. Under these conditions ([MDO]o = 10.1 M, [BnOH]o = 100.7 mM, [ZnEt2]o = 2.0 
mM, tpolym = 8 h, room temperature), combining MDO with a twofold excess of diethylzinc 
with respect to benzyl alcohol resulted in rapid polymerization to high fractional monomer 
conversions (>95%) with relatively narrow molar mass distributions (Ð < 1.3). Several 
polymers were synthesized in this manner, using varying ratios of [MDO]o/[BnOH]o to 
generate polymers with molar masses from 7.92 kg mol-1 to 42.8 kg mol-1 (Table 4-1). 
These polymers could be isolated from the residual monomer by precipitation, forming 
white solids. In all cases, NMR spectra of these polymers contained only a small fraction 
(< 1%) of the characteristic acetal methyl and methine resonances present in the monomer, 
while methylene resonances persisted after polymerization (δ = 4.35 and 2.65 ppm in the 
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1H NMR spectrum; 60.25 and 33.76 ppm in the 13C NMR spectrum, Figure 4-10). This, 
along with the loss of methylene proton splitting due to the acetal stereocenter, suggested 
that acetal functionality was no longer present following polymerization. Efforts to 
synthesize P(3-HPA) polymers with molar masses beyond approximately 50 kg mol-1 were 
met inconsistent final molecular weights and may have been limited by initiation due to 
residual monomer hydrolysis products with similar boiling points to MDO that were 
incompletely removed by distillation. 
 
Figure 4-11: Electrospray ionization (ESI-MS) mass spectra of P(3-HPA) for several molar 
masses using 9:1 MeOH:CH2Cl2, where the numbers in sample names indicate the number-
average degree of polymerization. The repeat unit of m/z = 72.02 found in all polymers is 
consistent with a molecule lacking MDO’s acetal functionality, resulting in a 3-HPA repeat 
unit. High molar mass peaks were not observed, potentially as a result of polymer 
fragmentation during ionization. Exact m/z values for all polymers were consistent with 
retention of a single acetal, possibly as an uneliminated end group. For HPA131 and 
HPA594, a peak consistent with a methanol adduct could also be observed. 
Characterization data for these polymers is summarized in Table 4-1. 
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Figure 4-12: DSC thermograms for P(3-HPA) samples, with the numbers in sample names 
indicating the number-average degree of polymerization. Clear melting transitions were 
apparent for these polymers, ranging from 58.4 °C to 78.5 °C, indicating crystallinity. The 
glass transition temperature was quite low, ranging from -27.0 °C to -33.2 °C. Traces have 
been shifted vertically to aid visual comparison but relative peak heights and slopes have 
not been adjusted. Characterization data for these samples are summarized in Table 4-1. 
To verify the structural assignment of P(3-HPA) to these polymers, electrospray 
ionization mass spectrometry (ESI-MS) was used to verify the repeat unit and differential 
scanning calorimetry (DSC) was used to measure thermal properties for comparison with 
previous work. While high molar mass ions were not observed in mass spectra (Figure 
4-11), fragments could be clearly distinguished with a repeat of m/z = 72.02, consistent 
with the expected repeat unit for P(3-HPA). The exact m/z values of fragments were 
consistent with the presence of a single acetal-containing repeat unit (discussed in more 
detail below when considering a possible polymerization mechanism in Figure 4-14), as 
well as the expected m/z values for acetal-free P(3-HPA). DSC thermograms (Figure 4-12) 
of each polymer contained a clear glass transition temperature (Tg) ranging from -27.0 °C 
to -33.2 °C, and a melting endotherm at a temperature (Tm) ranging from 58.4 °C to 78.5 
°C. Values of both Tg and Tm were consistent with those reported previously for P(3-HPA) 
synthesized by a macrocyclic route, 356 and further supported the structural assignments 
made for this polymer using NMR spectroscopy and mass spectroscopy. 
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Figure 4-13: To investigate the loss of the MDO acetal functionality, the polymerization of 
MDO to P(3-HPA) was performed in CD2Cl2 to allow in situ tracking of byproducts using 
1H NMR spectroscopy. As the polymerization proceeded, the increase in resonances from 
P(3-HPA) methylene protons at 4.35 (b) and 2.65 ppm (c) was accompanied by a 
commensurate increase in resonances at δ = 9.77 (a) and 2.18 (d) ppm consistent with 
acetaldehyde. Polymerizations were conducted using [MDO]o = 1 M, [BnOH]o = 10 mM, 
and [ZnEt2]o = 20 mM at room temperature. 
In an effort to determine the source of acetal loss, a solution polymerization of 
MDO was set up at room temperature in CD2Cl2 ([MDO]o = 1 M, [BnOH]o = 10 mM, and 
[ZnEt2]o = 20 mM) to allow tracking of both polymerization and evolution of byproducts 
in situ (Figure 4-13). As MDO was converted to P(3-HPA), apparent as an increase in 
MDO methylene resonances at 4.35 and 2.65 ppm, a proportional increase was also 
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observed in resonances at 9.77 and 2.18 ppm consistent with acetaldehyde, the expected 
aldehyde form of the acetal group present in MDO.  
Combined with the NMR and mass spectroscopic characterization data above, these 
results suggested that the loss of acetal functionality that occurred during polymerization 
of MDO to P(3-HPA) was the result of elimination of acetaldehyde, which is a gas at room 
temperature. This ROTEP-elimination reaction is analogous to ring opening-elimination 
reactions used to form synthetic polypeptides, in which CO2 is eliminated as a volatile 
byproduct.357,358  
 
Figure 4-14: Proposed mechanism for elimination of acetaldehyde from MDO to form P(3-
HPA). At higher ZnEt2 catalyst concentrations, following the coordination-insertion ring-
opening of MDO,359,360 two zinc sites can complex with the acetal-containing chain end 
and undergo chain transfer, eliminating acetaldehyde and leaving a 3-HPA repeat unit. At 
lower catalyst concentrations, the incidence of two such sites forming the required 
transition state shown in this mechanism is quite low, minimizing elimination and leading 
to retention of the acetal in PMDO. 
A possible mechanistic route explaining why acetaldehyde was lost at high catalyst 
concentrations, while the acetal group is retained at lower catalyst concentrations, is shown 
in Figure 4-14. Here, following the coordination-insertion ring-opening of MDO by zinc 
by the standard mechanism,359,360 a second catalytic site coordinates with the acetal end 
group. At this point, chain transfer to the second catalytic site occurs, leading to elimination 
of the acetal as acetaldehyde and leaving a 3-HPA repeat unit. Due to the increased entropy 
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associated with loss of this volatile byproduct, this process would be expected to be quite 
thermodynamically favorable. At lower catalyst concentrations, the decreased likelihood 
of two such sites forming the required complex results in retention of the acetal to form an 
MDO repeat unit. This mechanism explains the results of P(3-HPA) ESI-MS (Figure 4-11), 
where exact masses were observed consistent with a single acetal unit being present. In a 
polymerization where the catalyst concentration is sufficiently high, prior to coordination 
with the second catalytic site the chain would be expected to contain a single acetal as an 
end group. While increasing [ZnEt2] was found anecdotally to increase the polymerization 
rate in reactions forming both P(3-HPA) and PMDO, in the absence of direct measurement 
of the order of the reaction in catalyst, kinetic data were fit to the pseudo-first order rate 





) = 𝑘𝑎𝑝𝑝 ∙ 𝑡 
Figure 4-15: Pseudo-first order rate law used to fit kinetics data for polymerization of MDO 
to form P(3-HPA) and PMDO. 






Figure 4-16: Diethylzinc-catalyzed bulk polymerization of MDO to low-acetal P(3-HPA) 
was tracked by 1H NMR spectroscopy and SEC of aliquots taken during polymerization. 
A) When monomer conversion was tracked by 1H NMR spectroscopy, conversion data 
indicated that within several hours the polymerization was essentially complete. The first 
several hours of polymerization (up to 90% monomer conversion) were linearized (inset) 
using Figure 4-15 to determine the apparent first order rate constant kapp = 0.24 h
-1 at 23 
°C, [MDO]o = 9.26 M, [BnOH]o = 46.3 mM, and [ZnEt2]o = 87 mM. B) Molar mass (●, 
apparent Mn versus polystyrene standards) and the molar mass distribution (○, Ð) were also 
tracked by SEC during this reaction. Molar mass increased linearly with conversion of 
monomer, consistent with a controlled polymerization, and the molar mass distributions 
were relatively narrow (Ð < 1.3) throughout the polymerization. 
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In order to more fully characterize the behavior of diethylzinc-catalyzed bulk 
polymerizations of MDO to P(3-HPA), the reaction was tracked by both 1H NMR 
spectroscopy and SEC of aliquots removed during the reaction. As shown in Figure 4-16A, 
within 5 h nearly 90% of MDO had been converted to P(3-HPA). To extract kinetic 
parameters for the polymerization, conversion data from this 5 h portion were used. Using 
Figure 4-15 and the experimentally determined ρMDO = 1.183 g mL-1 and the literature 
value361 of ρP(3-HPA) = 1.38 g mL-1, it was possible to extract the pseudo-first order rate 
constant kapp = 0.24 h
-1 at 23 °C when [MDO]o = 9.26 M, [BnOH]o = 46.3 mM, and [ZnEt2]o 
= 87 mM (inset, Figure 4-16A). The apparent molar mass of the aliquots was also 
determined using SEC, and was plotted as a function of monomer conversion (Figure 
4-16B). The correlation between these values was linear, consistent with a controlled 
polymerization, and the breadth of the molar mass distribution remained relatively low (Ð 
< 1.3) throughout the polymerization. 
The polymerization of MDO using relatively high catalyst loadings ([ZnEt2]o = 20 
mM - 150 mM) provides a route to P(3-HPA) with only trace incorporation of the acetal 
functionality, with the vast majority of the hydrolytically labile linkage eliminated during 
polymerization as volatile acetaldehyde. This represents a new route to controlled 
polymerization yielding P(3-HPA) in the bulk over practically convenient time periods 
with molar mass distributions narrower than existing condensation,362 microbial,363,364 
ring-opening,365–368 and macrocyclic356 syntheses. 
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Table 4-2: Several polymers were synthesized by diethylzinc-catalyzed bulk 
polymerization of 2-methyl-1,3-dioxan-4-one (MDO) monomer using benzyl alcohol as 
the initiator. At low catalyst loadings, the acetal group was retained, resulting in PMDO. 
The number average degree of polymerization (by 1H NMR spectroscopy) for each 

















MDO66 1.7 7.64 8.1* 1.62* 116.05 >98 -32.3 - 
MDO77 1.3 8.96 11.1* 1.62* 116.05 >98 -25.7 - 
MDO259 0.41 30.1 33.8* 1.61* 116.05 >98 -31.1 - 






Figure 4-17: Representative A) 1H and B) 13C NMR spectra and structural assignments of 
PMDO synthesized by diethylzinc-catalyzed polymerization of MDO at lower (0.41 mM 
– 1.7 mM) catalyst concentrations. Spectra here are from sample MDO259 (30.1 kg mol-
1), where the polymerization was conducted in the bulk at room temperature using [ZnEt2]o 
= 0.41 mM, [BnOH]o = 20.3 mM, and tpolym = 120 h. Characterization data for these 
polymers are summarized in Table 4-2, and NMR spectra for other molar masses of PMDO 
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Synthesis of Poly(2-methyl-1,3-dioxan-4-one) 
To explore the effect of catalyst loading on polymer structure, bulk polymerization 
of MDO was also undertaken using ZnEt2 at much lower concentrations ([ZnEt2]o = 0.41 
mM – 1.7 mM). Several molar masses were targeted by varying the initial ratio of MDO 
monomer to benzyl alcohol initiator at room temperature. Under these conditions, as the 
polymerizations proceeded, the viscosity of the mixture slowly increased over several days, 
but the reaction remained a clear liquid rather than the white solid that developed during 
higher-catalyst polymerizations forming P(3-HPA). The polymer could be isolated from 
remaining monomer by opening the vessel to air to quench polymerization, dissolution of 
the reaction mixture in CH2Cl2, and precipitation into 9:1 hexanes:tetrahydrofuran to 
isolate a clear, viscous liquid. NMR spectra contained clear resonances from acetal 
methane and methine groups with integrations of 1H NMR spectra consistent with nearly 
complete retention of this functional group (δ = 5.92 and 1.33 ppm in 1H NMR spectrum; 
96.59 and 32.23 ppm in 13C NMR spectrum, Figure 4-17). Also, the distinct splitting 
pattern of methylene protons due to the acetal stereocenter in the monomer (multiplets at δ 
= 4.22 and 3.94 ppm), lost in P(3-HPA), was preserved under these conditions (δ = 3.88 
and 3.76 ppm). However, SEC of polymers prepared under these conditions indicated that 
molar mass distributions were broader than those observed for P(3-HPA) (Ð ≈ 1.6), an 
aspect of these polymerizations that will be discussed below. Additionally, synthesis of 
high PMDO with molar mass beyond approximately 50 kg mol-1 was, as with P(3-HPA), 
inconsistent, potentially due to initiation from residual monomer hydrolysis products. 
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Figure 4-18: ESI-MS in 9:1 MeOH:CH2Cl2 for several molar masses of PMDO, with 
numbers in the sample names indicating the number-average degree of polymerization. As 
with P(3-HPA) samples, high molar mass ions were not observed, but the repeat unit is 
consistent with that expected for retention of the MDO monomer’s acetal functionality to 




Figure 4-19: DSC thermograms for PMDO samples, with the numbers in sample names 
indicating the number-average degree of polymerization. Unlike P(3-HPA), no significant 
crystallinity was observed in PMDO samples, as evidenced by the lack of a melting 
endotherm. The glass transition temperature (Tg) for PMDO, like that of P(3-HPA) 
polymers, was quite low, ranging from -25.7 °C to -32.3 °C. Traces have been shifted 
vertically to aid visual comparison but relative peak heights and slopes have not been 
adjusted. Characterization data for these samples are summarized in Table 4-2. 
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To verify that the polymer produced at low catalyst loadings was structurally 
distinct from P(3-HPA), ESI-MS and DSC were again used. ESI-MS was used to determine 
the polymers’ repeat unit (Figure 4-18), allowing identification of a repeating unit of m/z 
= 116.05, the expected value for a polymer retaining MDO’s acetal functionality in each 
repeat unit. Thermal properties also departed from those observed for P(3-HPA). While 
glass transition temperatures remained low (Tg = -25.7 °C to -32.3 °C), no melting 
endotherms were observed (Figure 4-19). 
The combination of diverse characterization data for this polymer (summarized in 
Table 4-2) indicate that by decreasing the catalyst concentration in the polymerization 
medium acetal functionality could be retained with minimal elimination as acetaldehyde, 
leading to PMDO, a chemically distinct polymer from P(3-HPA), as summarized in Figure 












Figure 4-20: Bulk polymerization of MDO to high-acetal PMDO at low diethylzinc 
concentrations was monitored by analyzing 1H NMR spectra and SEC elugrams of aliquots 
removed during the polymerization. A) Monomer conversion (●) was tracked by 1H NMR 
spectroscopy. Results showed that MDO monomer was not fully consumed even at longer 
reaction times and that the reaction ceased to consume monomer beyond [M]t/[M]o ≈ 0.6. 
The first 150 h (○, to approximately 50% monomer consumption) of the polymerization 
were linearized using Figure 4-15 to determine the apparent first order rate constant kapp = 
0.0079 h-1 where [MDO]o = 10.1 M, [BnOH]o = 49.4 mM, and [ZnEt2]o = 1.0 mM using 
[M]eq = 4.53 M at room temperature. B) Apparent molar mass (Mn, ●) and molar mass 
distribution (Ð, ○) were tracked by SEC. Consistent with a controlled polymerization, the 
relationship between monomer consumption and molar mass was linear. Polydispersity 
was relatively high, which may have been the result of significant depolymerization 
throughout the reaction due to the relatively high value of [M]eq. No values of Ð are 
reported for early time points due the inherent inaccuracy of measuring this value at very 
low molar mass. 
   165 
 
Kinetics of Polymerization of MDO to PMDO 
Bulk polymerization of MDO at low catalyst loadings ([BnOH]o = 49.4 mM and 
[ZnEt2]o = 1.0 mM at room temperature) was tracked by removing aliquots from the 
reaction and analyzing them by 1H NMR spectroscopy and SEC. Tracking monomer 
consumption by 1H NMR spectroscopy (Figure 4-20A) revealed that in contrast to 
polymerizations at higher catalyst loadings yielding P(3-HPA), polymerizations yielding 
PMDO reached much lower monomer conversions (under 60%), and were much slower 
(approximately 200 h to reach [M]t/[M]o = 0.5). Using measured values of ρMDO = 1.183 g 
mL-1 and ρPMDO = 1.421 g mL-1, it was determined that at room temperature [M]eq = 4.53 
M. Using this value of [M]eq, the conversion data were again linearized using Figure 4-15 
to determine the room temperature pseudo-first order rate constant kapp = 0.0079 h
-1 under 
these reaction conditions. This indicates reaction times on the order of several days are 
necessary in order to attain sufficiently high conversions for most practical applications. 
SEC was used to track the evolution of molar mass and polydispersity during the 
polymerization (Figure 4-20B). Plotting of molar mass versus consumption of monomer 
indicated the relationship was linear (R2 = 0.968), suggesting a controlled polymerization. 
However, the breadth of the molar mass distribution (Ð > 1.5) exceeded the low values 
observed for the polymerization of P(3-HPA) and many other controlled polymerizations. 
This behavior may be the result of the relatively high value of [M]eq (4.53 M under these 
conditions). As the concentration of monomer at any point of polymerization is not far 
from the equilibrium monomer concentration (i.e. [M]t >> [M]eq is not satisfied), it is likely 
that depolymerization is significant even at low monomer conversions. This may lead to 
broader molar mass distributions than when polymerization is nearly irreversible, and is a 
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phenomenon that has been explored in previous theoretical and experimental studies.369–
373  
 
Figure 4-21: Polymerization thermodynamics for polymerization of MDO to PMDO. 
Parallel polymerizations were performed in the bulk using [BnOH]o = 223 mM and 
[ZnEt2]o = 4.33 mM at a range of temperatures, with polymerizations allowed to proceed 
for at least two weeks to ensure that equilibrium had been reached before quenching at the 
reaction temperature. Final monomer conversions were used to calculate values of [M]eq at 
each temperature using ρMDO = 1.183 g mL-1 and ρPMDO = 1.421 g mL-1. Using these data 
and Figure 4-22 (taking [M]s = 1 M) it was possible to calculate ΔHp = -11.6 kJ mol-1 and 






) =  ∆𝐻𝑝 (
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𝑇
) − ∆𝑆𝑝 
Figure 4-22: Equation used to determine thermodynamic parameters ΔHp and ΔSp from 
equilibrium monomer concentration measurements (Figure 4-21), where [M]s was taken 
to be 1M.  
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Thermodynamics of MDO Polymerization to PMDO 
To further characterize and explore the source of the limited polymerization 
observed in low-catalyst reactions producing PMDO, a number of polymerizations with 
identical starting conditions ([MDO]o = 10.1 M, [BnOH]o = 223 mM and [ZnEt2]o = 4.33 
mM) were allowed to reach equilibrium over at least two weeks at a variety of temperatures 
and quenched at the polymerization temperature. By using 1H NMR spectroscopy to 
measure the amount of remaining monomer at each of these temperatures and using 
measured values of ρMDO = 1.183 g mL-1 and ρPMDO = 1.421 g mL-1, a linear fit to Figure 
4-22 was used to determine that the thermodynamic parameters for this polymerization 
were ΔHp = -11.6 kJ mol-1 and ΔSp = -51.8 J mol-1 K-1 (Figure 4-21). Using these 
thermodynamic parameters and the density of MDO, the theoretical ceiling temperature for 
neat monomer was calculated to be 90.6 °C.341 The enthalpic component was consistent 
with similar measurements of other six-membered lactones with similar chemical structure, 
such as δ-valerolactone (-8.4 to -10.5 kJ mol-1), and δ-caprolactone (-13.8 kJ mol-1),374 
though less than that observed for δ-decalactone (-17.1 kJ mol-1).375 In contrast, the entropic 
component, while unfavorable as expected, was more significant than most of these similar 
molecules. At -51.8 J mol-1 K-1 it was more unfavorable than δ-valerolactone (-14.7 to -
15.0 J mol-1 K-1), and δ-caprolactone (-41.2 J mol-1 K-1),374 and was closer to that observed 
for δ-decalactone (-54 J mol-1 K-1).  
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Figure 4-23: Degradation of polymers as a function of pH. Both A) P(3-HPA) and B) 
PMDO were subjected to degradation at room temperature in a 100 mM phosphate-citrate 
buffer at pH 7.4, 6.4, 5.4 and 4.4. Samples were periodically lyophilized and analyzed by 
SEC to determine changes in molar mass. In P(3-HPA), which lacks the acetal linkage, 
little degradation occurred even at low pH. In PMDO, where acetal linkages were preserved 
during polymerization, degradation was observed at all pH values, with an increase in 
degradation rates as the pH decreased. 
 




Having characterized the syntheses of P(3-HPA) and PMDO, it was essential to 
determine the degradation characteristics of these polymers to assess their susceptibility to 
degradation under conditions relevant for drug delivery applications. Samples of PMDO, 
with initial SEC apparent molar mass of 17.9 kg mol-1, and P(3-HPA), with initial SEC 
apparent molar mass of 8.1 kg mol-1, were subjected to treatment with a 100 mM 
phosphate-citrate buffer at pH 7.4, 6.4, 5.4, and 4.4. Degradation was tracked using the 
apparent molar mass from SEC elugrams of samples taken during the experiment (Figure 
4-23). In the P(3-HPA) system, little degradation was observed at any pH. This lack of 
degradation may be due to a combination of the crystallinity present in the polymer and its 
relative hydrophobicity. These results are consistent with previous work using PMCL,328 
which under comparable conditions did not degrade appreciably over several weeks. They 
are also consistent with experiments performed using homopolymers and block 
copolymers of polylactide and polymenthide,376 which degraded substantially over a time 
scale of weeks to months, but showed little hydrolysis over the much shorter 10 day time 
span monitored here. In contrast, PMDO experienced significant degradation at all pH 
levels. PMDO degradation was considerably faster at lower pH, with apparent molar mass 
decreasing six fold over 240 h at pH 4. This result is faster than that observed for the 
polyesters mentioned above, and broadly consistent with the relative rates of degradation 
observed in the past for other systems incorporating acetal linkages.343 Degradation was, 
as expected, slower than that observed for the more hydrolytically-sensitive ketals.335,345  
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4.3 Conclusions 
A key attribute for effective targeted drug delivery is triggered release of the 
payload from the carrier upon reaching the target site. In targeted cancer therapy, low pH 
is a particularly appealing trigger for release due to the combination of subphysiological 
pH within tumors and a further, pronounced increase in acidity experienced by the carrier 
following cellular uptake into the endosome. Our previous efforts to induce pH-triggered 
release from polymeric carriers with simple polyester backbones were limited by negligible 
degradation at physiologically-relevant low pH conditions. This prompted the current 
investigation of integrating the more acid-labile acetal linkage into the polyester backbone. 
To make a polymer containing an acetal group, the MDO monomer was used, and 
a new synthetic route to this acetal-containing cyclic ester was developed and 
characterized. Several approaches to polymerize this monomer were investigated, leading 
to reproducible and controlled bulk polymerizations using diethylzinc as a catalyst. By 
varying the amount of this catalyst present in the system, it was possible to generate two 
distinct polymers. At high catalyst concentrations, nearly all acetal functionality was 
expelled as volatile acetaldehyde to form slow-degrading P(3-HPA) by a novel route. At 
low catalyst concentrations, nearly all of the acetal linkages were retained to form the new 
acid-sensitive polymer PMDO.  
Development of PMDO represents a step towards new, more pH responsive drug 
delivery vehicles. While this particular system is limited by unfavorable thermodynamics 
and slow polymerization kinetics, the synthetic approaches employed to synthesize PMDO 
are amenable to synthesis of analogous monomers and polymers that could address some 
   171 
 
of the practical shortcomings of this system while maintaining the advantages of this new 
acid-sensitive polymer. 
4.4 Experimental 
Materials and Analysis 
All chemicals were obtained from Sigma-Aldrich (St. Louis, MO) and used as received 
unless otherwise noted. 1H, 13C, and COSY NMR spectra were obtained at room 
temperature on a Varian VAC-300 spectrometer in CDCl3 at 300 MHz for 
1H and COSY 
NMR spectra and 75 MHz for 13C NMR spectra. Reported chemical shifts were referenced 
to CHCl3 at 7.26 ppm for 
1H NMR spectra and 77.23 ppm for 13C NMR spectra. 
Integrations of 1H NMR data are referenced to initiator BnOH methylene protons at 5.10 
ppm. Elemental Analysis of MDO was performed by Atlantic Microlab (Norcross, GA). 
DSC was performed using a TA Instruments Q2000 at a scanning rate of 5 °C min-1. DSC 
data analysis was performed using TA Instruments TRIOS software and utilizing the 
second heating curve. ESI-MS data were acquired using a Bruker BioTOF instrument with 
samples dissolved at approximately 0.05 mg mL-1 in 9:1 MeOH:CH2Cl2 and data were 
analyzed using Bruker DataAnalysis software with masses calibrated using poly(propylene 
glycol) standards. PMDO samples were analyzed by SEC using an Agilent 1260 series 
chromatograph (THF, 35 °C, 1 mL min-1) with three Styragel columns and equipped with 
a Wyatt Dawn Heleos-II LS light scattering detector and Optilab T-rEX RI detector, the 
latter of which was used for analysis. SEC for P(3-HPA) samples was performed using a 
Hewlett-Packard series 1100 liquid chromatography system (CHCl3, 35 °C, 1 mL min
-1), 
equipped with a Hewlett-Packard 1047A RI detector and three PLgel 5 μm MIXED-C 
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columns. Significant peak broadening occurred during SEC for PMDO in CHCl3 and for 
P(3-HPA) in THF, even at high dilutions. As a result, SEC of PMDO used THF and SEC 
of P(3-HPA) used CHCl3. In both cases, apparent molar masses were reported versus 
polystyrene standards (Polymer Laboratories). 
Synthesis of 2-methyl-1,3-dioxan-4-one (MDO) 
MDO was prepared by Baeyer-Villiger oxidation of racemic 2-methyltetrahydrofuran-
3-one (Sigma FG ≥ 97%) using mCPBA in CH2Cl2 following analogous procedures to 
those used previously to introduce ester functionality to a range of 
monomers.194,252,353,377,378 Reactions were performed with a 1.3-fold molar excess of 
mCPBA relative to 2-methyltetrahydrofuran-3-one at approximately 10 w/v % in CH2Cl2. 
To minimize MDO hydrolysis by water present in mCPBA, after dissolution into CH2Cl2 
the mCPBA solution was dried over MgSO4, which was then removed by filtration. The 
solvent-mCPBA mixture was cooled to 0 °C in an ice bath and 2-methyltetrahydrofuran-
3-one was added dropwise over 45 min while vigorously stirring. The solution was allowed 
to warm to room temperature over 3–4 h. The precipitated meta-chlorobenzoic acid 
(mCBA) byproduct was removed by filtration, the volume of solvent was reduced using 
rotary evaporation and mCBA again removed by filtration. The mixture was then cooled 
in a dry ice/acetone bath and mCBA filtered again. Cooling and filtration was repeated 
until no further precipitate formed during cooling. The solution was then washed twice 
with saturated sodium bicarbonate, once with brine, and stirred over MgSO4. It should be 
noted that complete neutralization of reaction mixture with sodium bicarbonate solution 
was essential to avoid excessive hydrolysis of the monomer with commensurate losses to 
reaction yield. CH2Cl2 was removed using a rotary evaporator and the resulting crude oil 
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was dried with calcium hydride and distilled (44 °C at 400 mTorr) to give racemic MDO 
in 40–60% overall yield. The monomer was stored under nitrogen in the glove box at –23 
°C, where it solidified. 1H NMR (CDCl3): δ 5.43 (q, 1H, -O-CH(CH3)-O-), 4.22 (ddd, 1H, 
–C(O)-CH2- CH2-O-), 3.94 (ddd, 1H, –C(O)-CH2-CH2-O-), 2.81 (ddd, 1H, –C(O)-CH2-
CH2-O-), 2.61 (ddd, 1H, –C(O)-CH2-CH2-O-), 1.52 (d, 3H, -O-CH(CH3)-O-). 13C NMR 
(CDCl3): δ 167.35, 101.08, 63.23, 29.84, 21.02. Elemental Analysis: calculated: C: 
51.72%, H 6.94%. Experimental: C: 51.92%, H 7.07%. Tm = 10.8 °C by DSC. 
Initial MDO Polymerization Efforts 
Polymerization of MDO was first attempted using poly(ethylene oxide) (PEO) 
methyl ether (Mn = 2 kg mol
-1) as a macroinitiator and employing several common catalyst 
systems. Polymerizations were conducted under nitrogen in a dry box using flame-dried 
pressure vessels with Teflon stir bars and were sealed prior to removal from the box. In all 
cases, PEO was dried by heating the polymer to 80 °C under vacuum for at least 18 h prior 
to polymerizations. Polymerizations included MDO at a molar excess of 200:1 with respect 
to macroinitiator hydroxyl end groups ([PEO]o = 85 mg per 1 g MDO). 
For reactions using tin octoate as the catalyst, conditions for bulk polymerization 
mimicked those used for polymerization of PEO-PMCL and VS-PEO-PMCL, though two 
reaction temperatures were investigated ([SnOct2]o ≈ 10 mM, Tpolym = 110 °C and 60 °C, 
tpolym = 1 h or 8 h). SEC elugrams for these polymerizations can be seen in Figure 4-7. 
For polymerizations with TEA as the catalyst, solution polymerization conditions 
similar to those used by others for PEO-PMCL194 were used ([M]o ≈ 1.5 M, Tpolym = 60 °C 
in both THF and CH2Cl2, tpolym = 1 h) and two concentrations of TEA (added from 1 M 
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stock in hexanes) with respect to PEO macroinitiator were used ([TEA]o/[PEO]o = 1.1 and 
[TEA]o/[PEO]o = 2.2). SEC elugrams for these polymerizations can be seen in Figure 4-8. 
Polymerization in the bulk using the organocatalyst triazabicyclodecene (TBD) was 
also investigated. Conditions were analogous to those used for bulk polymerization of δ-
decalactone ([TBD]o = 30 mM),
375 but performed at room temperature. The SEC traces of 
these polymerizations can be seen in Figure 4-9.  
 
Figure 4-24: NMR spectra and structural assignments for several molar masses of P(3-
HPA) synthesized by diethylzinc-catalyzed polymerization of MDO from benzyl alcohol 
with peak assignments for A) 1H and B) 13C spectra. Numbers in the sample names indicate 
the number-average degree of polymerization and characterization data for these polymers 
are summarized in Table 4-1. 
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Figure 4-25: Spectroscopic characterization of PMDO samples and peak assignments for 
A) 1H and B) 13C spectra. The number in sample names refers to the number-average degree 
of polymerization. Characterization data for these polymers are summarized in Table 4-2. 
Synthesis of Polymers Using Diethylzinc 
Polymerizations using diethylzinc catalyst for ROTEP of MDO were set up in a dry 
box using flame-dried glassware with a Teflon stir bar and were sealed prior to removal 
from the box. For a typical polymerization, the appropriate amount of racemic MDO 
monomer (generally 1.5 g) was added to the reaction vessel. An appropriate amount of 
benzyl alcohol initiator was added to target the desired molar mass, using an ultimate 
conversion of 55% for PMDO and 80% for P(3-HPA) for calculations. Diethylzinc catalyst 
   176 
 
(1.0 M in hexanes), typically using [C]o:[I]o = 0.02:1 for high-acetal PMDO and [C]o:[I]o 
= 2:1 for low-acetal P(3-HPA), was then added to the reaction mixture by microsyringe 
and allowed to mix thoroughly. The reaction vessels were sealed and allowed to react while 
stirring at room temperature. While still in the glove box, periodic samples were taken for 
analysis by SEC and 1H NMR spectroscopy. To isolate polymers, reaction vessels were 
opened to air, halting the reaction, and the reaction mixture was dissolved completely in 
CH2Cl2. Polymers were then precipitated by dropwise addition of the dissolved reaction 
mixture into 9:1 hexanes:THF, and dried under vacuum. For P(3-HPA) (given degree of 
polymerization = 100): 1H NMR (CDCl3): δ 7.31 (m, 0.05H, Ph-CH2-O-), 5.10 (s, 0.02H, 
Ph-CH2-O-), 4.35 (t, 2H, –C(O)-CH2-CH2-O-), 2.65 (t, 2H, –C(O)-CH2-CH2-O-). 13C 
NMR (CDCl3): δ 170.45, 60.25, 33.76. For PMDO (given degree of polymerization = 100): 
1H NMR (CDCl3): δ 7.31 (m, 0.05H, Ph-CH2-O-), 5.92 (q, 1H, -O-CH(CH3)-O-), 5.10 (s, 
0.02H, Ph-CH2-O-), 3.88 (m, 1H, –C(O)-CH2-CH2-O-), 3.76 (m, 1H, –C(O)-CH2-CH2-O-
), 2.57 (m, 2H, –C(O)-CH2-CH2-O-), 1.33 (d, 3H, -O-CH(CH3)-O-). 13C NMR (CDCl3): δ 
171.04, 96.59, 64.50, 32.23, 20.84. 
To monitor byproduct formation, a polymerization was performed in solution using 
CD2Cl2 which had been dried for 18 h by stirring over 3 Å molecular sieves and degrassed 
by three freeze-pump-thaw cycles before being brought into the glove box. The solvent 
(750 μL) was added to a flame-dried round-bottom flask containing a Teflon-coated stir 
bar. MDO was then added (to [MDO] = 1 M) followed by benzyl alcohol (to [BnOH] = 10 
mM). After stirring for 10 min, diethylzinc was added (1 M in hexanes, to [ZnEt2] =  20 
mM). This solution was allowed to mix for 5 minutes, then loaded into a throughly dried 
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NMR tube and sealed while still in the glove box. Over the next several hours, 1H spectra 
of the reaction were periodically collected and used to monitor polymerization and 
byproducts as described in the main text. 
Density Measurements 
The density of MDO was measured by determining the mass of known volumes of 
the monomer dispensed by a calibrated micropipette. Nine separate measurements were 
taken to determine ρMDO = 1.183 ± 0.018 g mL-1. To measure the density of PMDO, a 
volumetric flask with a fritted glass cap was filled with cyclohexane, a poor solvent for 
PMDO. The flask was capped, any bubbles excluded, and excess cyclohexane allowed to 
evaporate until mass measurements stabilized for 30 s, then the mass of cyclohexane and 
flask was recorded. A known mass of PMDO was then added to the flask and the vessel 
was again capped, which displaced a volume of cyclohexane. This cyclohexane was wiped 
off, and the solvent residue was allowed to evaporate until the mass had again stabilized 
for 30 s. The mass of the flask, the remaining cyclohexane and the added polymer was then 
measured. The volume of the excluded cyclohexane and the density of the polymer were 
calculated using ρCHX = 0.7781 g mL-1 and the known mass of the added polymer. This 
measurement was performed four independent times (n=4) to determine that the density of 
PMDO at room temperature was 1.421 ± 0.072 g mL-1. For calculations involving the 
density of P(3-HPA), the room temperature density of the polymer was taken to be 1.38 g 
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Thermodynamic Characterization 
To explore the source of the limited conversion observed for PMDO, a series of 
experiments were conducted to measure equilibrium monomer conversions of identical 
reaction mixtures at a variety of temperatures. In a sample reaction, in a glove box under 
nitrogen, 1 g (8.62 mmol) of MDO was combined with 8.9 μL of (89 μmol) benzyl alcohol 
and allowed to mix thoroughly for approximately 10 minutes. 1.7 μL of ZnEt2 (1 M in 
hexanes, 1.7 μmol) was then added and allowed to mix for an additional 10 minutes. The 
reaction was then split into four separate reaction vessels, each of which was sealed. These 
were brought to temperatures ranging from 23 °C to 60 °C and stirred by magnetic stir bar 
for 14 days. The vessels were opened to air, the reaction mixture dissolved in CDCl3, and 
the fraction of remaining monomer determined using 1H NMR spectroscopy. From these 
experiments, [M]eq values for a given temperature were calculated using ρMDO = 1.183 g 
mL-1 and ρPMDO = 1.421 g mL-1. Values of [M]eq for each temperature were measured in at 
least three separate experiments. Integrations used to determine monomer conversion in 1H 
NMR spectra (methylene protons from MDO at δ = 4.22 ppm and PMDO at δ = 3.76 ppm 
as well as methyl protons from MDO at 1.52 ppm, and PMDO at 1.33 ppm) did not change 
appreciably over several days, suggesting depolymerization was not a significant factor 
after opening to air and dilution. 
As a control experiment to determine if the value of [M]eq would shift reversibly 
with temperature, a polymerization was set up as described for the above equilibrium 
experiments but not initially split into separate reaction vessels. This reaction was allowed 
to react at 40 °C for 7 days. An aliquot taken from the reaction at this point showed that 
43% of MDO had been converted to PMDO over 7 days ([M] = 6.3 M). In a glove box, the 
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viscous liquid was split into two vessels which were each sealed and allowed to react for 
an additional 14 days, one at room temperature and one at 60 °C. The vessels were then 
opened, the reaction mixture dissolved in CDCl3, and conversion measured by 
1H NMR 
spectroscopy, from which values of [M] were determined using experimentally measured 
densities of MDO and PMDO. The conversion of the room temperature reaction reached 
58% ([M] = 4.7 M) while the polymerization at 60 °C reached 33% ([M] = 7.2 M). These 
values were consistent with [M]eq values measured in samples heated directly to these 
temperatures (Figure 4-21), and indicated that equilibrium monomer concentration could, 
as expected for an equilibrium process, be reversibly shifted by a change in temperature. 
Catalyst Activity 
To verify the diethylzinc catalyst was not deactivated after extended time periods, 
a bulk polymerization was set up using 1 g of MDO under conditions previously observed 
to result in high-acetal PMDO ([ZnEt2]o = 2.3 mM, [BnOH]o = 100.5 mM). The reaction 
was sealed and allowed to proceed for 21 days at room temperature. An aliquot of the 
viscous liquid was taken and found to have conversion (by 1H NMR spectroscopy) of 
approximately 58% (degree of polymerization 58, apparent molar mass 4.5 kg mol-1 by 
SEC), near the result observed in similar kinetics studies (Figure 4-20). The liquid was then 
divided in two under nitrogen and monomer (approximately 0.5 g) added to one portion. 
Both portions were sealed and allowed to react while mixing for an additional 5 days at 
room temperature before being opened to air. The sample with no additional monomer 
maintained the same conversion of MDO at 21 days and had an apparent molar mass of 4.6 
kg mol-1 by SEC. The sample with additional monomer had an increased degree of 
polymerization (74 by 1H NMR spectroscopy) and its apparent molar mass by SEC had 
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increased to 11.0 kg mol-1. This increase in molar mass showed that the catalyst remained 
active for polymerization even after weeks in the reaction medium. 
  
   181 
 
5 Bibliography 
(1)  Ehrlich, P. Münch. Med. Wschr. 1901, 18, 2123. 
(2)  Winau, F.; Westphal, O.; Winau, R. Microbes and Infection 2004, 6, 786–789. 
(3)  Majer, M.; Akerley, W.; Kuwada, S. K. Anti-Cancer Agents in Medicinal 
Chemistry 2007, 7, 492–503. 
(4)  Greene, F. L.; Page, D. L.; Fleming, G. F. AJCC Cancer Staging Manual 2002. 
(5)  Sabin, L. H.; Wittekind, C. UICC: TNM Classification of Malignant Tumours; 6th 
ed.; Jogn Wiley and Sons: London, 2002. 
(6)  Greene, F. L. M. D.; Stewart, A. K. M. A.; Norton, H. J. P. Annals of Surgery 
2002, 236, 416–421. 
(7)  Andre, N.; Schmiegel, W. Gut 2005, 54, 1194–1202. 
(8)  Gill, S.; Loprinzi, C. L.; Sargent, D. J.; Thome, S. D.; Alberts, S. R.; Haller, D. G.; 
Benedetti, J.; Francini, G.; Shepherd, L. E.; Francois Seitz, J.; Labianca, R.; Chen, 
W.; Cha, S. S.; Heldebrant, M. P.; Goldberg, R. M. J Clin Oncol 2004, 22, 1797–
1806. 
(9)  Graham, J.; Muhsin, M.; Kirkpatrick, P. Nat Rev Drug Discov 2004, 3, 11–12. 
(10)  Barabas, K.; Milner, R.; Lurie, D.; Adin, C. Veterinary and Comparative 
Oncology 2008, 6, 1–18. 
(11)  Stewart, D. J.; Benjamin, R. S.; Luna, M.; Feun, L.; Caprioli, R.; Seifert, W.; Loo, 
T. L. Cancer Chemotherapy and Pharmacology 1982, 10, 51–54. 
(12)  Siddik, Z. H. Oncogene 2003, 22, 7265–7279. 
(13)  Iyer, L.; Ratain, M. J. Cancer Chemotherapy and Pharmacology 1998, 42, S31–
S43. 
(14)  Baselga, J. Oncologist 2002, 7, 2–8. 
(15)  Kabbinavar, F.; Hurwitz, H. I.; Fehrenbacher, L.; Meropol, N. J.; Novotny, W. F.; 
Lieberman, G.; Griffing, S.; Bergsland, E. J Clin Oncol 2003, 21, 60–65. 
   182 
 
(16)  Adam, R.; Avisar, E.; Ariche, A.; Giachetti, S.; Azoulay, D.; Castaing, D.; 
Kunstlinger, F.; Levi, F.; Bismuth, F. Annals of Surgical Oncology 2001, 8, 347–
353. 
(17)  Ki Young, C.; Saltz, L. B. Cancer Journal 2007, 13, 192–197. 
(18)  Saltz, L. B.; Douillard, J.-Y.; Pirotta, N.; Alakl, M.; Gruia, G.; Awad, L.; Elfring, 
G. L.; Locker, P. K.; Miller, L. L. Oncologist 2001, 6, 81–91. 
(19)  Levis, M.; Pham, R.; Smith, B. D.; Small, D. Blood 2004, 104 , 1145–1150. 
(20)  Soriano, A. F.; Helfrich, B.; Chan, D. C.; Heasley, L. E.; Bunn, P. A.; Chou, T.-C. 
Cancer Research 1999, 59 , 6178–6184. 
(21)  Partridge, A. H.; Winer, E. P. Breast Disease 2004, 21, 55–64. 
(22)  Matsumura, Y.; Maeda, H. Cancer Res 1986, 46, 6387–6392. 
(23)  Meng, F.; Zhong, Z.; Feijen, J. Biomacromolecules 2009, 10, 197–209. 
(24)  Ganta, S.; Devalapally, H.; Shahiwala, A.; Amiji, M. Journal of Controlled 
Release 2008, 126, 187–204. 
(25)  Noguchi, Y.; Wu, J.; Duncan, R.; Strohalm, J.; Ulbrich, K.; Akaike, T.; Maeda, H. 
Cancer Science 1998, 89, 307–314. 
(26)  Van Vlerken, L. E.; Duan, Z.; Seiden, M. V; Amiji, M. M. Cancer Res 2007, 67, 
4843–4850. 
(27)  Hobbs, S. K.; Monsky, W. L.; Yuan, F.; Roberts, W. G.; Griffith, L.; Torchilin, V. 
P.; Jain, R. K. Proceedings of the National Academy of Sciences of the United 
States of America 1998, 95, 4607–4612. 
(28)  Yuan, F.; Dellian, M.; Fukumura, D.; Leunig, M.; Berk, D. A.; Torchilin, V. P.; 
Jain, R. K. Cancer Res 1995, 55, 3752–3756. 
(29)  Unezaki, S.; Maruyama, K.; Hosoda, J.-I.; Nagae, I.; Koyanagi, Y.; Nakata, M.; 
Ishida, O.; Iwatsuru, M.; Tsuchiya, S. International Journal of Pharmaceutics 
1996, 144, 11–17. 
(30)  Skinner, S. A.; Tutton, P. J. M.; O’Brien, P. E. Cancer Res 1990, 50, 2411–2417. 
(31)  Iyer, A. K.; Khaled, G.; Fang, J.; Maeda, H. Drug Discovery Today 2006, 11, 812–
818. 
   183 
 
(32)  Moghimi, S. M.; Hunter, A. C.; Murray, J. C. Pharmacol Rev 2001, 53, 283–318. 
(33)  Wisse, E.; Braet, F.; Dianzhong Luo; De Zanger, R.; Jans, D.; Crabbe, E.; 
Vermoesen, A. N. Toxicologic Pathology 1996, 24 , 100–111. 
(34)  Takakura, Y.; Mahato, R. I.; Hashida, M. Advanced Drug Delivery Reviews 1998, 
34, 93–108. 
(35)  Sonavane, G.; Tomoda, K.; Makino, K. Colloids and Surfaces B: Biointerfaces 
2008, 66, 274–280. 
(36)  Cho, K.; Wang, X.; Nie, S.; Chen, Z.; Shin, D. M. Clinical Cancer Research 2008, 
14, 1310–1316. 
(37)  Seymour, L. W. Critical Reviews in Therapeutic Drug Carrier Systems 1992, 9, 
135–187. 
(38)  Torzilli, P. A.; Arduino, J. M.; Gregory, J. D.; Bansal, M. Journal of Biomechanics 
1997, 30, 895–902. 
(39)  Conhaim, R. L.; Eaton, A.; Staub, N. C.; Heath, T. D. Journal of Applied 
Physiology 1988, 64 , 1134–1142. 
(40)  Nakaoka, R.; Tabata, Y.; Yamaoka, T.; Ikada, Y. Journal of Controlled Release 
1997, 46, 253–261. 
(41)  Moghimi, S. M. Advanced Drug Delivery Reviews 1995, 17, 103–115. 
(42)  Moghimi, S. M. Advanced Drug Delivery Reviews 1995, 17, 61–73. 
(43)  Caliceti, P.; Veronese, F. M. Advanced Drug Delivery Reviews 2003, 55, 1261–
1277. 
(44)  Rothenfluh, D. A.; Bermudez, H.; O/’Neil, C. P.; Hubbell, J. A. Nat Mater 2008, 
7, 248–254. 
(45)  Liu, D.; Mori, A.; Huang, L. Biochimica et Biophysica Acta - Biomembranes 1992, 
1104, 95–101. 
(46)  Arfors, K. E.; Rutili, G.; Svensjo, E. Acta Physiologica Scandanavica 1979, 463, 
93–103. 
(47)  Gaumet, M.; Vargas, A.; Gurny, R.; Delie, F. European Journal of Pharmaceutics 
and Biopharmaceutics 2008, 69, 1–9. 
   184 
 
(48)  Storm, G.; Belliot, S. O.; Daemen, T.; Lasic, D. D. Advanced Drug Delivery 
Reviews 1995, 17, 31–48. 
(49)  Göppert, T. M.; Müller, R. H. European Journal of Pharmaceutics and 
Biopharmaceutics 2005, 60, 361–372. 
(50)  Vonarbourg, A.; Passirani, C.; Saulnier, P.; Benoit, J.-P. Biomaterials 2006, 27, 
4356–4373. 
(51)  Moghimi, S. M.; Hedeman, H.; Muir, I. S.; Illum, L.; Davis, S. S. Biochimica et 
Biophysica Acta (BBA) - General Subjects 1993, 1157, 233–240. 
(52)  Owens III, D. E.; Peppas, N. A. International Journal of Pharmaceutics 2006, 307, 
93–102. 
(53)  Li, S.-D.; Huang, L. Molecular Pharmaceutics 2008, 5, 496–504. 
(54)  Chanan-Khan, A.; Szebeni, J.; Savay, S.; Liebes, L.; Rafique, N. M.; Alving, C. 
R.; Muggia, F. M. Ann Oncol 2003, 14, 1430–1437. 
(55)  Dobrovolskaia, M. A.; Aggarwal, P.; Hall, J. B.; McNeil, S. E. Molecular 
Pharmaceutics 2008, 5, 487–495. 
(56)  Reddy, S. T.; Van der Vlies, A. J.; Simeoni, E.; Angeli, V.; Randolph, G. J.; 
O’Neil, C. P.; Lee, L. K.; Swartz, M. A.; Hubbell, J. A. Nat Biotech 2007, 25, 
1159–1164. 
(57)  Nagayama, S.; Ogawara, K.; Fukuoka, Y.; Higaki, K.; Kimura, T. International 
Journal of Pharmaceutics 2007, 342, 215–221. 
(58)  Bartlett, D. W.; Davis, M. E. Bioconjugate Chem. 2007, 18, 456–468. 
(59)  Stolnik, S.; Illum, L.; Davis, S. S. Advanced Drug Delivery Reviews 1995, 16, 
195–214. 
(60)  Claesson, P. M.; Blomberg, E.; Fröberg, J. C.; Nylander, T.; Arnebrant, T. 
Advances in Colloid and Interface Science 1995, 57, 161–227. 
(61)  Leckband, D.; Israelachvili, J. Quarterly Reviews of Biophysics 2001, 34, 105–
267. 
(62)  Chonn, A.; Semple, S. C.; Cullis, P. R. Journal of Biological Chemistry 1992, 267 
, 18759–18765. 
   185 
 
(63)  Juliano, R. L.; Stamp, D. Biochemical and Biophysical Research Communications 
1975, 63, 651–658. 
(64)  Devine, D. V; Wong, K.; Serrano, K.; Chonn, A.; Cullis, P. R. Biochimica et 
Biophysica Acta (BBA) - Biomembranes 1994, 1191, 43–51. 
(65)  Macritchie, F. Journal of Colloid and Interface Science 1972, 38, 484–488. 
(66)  Jeon, S. I.; Lee, J. H.; Andrade, J. D.; De Gennes, P. G. Journal of Colloid and 
Interface Science 1991, 142, 149–158. 
(67)  L., P. K.; M., W. G.; Prime, K. L.; Whitesides, G. M. J. Am. Chem. Soc. 1993, 
115, 10714. 
(68)  Van Vlerken, L.; Vyas, T.; Amiji, M. Pharmaceutical Research 2007, 24, 1405–
1414. 
(69)  Alexis, F.; Pridgen, E.; Molnar, L. K.; Farokhzad, O. C. Molecular Pharmaceutics 
2008, 5, 505–515. 
(70)  Gabizon, A.; Catane, R.; Uziely, B.; Kaufman, B.; Safra, T.; Cohen, R.; Martin, F.; 
Huang, A.; Barenholz, Y. Cancer Research 1994, 54 , 987–992. 
(71)  Gabizon, A.; Shmeeda, H.; Barenholz, Y. Clinical Pharmacokinetics 2003, 42. 
(72)  Vonarbourg, A.; Passirani, C.; Saulnier, P.; Simard, P.; Leroux, J. C.; Benoit, J. P. 
Journal of Biomedical Materials Research Part A 2006, 78A, 620–628. 
(73)  Al-Hanbali, O.; Rutt, K. J.; Sarker, D. K.; Hunter, A. C.; Moghimi, S. M. Journal 
of Nanoscience and Nanotechnology 2006, 6, 3126–3133. 
(74)  Allen, T. M. Advanced Drug Delivery Reviews 1994, 13, 285–309. 
(75)  Papisov, M. I. Advanced Drug Delivery Reviews 1998, 32, 119–138. 
(76)  Kirpotin, D. B.; Drummond, D. C.; Shao, Y.; Shalaby, M. R.; Hong, K.; Nielsen, 
U. B.; Marks, J. D.; Benz, C. C.; Park, J. W. Cancer Research 2006, 66, 6732–
6740. 
(77)  Perez, R. P. European Journal of Cancer 1998, 34, 1535–1542. 
(78)  Ohmichi, M.; Hayakawa, J.; Tasaka, K.; Kurachi, H.; Murata, Y. Trends in 
Pharmacological Sciences 2005, 26, 113–116. 
   186 
 
(79)  Iinuma, H.; Maruyama, K.; Okinaga, K.; Sasaki, K.; Sekine, T.; Ishida, O.; 
Ogiwara, N.; Johkura, K.; Yonemura, Y. International Journal of Cancer 2002, 
99, 130–137. 
(80)  Krieger, M. L.; Eckstein, N.; Schneider, V.; Koch, M.; Royer, H.-D.; Jaehde, U.; 
Bendas, G. International Journal of Pharmaceutics 2010, 389, 10–17. 
(81)  Mai, J.; Song, S.; Rui, M.; Liu, D.; Ding, Q.; Peng, J.; Xu, Y. Journal of 
Controlled Release 2009, 139, 174–181. 
(82)  Dhar, S.; Gu, F. X.; Langer, R.; Farokhzad, O. C.; Lippard, S. J. Proceedings of 
the National Academy of Sciences 2008, 105, 17356–17361. 
(83)  Cao, Z.; Tong, R.; Mishra, A.; Xu, W.; Wong, G. C. L.; Cheng, J.; Lu, Y. 
Angewandte Chemie International Edition 2009, 48, 6494–6498. 
(84)  Mukhopadhyay, S.; Barnés, C. M.; Haskel, A.; Short, S. M.; Barnes, K. R.; 
Lippard, S. J. Bioconjugate Chemistry 2007, 19, 39–49. 
(85)  Levine, R. M.; Scott, C. M.; Kokkoli, E. Soft Matter 2013, 9, 985–1004. 
(86)  Conner, S. D.; Schmid, S. L. Nature 2003, 422, 37–44. 
(87)  Le Roy, C.; Wrana, J. L. Nat Rev Mol Cell Biol 2005, 6, 112–126. 
(88)  Rejman, J.; Bragonzi, A.; Conese, M. Mol Ther 2005, 12, 468–474. 
(89)  Marsh, M.; McMahon, H. T. Science 1999, 285 , 215–220. 
(90)  Breunig, M.; Bauer, S.; Goepferich, A. European Journal of Pharmaceutics and 
Biopharmaceutics 2008, 68, 112–128. 
(91)  Nori, A.; Kopecek, J. Advanced Drug Delivery Reviews 2005, 57, 609–636. 
(92)  Minko, T.; Dharap, S. S.; Pakunlu, R. I.; Wang, Y. Current Drug Targets 2004, 5, 
389–406. 
(93)  Byrne, J. D.; Betancourt, T.; Brannon-Peppas, L. Advanced Drug Delivery 
Reviews 2008, 60, 1615–1626. 
(94)  Brannon-Peppas, L.; Blanchette, J. O. Advanced Drug Delivery Reviews 2004, 56, 
1649–1659. 
   187 
 
(95)  Pendley, C.; Schantz, A.; Wagner, C. Current opinion in molecular therapeutics 
2003, 5, 172–179. 
(96)  Jain, R. K. Cancer Research 1990, 50 , 814s–819s. 
(97)  Chapman, A. P. Advanced Drug Delivery Reviews 2002, 54, 531–545. 
(98)  Atobe, K.; Ishida, T.; Ishida, E.; Hashimoto, K.; Kobayashi, H.; Yasuda, J.; Aoki, 
T.; Obata, K.; Kikuchi, H.; Akita, H.; Asai, T.; Harashima, H.; Oku, N.; Kiwada, 
H. Biological and Pharmaceutical Bulletin 2007, 30, 972–978. 
(99)  Maruyama, K.; Takahashi, N.; Tagawa, T.; Nagaike, K.; Iwatsuru, M. FEBS 
Letters 1997, 413, 177–180. 
(100)  Backer, M. V; Gaynutdinov, T. I.; Patel, V.; Bandyopadhyaya, A. K.; 
Thirumamagal, B. T. S.; Tjarks, W.; Barth, R. F.; Claffey, K.; Backer, J. M. 
Molecular Cancer Therapeutics 2005, 4 , 1423–1429. 
(101)  Duda, D. G.; Batchelor, T. T.; Willett, C. G.; Jain, R. K. Trends in Molecular 
Medicine 2007, 13, 223–230. 
(102)  Torchilin, V. P. Nat Rev Drug Discov 2005, 4, 145–160. 
(103)  Thomas, T. P.; Shukla, R.; Kotlyar, A.; Liang, B.; Ye, J. Y.; Norris, T. B.; Baker, 
J. R. Biomacromolecules 2008, 9, 603–609. 
(104)  Merrifield, R. B. Journal of the American Chemical Society 1963, 85, 2149–2154. 
(105)  Berndt, P.; Fields, G. B.; Tirrell, M. Journal of the American Chemical Society 
1995, 117, 9515–9522. 
(106)  Aina, O. H.; Liu, R.; Sutcliffe, J. L.; Marik, J.; Pan, C.-X.; Lam, K. S. Molecular 
Pharmaceutics 2007, 4, 631–651. 
(107)  Liu, R.; Enstrom, A. M.; Lam, K. S. Experimental Hematology 2003, 31, 11–30. 
(108)  Myrberg, H.; Zhang, L.; xe; e, M.; Langel; xdc; lo Bioconjugate Chem. 2008, 19, 
70–75. 
(109)  Chen, Y.; Mant, C. T.; Farmer, S. W.; Hancock, R. E. W.; Vasil, M. L.; Hodges, 
R. S. Journal of Biological Chemistry 2005, M413406200. 
(110)  Pisabarro, M. T.; Serrano, L. Biochemistry 1996, 35, 10634–10640. 
   188 
 
(111)  Stachelhaus, T.; Schneider, A.; Marahiel, M. A. Science 1995, 269 , 69–72. 
(112)  Varner, J. A.; Cheresh, D. A. Current Opinion in Cell Biology 1996, 8, 724–730. 
(113)  Hynes, R. O. Cell 2002, 110, 673–687. 
(114)  Wester, H.-J.; Kessler, H. J Nucl Med 2005, 46, 1940–1945. 
(115)  Hill, E.; Shukla, R.; Park, S. S.; Baker, J. R. Bioconjugate Chem. 2007, 18, 1756–
1762. 
(116)  Mitra, A.; Coleman, T.; Borgman, M.; Nan, A.; Ghandehari, H.; Line, B. R. 
Journal of Controlled Release 2006, 114, 175–183. 
(117)  Pilkington-Miksa, M. A.; Sarkar, S.; Writer, M. J.; Barker, S. E.; Shamlou, P. A.; 
Hart, S. L.; Hailes, H. C.; Tabor, A. B. European Journal of Organic Chemistry 
2008, 2008, 2900–2914. 
(118)  Xiong, X. B.; Mahmud, A.; Uludag, H.; Lavasanifar, A. Biomacromolecules 2007, 
8, 874–884. 
(119)  Pierschbacher, M. D.; Ruoslahti, E. Nature 1984, 309, 30–33. 
(120)  Ruoslahti, E.; Pierschbacher, M. D. Science 1987, 238, 491. 
(121)  Ruoslahti, E.; Pierschbacher, M. D. Cell 1986, 44, 517–518. 
(122)  Kim, S.; Bell, K.; Mousa, S. A.; Varner, J. A. The American Journal of Pathology 
2000, 156, 1345–1362. 
(123)  Muschler, J. L.; Horwitz, A. F. Development 1991, 113, 327–37. 
(124)  Van Golen, K. L.; Bao, L.; Brewer, G. J.; Pienta, K. J.; Kamradt, J. M.; Livant, D. 
L.; Merajver, S. D. Neoplasia 2002, 4, 373–379. 
(125)  Gong, J.; Wang, D. H.; Sun, L. Z.; Zborowska, E.; Wilson, J. K. V.; Brattain, M. 
G. Cell Growth & Differentiation 1997, 8, 83–90. 
(126)  Jayne, D. G.; Heath, R. M.; Dewhurst, O.; Scott, N.; Guillou, P. J. European 
Journal of Surgical Oncology 2002, 28, 30–36. 
(127)  Ellis, L. M. American Surgery 2003, 69, 3–10. 
   189 
 
(128)  Jia, Y.; Zeng, Z.-Z.; Markwart, S. M.; Rockwood, K. F.; Ignatoski, K. M. W.; 
Ethier, S. P.; Livant, D. L. Cancer Research 2004, 64, 8674–8681. 
(129)  Chen, J.; De, S.; Brainard, J.; Byzova, T. V. Cell Communication and Adhesion 
2004, 11, 1–11. 
(130)  Maglott, A.; Bartik, P.; Cosgun, S.; Klotz, P.; Rondé, P.; Fuhrmann, G.; Takeda, 
K.; Martin, S.; Dontenwill, M. Cancer Research 2006, 66, 6002–6007. 
(131)  Mizejewski, G. J. Proceedings of the Society for Experimental Biology and 
Medicine 1999, 222, 124–138. 
(132)  Dingemans, A.-M. C.; Van den Boogaart, V.; Vosse, B. A.; Van Suylen, R.-J.; 
Griffioen, A. W.; Thijssen, V. L. Molecular cancer 2010, 9, 152. 
(133)  Aucoin, L.; Griffith, C. M.; Pleizier, G.; Deslandes, Y.; Sheardown, H. Journal of 
Biomaterials Science, Polymer Edition 2002, 13, 447–462. 
(134)  Kao, W. J. Biomaterials 1999, 20, 2213–2221. 
(135)  Kim, T.-I.; Jang, J.-H.; Lee, Y.-M.; Ryu, I.-C.; Chung, C.-P.; Han, S.-B.; Choi, S.-
M.; Ku, Y. Biotechnology Letters 2002, 24, 2029–2033. 
(136)  Benoit, D. S. W.; Anseth, K. S. Biomaterials 2005, 26, 5209–5220. 
(137)  Petrie, T. A.; Capadona, J. R.; Reyes, C. D.; García, A. J. Biomaterials 2006, 27, 
5459–5470. 
(138)  Mardilovich, A.; Craig, J. A.; McCammon, M. Q.; Garg, A.; Kokkoli, E. Langmuir 
2006, 22, 3259–3264. 
(139)  Pangburn, T. O.; Bates, F. S.; Kokkoli, E. Soft Matter 2012, 8, 4449–4461. 
(140)  Shroff, K.; Pearce, T. R.; Kokkoli, E. Langmuir 2011, 28, 1858–1865. 
(141)  Demirgöz, D.; Pangburn, T. O.; Davis, K. P.; Lee, S.; Bates, F. S.; Kokkoli, E. Soft 
Matter 2009, 5, 2011–2019. 
(142)  Demirgöz, D.; Garg, A.; Kokkoli, E. Langmuir 2008, 24, 13518–13524. 
(143)  Garg, A.; Tisdale, A. W.; Haidari, E.; Kokkoli, E. International Journal of 
Pharmaceutics 2009, 366, 201–210. 
   190 
 
(144)  Garg, A.; Kokkoli, E. Current Pharmaceutical Biotechnology 2011, 12, 1135–
1143. 
(145)  Atchison, N. A.; Fan, W.; Papas, K. K.; Hering, B. J.; Tsapatsis, M.; Kokkoli, E. 
Langmuir 2010, 26, 14081–14088. 
(146)  Shroff, K.; Kokkoli, E. Langmuir 2012, 28, 4729–4736. 
(147)  Pangburn, T. O.; Georgiou, K.; Bates, F. S.; Kokkoli, E. Langmuir 2012, 28, 
12816–12830. 
(148)  Adil, M. M.; Belur, L.; Pearce, T. R.; Levine, R. M.; Tisdale, A. W.; Sorenson, B. 
S.; McIvor, R. C.; Kokkoli, E. Biomaterials Science 2013, In Press. 
(149)  Pangburn, T. O.; Petersen, M. A.; Waybrant, B.; Adil, M. M.; Kokkoli, E. Journal 
of Biomechanical Engineering 2009, 131, 74005. 
(150)  Liechty, W. B.; Kryscio, D. R.; Slaughter, B. V.; Peppas, N. A. Annual Review of 
Chemical and Biomolecular Engineering 2010, 1, 149–173. 
(151)  Flenniken, M. L.; Liepold, L. O.; Crowley, B. E.; Willits, D. A.; Young, M. J.; 
Douglas, T. Chemical Communications 2005, 4, 447–449. 
(152)  Letchford, K.; Burt, H. European Journal of Pharmaceutics and Biopharmaceutics 
2007, 65, 259–269. 
(153)  Agarwal, A.; Saraf, S.; Asthana, A.; Gupta, U.; Gajbhiye, V.; Jain, N. K. 
International Journal of Pharmaceutics 2008, 350, 3–13. 
(154)  Christian, N. A.; Milone, M. C.; Ranka, S. S.; Li, G.; Frail, P. R.; Davis, K. P.; 
Bates, F. S.; Therien, M. J.; Ghoroghchian, P. P.; June, C. H.; Hammer, D. A. 
Bioconjugate Chem. 2007, 18, 31–40. 
(155)  Bhadra, D.; Bhadra, S.; Jain, S.; Jain, N. K. International Journal of 
Pharmaceutics 2003, 257, 111–124. 
(156)  Khandare, J. J.; Jayant, S.; Singh, A.; Chandna, P.; Wang, Y.; Vorsa, N.; Minko, 
T. Bioconjugate Chem. 2006, 17, 1464–1472. 
(157)  Hiemenz, P. C.; Rajagopalan, R. Principles of Colloid and Surface Chemistry; 
CRC Press: Boca Raton, FL, 1997. 
(158)  Lindman, B. In Surfactants; Tadros, T. F., Ed.; Academic Press: London, 1984. 
   191 
 
(159)  McBain, J. W.; Salmon, C. S. Proceedings of the Royal Society of London. Series 
A, Containing Papers of a Mathematical and Physical Character 1920, 97, 44–65 
CR  – Copyright &#169; 1920 The Royal Societ. 
(160)  Tanford, C. The Hydrophobic Effect: Formation of Micelles and Biological 
Membranes; John Wiley & Sons, Inc.: New York, 1973. 
(161)  Israelachvili, J. Intermolecular and Surface Forces; Academic Press: London, 
1992. 
(162)  Pearce, T. R.; Shroff, K.; Kokkoli, E. Advanced Materials 2012, 24, 3803–3822. 
(163)  Yu, C.; Hu, Y.; Duan, J.; Yuan, W.; Wang, C.; Xu, H.; Yang, X.-D. PLoS ONE 
2011, 6, e24077. 
(164)  Chu, T. C.; Marks, J. W.; Lavery, L. A.; Faulkner, S.; Rosenblum, M. G.; 
Ellington, A. D.; Levy, M. Cancer Research 2006, 66, 5989–5992. 
(165)  Nimjee, S. M.; Rusconi, C. P.; Sullenger, B. A. Annual Review of Medicine 2005, 
56, 555–+. 
(166)  Bagalkot, V.; Farokhzad, O. C.; Langer, R.; Jon, S.; Vaishali Bagalkot, O. C. F. R. 
L. S. J. Angewandte Chemie International Edition 2006, 45, 8149–8152. 
(167)  Lasic, D. D.; Needham, D. Chemical Reviews 1995, 95, 2601–2628. 
(168)  Oku, N.; Anonymous Advanced Drug Delivery Reviews 1999, 40, 63–73. 
(169)  Safra, T.; Muggia, F.; Jeffers, S.; Tsao-Wei, D. D.; Groshen, S.; Lyass, O.; 
Henderson, R.; Berry, G.; Gabizon, A. Ann Oncol 2000, 11, 1029–1033. 
(170)  Jain, S.; Bates, F. S. Macromolecules 2004, 37, 1511–1523. 
(171)  Bywater, S. In Physical Chemistry; Springer Berlin / Heidelberg, 1979; Vol. 30, 
pp. 89–116. 
(172)  Matyjaszewski, K.; Miller, P. J.; Pyun, J.; Kickelbick, G.; Diamanti, S. 
Macromolecules 1999, 32, 6526–6535. 
(173)  Watzlawek, M.; Likos, C. N.; Löwen, H. Physical Review Letters 1999, 82, 5289–
5292. 
(174)  Cui, H.; Chen, Z.; Zhong, S.; Wooley, K. L.; Pochan, D. J. Science 2007, 317 , 
647–650. 
   192 
 
(175)  Laschewsky, A. Current Opinion in Colloid &amp; Interface Science 2003, 8, 
274–281. 
(176)  Edmonds, W. F.; Li, Z.; Hillmyer, M. A.; Lodge, T. P. Macromolecules 2006, 39, 
4526–4530. 
(177)  Li, Z.; Kesselman, E.; Talmon, Y.; Hillmyer, M. A.; Lodge, T. P. Science 2004, 
306 , 98–101. 
(178)  Bates, F. S.; Hillmyer, M. A.; Lodge, T. P.; Bates, C. M.; Delaney, K. T.; 
Fredrickson, G. H. Science 2012, 336 , 434–440. 
(179)  Hajduk, D. A.; Kossuth, M. B.; Hillmyer, M. A.; Bates, F. S. The Journal of 
Physical Chemistry B 1998, 102, 4269–4276. 
(180)  Halperin, A.; Tirrell, M.; Lodge, T. Macromolecules: Synthesis, Order and 
Advanced Properties 1992, 31–71. 
(181)  Zhang, L.; Eisenberg, A. Polymers for Advanced Technologies 1998, 9, 677–699. 
(182)  Stals, P. J. M.; Li, Y.; Burdyńska, J.; Nicolaÿ, R.; Nese, A.; Palmans, A. R. A.; 
Meijer, E. W.; Matyjaszewski, K.; Sheiko, S. S. Journal of the American Chemical 
Society 2013. 
(183)  Zhang, L.; Eisenberg, A. Macromolecules 1999, 32, 2239–2249. 
(184)  Yu, Y.; Zhang, L.; Eisenberg, A. Macromolecules 1998, 31, 1144–1154. 
(185)  Gast, A. P.; Vinson, P. K.; Cogan-Farinas, K. A. Macromolecules 1993, 26, 1774–
1776. 
(186)  Zhang, L.; Barlow, R. J.; Eisenberg, A. Macromolecules 1995, 28, 6055–6066. 
(187)  Antonietti, M.; Heinz, S.; Schmidt, M.; Rosenauer, C. Macromolecules 1994, 27, 
3276–3281. 
(188)  Won, Y. Y.; Davis, H. T.; Bates, F. S.; Agamalian, M.; Wignall, G. D. J. Phys. 
Chem. B 2000, 104, 7134–7143. 
(189)  Gao, Z.; Varshney, S. K.; Wong, S.; Eisenberg, A. Macromolecules 1994, 27, 
7923–7927. 
(190)  Jain, S.; Bates, F. S. Science 2003, 300, 460–464. 
   193 
 
(191)  Zhang, L.; Shen, H.; Eisenberg, A. Macromolecules 1997, 30, 1001–1011. 
(192)  Lim Soo, P.; Eisenberg, A. Journal of Polymer Science Part B: Polymer Physics 
2004, 42, 923–938. 
(193)  Shen, H.; Eisenberg, A. The Journal of Physical Chemistry B 1999, 103, 9473–
9487. 
(194)  Zupancich, J. A.; Bates, F. S.; Hillmyer, M. A. Macromolecules 2006, 39, 4286–
4288. 
(195)  Jain, S.; Dyrdahl, M. H. E.; Gong, X.; Scriven, L. E.; Bates, F. S. Macromolecules 
2008, 41, 3305–3316. 
(196)  Aniansson, E. A. G.; Wall, S. N.; Almgren, M.; Hoffmann, H.; Kielmann, I.; 
Ulbricht, W.; Zana, R.; Lang, J.; Tondre, C. The Journal of Physical Chemistry 
1976, 80, 905–922. 
(197)  Halperin, A.; Alexander, S. Macromolecules 1989, 22, 2403–2412. 
(198)  Lund, R.; Willner, L.; Richter, D.; Dormidontova, E. E. Macromolecules 2006, 39, 
4566–4575. 
(199)  Bermudez, H.; Brannan, A. K.; Hammer, D. A.; Bates, F. S.; Discher, D. E. 
Macromolecules 2002, 35, 8203–8208. 
(200)  Creutz, S.; Van Stam, J.; Antoun, S.; De Schryver, F. C.; Jérôme, R. 
Macromolecules 1997, 30, 4078–4083. 
(201)  Won, Y. Y.; Davis, H. T.; Bates, F. S. Macromolecules 2003, 36, 953–955. 
(202)  Davis, K. P.; Lodge, T. P.; Bates, F. S. Macromolecules 2008, 41, 8289–8291. 
(203)  Terreau, O.; Luo, L.; Eisenberg, A. Langmuir 2003, 19, 5601–5607. 
(204)  Larsen, A. L.; Terentjev, E. M. Macromolecules 2006, 39, 9508–9518. 
(205)  Ghoroghchian, P. P.; Lin, J. J.; Brannan, A. K.; Frail, P. R.; Bates, F.; Therien, M. 
J.; Hammer, D. A. Soft Matter 2006, 2, 973–980. 
(206)  Lee, J. C. M.; Santore, M.; Bates, F. S.; Discher, D. E. Macromolecules 2002, 35, 
323–326. 
   194 
 
(207)  Cai, S.; Vijayan, K.; Cheng, D.; Lima, E.; Discher, D. Pharmaceutical Research 
2007, 24, 2099–2109. 
(208)  Allen, C.; Maysinger, D.; Eisenberg, A. Colloids and Surfaces B: Biointerfaces 
1999, 16, 3–27. 
(209)  Kumar, V.; Prud’homme, R. K. Journal of Pharmaceutical Sciences 2008, 97, 
4904–4914. 
(210)  Park, J. H.; Lee, S.; Kim, J.-H.; Park, K.; Kim, K.; Kwon, I. C. Progress in 
Polymer Science 2008, 33, 113–137. 
(211)  Sethuraman, V.; Lee, M.; Bae, Y. Pharmaceutical Research 2008, 25, 657–666. 
(212)  Wang, Y.-C.; Tang, L.-Y.; Sun, T.-M.; Li, C.-H.; Xiong, M.-H.; Wang, J. 
Biomacromolecules 2008, 9, 388–395. 
(213)  Sutton, D.; Nasongkla, N.; Blanco, E.; Gao, J. Pharmaceutical Research 2007, 24, 
1029–1046. 
(214)  Tong, R.; Cheng, J. Polymer Reviews 2007, 47, 345–381. 
(215)  Dalhaimer, P.; Engler, A. J.; Parthasarathy, R.; Discher, D. E. Biomacromolecules 
2004, 5, 1714–1719. 
(216)  Geng, Y.; Discher, D. E. Polymer 2006, 47, 2519–2525. 
(217)  Kim, Y.; Dalhaimer, P.; Christian, D. A.; Discher, D. E. Nanotechnology 2005, 16, 
S484–S491. 
(218)  Geng, Y.; Dalhaimer, P.; Cai, S.; Tsai, R.; Tewari, M.; Minko, T.; Discher, D. E. 
Nature Nanotechnology 2007, 2, 249–255. 
(219)  Discher, B. M.; Won, Y. Y.; Ege, D. S.; Lee, J. C. M.; Bates, F. S.; Discher, D. E.; 
Hammer, D. A. Science 1999, 284, 1143–1146. 
(220)  Ahmed, F.; Pakunlu, R. I.; Brannan, A.; Bates, F.; Minko, T.; Discher, D. E. 
Journal of Controlled Release 2006, 116, 150–158. 
(221)  Mueller, W.; Koynov, K.; Fischer, K.; Hartmann, S.; Pierrat, S.; BascheÌ•, T.; 
Maskos, M. Macromolecules 2009, 42, 357–361. 
(222)  Lee, J. C.-M.; Bermudez, H.; Discher, B. M.; Sheehan, M. A.; Won, Y.-Y.; Bates, 
F. S.; Discher, D. E. Biotechnology and Bioengineering 2001, 73, 135–145. 
   195 
 
(223)  Woodle, M. C.; Lasic, D. D. Biochimica et Biophysica Acta - Reviews on 
Biomembranes 1992, 1113, 171–199. 
(224)  Parr, M. J.; Ansell, S. M.; Choi, L. S.; Cullis, P. R. Biochimica et Biophysica Acta 
(BBA) - Biomembranes 1994, 1195, 21–30. 
(225)  Kenworthy, A. K.; Simon, S. A.; McIntosh, T. J. Biophysical journal1 1995, 68, 
1903–1920. 
(226)  Photos, P. J.; Bacakova, L.; Discher, B.; Bates, F. S.; Discher, D. E. Journal of 
Controlled Release 2003, 90, 323–334. 
(227)  Mather, B. D.; Viswanathan, K.; Miller, K. M.; Long, T. E. Prog Polym Sci 2006, 
31, 487–531. 
(228)  Binder, W. H.; Sachsenhofer, R. Macromolecular Rapid Communications 2007, 
28, 15–54. 
(229)  Hoyle, C. E.; Bowman, C. N. Angewandte Chemie International Edition 2010, 49, 
1540–1573. 
(230)  Golas, P. L.; Matyjaszewski, K. Chemical Society Reviews 2010, 39, 1338–1354. 
(231)  Hoyle, C. E.; Lowe, A. B.; Bowman, C. N. Chemical Society Reviews 2010, 39, 
1355–1387. 
(232)  Discher, B. M.; Bermudez, H.; Hammer, D. A.; Discher, D. E.; Won, Y.-Y.; Bates, 
F. S. The Journal of Physical Chemistry B 2002, 106, 2848–2854. 
(233)  Katz, J. S.; Levine, D. H.; Davis, K. P.; Bates, F. S.; Hammer, D. A.; Burdick, J. 
A. Langmuir 2009, 25, 4429–4434. 
(234)  Discher, D. E.; Ahmed, F. Annual Review of Biomedical Engineering 2006, 8, 
323–341. 
(235)  Dorr, R. T. The Annals of Pharmacotherapy 1994, 28 , 11–14. 
(236)  Park, J. W. Breast Cancer Research 2002, 4, 95–99. 
(237)  Immordino, M. L.; Brusa, P.; Arpicco, S.; Stella, B.; Dosio, F.; Cattel, L. Journal 
of Controlled Release 2003, 91, 417–429. 
(238)  Hillmyer, M. A.; Bates, F. S. Macromolecules 1996, 29, 6994–7002. 
   196 
 
(239)  Meng, F.; Hiemstra, C.; Engbers, G. H. M.; Feijen, J. Macromolecules 2003, 36, 
3004–3006. 
(240)  Ahmed, F.; Discher, D. E. Journal of Controlled Release 2004, 96, 37–53. 
(241)  Ghoroghchian, P. P.; Li, G.; Levine, D. H.; Davis, K. P.; Bates, F. S.; Hammer, D. 
A.; Therien, M. J. Macromolecules 2006, 39, 1673–1675. 
(242)  Sinha, V. R.; Bansal, K.; Kaushik, R.; Kumria, R.; Trehan, A. International 
Journal of Pharmaceutics 2004, 278, 1–23. 
(243)  Geng, Y.; Discher, D. E. Journal of the American Chemical Society 2005, 127, 
12780–12781. 
(244)  Ahmed, F.; Pakunlu, R. I.; Srinivas, G.; Brannan, A.; Bates, F.; Klein, M. L.; 
Minko, T.; Discher, D. E. Molecular Pharmaceutics 2006, 3, 340–350. 
(245)  Moghimi, S. M.; Hunter, A. C.; Murray, J. C.; Szewczyk, A. Science 2004, 303 , 
626–628. 
(246)  Savić, R.; Luo, L.; Eisenberg, A.; Maysinger, D. Science 2003, 300 , 615–618. 
(247)  Vangeyte, P.; Gautier, S.; Jerome, R. Colloids and Surfaces A: Physicochemical 
and Engineering Aspects1 2004, 242, 203–211. 
(248)  Aliabadi, H. M.; Elhasi, S.; Mahmud, A.; Gulamhusein, R.; Mahdipoor, P.; 
Lavasanifar, A. International Journal of Pharmaceutics 2007, 329, 158–165. 
(249)  Vangeyte, P.; Leyh, B.; Heinrich, M.; Grandjean, J.; Bourgaux, C.; Jerome, R. 
Langmuir 2004, 20, 8442–8451. 
(250)  Lin, J. J.; Ghoroghchian, P. P.; Zhang, Y.; Hammer, D. A. Langmuir 2006, 22, 
3975–3979. 
(251)  Trollsås, M.; Kelly, M. A.; Claesson, H.; Siemens, R.; Hedrick, J. L. 
Macromolecules 1999, 32, 4917–4924. 
(252)  Vangeyte, P.; Jérôme, R. Journal of Polymer Science Part A: Polymer Chemistry 
2004, 42, 1132–1142. 
(253)  Ghoroghchian, P. P.; Frail, P. R.; Li, G.; Zupancich, J. A.; Bates, F. S.; Hammer, 
D. A.; Therien, M. J. Chem. Mater. 2007, 2007, 1309–1318. 
   197 
 
(254)  Ghoroghchian, P. P.; Frail, P. R.; Susumu, K.; Blessington, D.; Brannan, A. K.; 
Bates, F. S.; Chance, B.; Hammer, D. A.; Therien, M. J. Proceedings of the 
National Academy of Sciences 2005, 102, 2922–2927. 
(255)  Zupancich, J. A.; Bates, F. S.; Hillmyer, M. A. Biomacromolecules 2009, 10, 
1554–1563. 
(256)  Kolb, H. C.; Finn, M. G.; Sharpless, K. B. Angewandte Chemie International 
Edition 2001, 40, 2004–2021. 
(257)  Finn, M. G.; Fokin, V. V Chemical Society Reviews 2010, 39, 1231–1232. 
(258)  Bouzide, A.; Sauvé, G. Organic Letters 2002, 4, 2329–2332. 
(259)  Bae, J. W.; Lee, E.; Park, K. M.; Park, K. D. Macromolecules 2009, 42, 3437–
3442. 
(260)  Y., D.; H., B.-P.; S., S.; B., F. G.; B., M. J.; M., T.; Dori, Y.; Bianco–Peled, H.; 
Satija, S. K.; Fields, G. B.; McCarthy, J. B.; Tirrell, M. Journal of Biomedical 
Materials Research 2000, 50, 75–81. 
(261)  Mardilovich, A.; Kokkoli, E. Biomacromolecules 2004, 5, 950–957. 
(262)  Haxton, K. J.; Burt, H. M. Journal of Pharmaceutical Sciences 2009, 98, 2299–
2316. 
(263)  Sanchez-Cano, C.; Hannon, M. J. Dalton Transactions 2009, 48, 10702–10711. 
(264)  Peleg-Shulman, T.; Gibson, D.; Cohen, R.; Abra, R.; Barenholz, Y. Biochimica et 
Biophysica Acta - Biomembranes 2001, 1510, 278–291. 
(265)  Working, P. K.; Newman, M. S.; Sullivan, T.; Brunner, M.; Podell, M.; Sahenk, 
Z.; Turner, N. Toxicological Sciences 1998, 46, 155–165. 
(266)  Zamboni, W. C.; Gervais, A. C.; Egorin, M. J.; Schellens, J. H. M.; Zuhowski, E. 
G.; Pluim, D.; Joseph, E.; Hamburger, D. R.; Working, P. K.; Colbern, G. Cancer 
Chemotherapy and Pharmacology 2004, 53, 329–336. 
(267)  Newman, M. S.; Colbern, G. T.; Working, P. K.; Engbers, C.; Amantea, M. A. 
Cancer Chemotherapy and Pharmacology 1999, 43, 1–7. 
(268)  Bandak, S.; Goren, D.; Horowitz, A.; Tzemach, D.; Gabizon, A. Anti-Cancer 
Drugs 1999, 10, 911–920. 
   198 
 
(269)  Rosenthal, D. I.; Yom, S. S.; Liu, L.; Machtay, M.; Algazy, K.; Weber, R. S.; 
Weinstein, G. S.; Chalian, A. A.; Miller, L. K.; Rockwell, K.; Tonda, M.; 
Schnipper, E.; Hershock, D. Investigational New Drugs 2002, 20, 343–349. 
(270)  White, S. C.; Lorigan, P.; Margison, G. P.; Margison, J. M.; Martin, F.; Thatcher, 
N.; Anderson, H.; Ranson, M. British Journal of Cancer 2006, 95, 822–828. 
(271)  Harrington, K. J.; Lewanski, C. R.; Northcote, A. D.; Whittaker, J.; Wellbank, H.; 
Vile, R. G.; Peters, A. M.; Stewart, J. S. W. Annals of Oncology 2001, 12, 493–
496. 
(272)  Seetharamu, N.; Kim, E.; Hochster, H.; Martin, F.; Muggia, F. Anticancer 
research 2010, 30, 541. 
(273)  Kuwada, S. K.; Li, X. Molecular Biology of the Cell 2000, 11, 2485–2496. 
(274)  Honoré, S.; Pichard, V.; Penel, C.; Rigot, V.; Prévôt, C.; Marvaldi, J.; Briand, C.; 
Rognoni, J.-B. Histochemistry and Cell Biology 2000, 114, 323–335. 
(275)  Croyle, M. A.; Walter, E.; Janich, S.; Roessler, B. J.; Amidon, G. L. Human Gene 
Therapy 1998, 9, 561–572. 
(276)  Kozlova, N. I.; Morozevich, G. E.; Chubukina, A. N.; Berman, A. E. Oncogene 
2001, 20, 4710–4717. 
(277)  Hidalgo, I. J.; Raub, T. J.; Borchardt, R. T. Gastroenterology 1989, 96, 736–49. 
(278)  Press, B.; Di Grandi, D. Current Drug Metabolism 2008, 9, 893–900. 
(279)  Birtwistle, M. R.; Kholodenko, B. N. Molecular Oncology 2009, 3, 308–320. 
(280)  Petersen, M. A.; Yin, L.; Kokkoli, E.; Hillmyer, M. A. Polymer Chemistry 2010, 1, 
1281–1290. 
(281)  Golla, E. D. Talanta 1973, 20, 199–210. 
(282)  Onaca, O.; Nallani, M.; Ihle, S.; Schenk, A.; Schwaneberg, U. Biotechnology 
Journal 2006, 1, 795–805. 
(283)  Avgoustakis, K.; Beletsi, A.; Panagi, Z.; Klepetsanis, P.; Karydas, A. G.; 
Ithakissios, D. S. Journal of Controlled Release 2002, 79, 123–135. 
(284)  Rexeisen, E. L.; Fan, W.; Pangburn, T. O.; Taribagil, R. R.; Bates, F. S.; Lodge, T. 
P.; Tsapatsis, M.; Kokkoli, E. Langmuir 2009, 26, 1953–1959. 
   199 
 
(285)  Greenspan, P.; Mayer, E. P.; Fowler, S. D. The Journal of Cell Biology 1985, 100 , 
965–973. 
(286)  Fowler, S. D.; Greenspan, P. Journal of Histochemistry & Cytochemistry 1985, 33 
, 833–836. 
(287)  Manders, E. M. M.; Verbeek, F. J.; Aten, J. A. Journal of Microscopy 1993, 169, 
375–382. 
(288)  Costes, S. V; Daelemans, D.; Cho, E. H.; Dobbin, Z.; Pavlakis, G.; Lockett, S. 
Biophysical journal 2004, 86, 3993–4003. 
(289)  Nair, L. S.; Laurencin, C. T. Progress in Polymer Science 2007, 32, 762–798. 
(290)  Sun, H.; Mei, L.; Song, C.; Cui, X.; Wang, P. Biomaterials 2006, 27, 1735–1740. 
(291)  Juliano, R. L.; Ming, X.; Nakagawa, O. Bioconjugate Chemistry 2011, 23, 147–
157. 
(292)  Mayor, S.; Pagano, R. E. Nature Reviews Molecular and Cellular Biology 2007, 8, 
603–612. 
(293)  Sottile, J.; Chandler, J. Molecular Biology of the Cell 2005, 16, 757–768. 
(294)  Shi, F.; Sottile, J. Journal of Cell Science 2008, 121, 2360–2371. 
(295)  Chunhua Shen  Chengfei Lu,, S. G. Polymers for Advanced Technologies 2008, 
19, 66–72. 
(296)  Jung, J. H.; Ree, M.; Kim, H. Catalysis Today 2006, 115, 283–287. 
(297)  Gan, Z.; Jim, T. F.; Li, M.; Yuer, Z.; Wang, S.; Wu, C. Macromolecules 1999, 32, 
590–594. 
(298)  Carstens, M. G.; Van Nostrum, C. F.; Verrijk, R.; De Leede, L. G. J.; Crommelin, 
D. J. A.; Hennink, W. E. Journal of Pharmaceutical Sciences 2008, 97, 506–518. 
(299)  Lam, C. X. F.; Savalani, M. M.; Teoh, S.-H.; Hutmacher, D. W. Biomedical 
Materials 2008, 3, 34108. 
(300)  Geisow, M. J.; D’Arcy Hart, P.; Young, M. R. The Journal of Cell Biology 1981, 
89, 645–652. 
   200 
 
(301)  Brown, M. S.; Dana, S. E.; Goldstein, J. L. Proceedings of the National Academy 
of Sciences U.S.A. 1975, 72, 2925–2929. 
(302)  Goldstein, J. L.; Brunschede, G. Y.; Brown, M. S. Journal of Biological Chemistry 
1975, 250, 7854–7862. 
(303)  Wagner, E.; Zatloukal, K.; Cotten, M.; Kirlappos, H.; Mechtler, K.; Curiel, D. T.; 
Birnstiel, M. L. Proceedings of the National Academy of Sciences U.S.A. 1992, 89, 
6099–6103. 
(304)  Bareford, L. M.; Swaan, P. W. Advanced Drug Delivery Reviews 2007, 59, 748–
758. 
(305)  Hostetter, A. A.; Osborn, M. F.; DeRose, V. J. ACS Chemical Biology 2012, 7, 
218–225. 
(306)  Reedijk, J.; Lohman, P. Pharmacy World & Science 1985, 7, 173–180. 
(307)  Larsen, A. K.; Escargueil, A. E.; Skladanowski, A. Pharmacology & Therapeutics 
2000, 85, 217–229. 
(308)  Akaboshi, M.; Kawai, K.; Maki, H.; Akuta, K.; Ujeno, Y.; Miyahara, T. Cancer 
Science 1992, 83, 522–526. 
(309)  Zhang, J.; Whan, R.; Hambley, T.; Begley, T. P. In Wiley Encyclopedia of 
Chemical Biology; John Wiley & Sons, Inc., 2007; pp. 1–10. 
(310)  Klein, A. V; Hambley, T. W. Chemical Reviews 2009, 109, 4911–4920. 
(311)  Huck, W. T. S. Materials Today 2008, 11, 24–32. 
(312)  Liu, F.; Urban, M. W. Progress in Polymer Science 2010, 35, 3–23. 
(313)  Hu, J.; Liu, S. Macromolecules 2010, 43, 8315–8330. 
(314)  Hoffman, A. S. Advanced Drug Delivery Reviews 2013, 65, 10–16. 
(315)  Meng, H.; Jinlian Hu Journal of Intelligent Material Systems and Structures 2010, 
21 , 859–885. 
(316)  Roy, D.; Cambre, J. N.; Sumerlin, B. S. Progress in Polymer Science 2010, 35, 
278–301. 
   201 
 
(317)  Esser-Kahn, A. P.; Odom, S. A.; Sottos, N. R.; White, S. R.; Moore, J. S. 
Macromolecules 2011, 44, 5539–5553. 
(318)  Doane, T. L.; Burda, C. Chemical Society Reviews 2012, 41, 2885–2911. 
(319)  Faraji, A. H.; Wipf, P. Bioorganic & Medicinal Chemistry 2009, 17, 2950–2962. 
(320)  Geisow, M. J.; Evans, W. H. Experimental Cell Research 1984, 150, 36–46. 
(321)  Tannock, I. F.; Rotin, D. Cancer Research 1989, 49, 4373–4384. 
(322)  Schmaljohann, D. Advanced Drug Delivery Reviews 2006, 58, 1655–1670. 
(323)  Dai, S.; Ravi, P.; Tam, K. C. Soft Matter 2008, 4, 435–449. 
(324)  Binauld, S.; Stenzel, M. H. Chemical Communications 2013, 49, 2082–2102. 
(325)  Panyam, J.; Labhasetwar, V. Advanced Drug Delivery Reviews 2012, 64, Supple, 
61–71. 
(326)  Mora-Huertas, C. E.; Fessi, H.; Elaissari, A. International Journal of 
Pharmaceutics 2010, 385, 113–142. 
(327)  Ma, X.; Zhou, Z.; Jin, E.; Sun, Q.; Zhang, B.; Tang, J.; Shen, Y. Macromolecules 
2012, 46, 37–42. 
(328)  Petersen, M. A.; Hillmyer, M. A.; Kokkoli, E. Bioconjugate Chemistry 2013. 
(329)  Falco, E.; Patel, M.; Fisher, J. Pharmaceutical Research 2008, 25, 2348–2356. 
(330)  Fife, T. H.; Jao, L. K. The Journal of Organic Chemistry 1965, 30, 1492–1495. 
(331)  Pchelintsev, V. V.; Sokolov, A. Y. Polymer Degradation and Stability 1988, 21, 
285–310. 
(332)  Cheng, J.; Ji, R.; Gao, S.-J.; Du, F.-S.; Li, Z.-C. Biomacromolecules 2011, 13, 
173–179. 
(333)  Morinaga, H.; Morikawa, H.; Wang, Y.; Sudo, A.; Endo, T. Macromolecules 2009, 
42, 2229–2235. 
(334)  Paramonov, S. E.; Bachelder, E. M.; Beaudette, T. T.; Standley, S. M.; Lee, C. C.; 
Dashe, J.; Frechet, J. M. J. Bioconjugate Chemistry 2008, 19, 911–919. 
   202 
 
(335)  Heffernan, M. J.; Murthy, N. Bioconjugate Chemistry 2005, 16, 1340–1342. 
(336)  Gillies, E. R.; Frechet, J. M. J. Chemical Communications 2003, 0, 1640–1641. 
(337)  Khaja, S. D.; Lee, S.; Murthy, N. Biomacromolecules2 2007, 8, 1391–1395. 
(338)  Pemba, A. G.; Flores, J. A.; Miller, S. A. Green Chemistry 2013, 15, 325–329. 
(339)  Penczek, S. Journal of Polymer Science Part A: Polymer Chemistry 2000, 38, 
1919–1933. 
(340)  Szymanski, R.; Kubisa, P.; Penczek, S. Macromolecules 1983, 16, 1000–1008. 
(341)  Odian, G. Principles of Polymerization; 4th ed.; John Wiley & Sons, Inc.: 
Hoboken, NJ, 2004. 
(342)  Heller, J.; Penhale, D. W. H.; Helwing, R. F. Journal of Polymer Science: Polymer 
Letters Edition 1980, 18, 293–297. 
(343)  Tomlinson, R.; Klee, M.; Garrett, S.; Heller, J.; Duncan, R.; Brocchini, S. 
Macromolecules 2002, 35, 473–480. 
(344)  Schacht, E.; Toncheva, V.; Vandertaelen, K.; Heller, J. Journal of Controlled 
Release 2006, 116, 219–225. 
(345)  Jain, R.; Standley, S. M.; Fréchet, J. M. J. Macromolecules 2007, 40, 452–457. 
(346)  Heller, J.; Barr, J.; Ng, S. Y.; Abdellauoi, K. S.; Gurny, R. Advanced Drug 
Delivery Reviews 2002, 54, 1015–1039. 
(347)  Murthy, N.; Thng, Y. X.; Schuck, S.; Xu, M. C.; Frechet, J. M. J. Journal of the 
American Chemical Society 2002, 124, 12398–12399. 
(348)  Zhang, L.; Bernard, J.; Davis, T. P.; Barner-Kowollik, C.; Stenzel, M. H. 
Macromolecular Rapid Communications 2008, 29, 123–129. 
(349)  Lee, S. J.; Min, K. H.; Lee, H. J.; Koo, A. N.; Rim, H. P.; Jeon, B. J.; Jeong, S. Y.; 
Heo, J. S.; Lee, S. C. Biomacromolecules 2011, 12, 1224–1233. 
(350)  Wolfe, P. S.; Wagener, K. B. Macromolecular Rapid Communications 1998, 19, 
305–308. 
(351)  Yamashita, M.; Nishida, H. Process for Preparation of 1,3-Dioxane-4-one 
Compounds by Cyclization 1997. 
   203 
 
(352)  Juge, S.; Genet, J.-P.; Mallart, S. Preparation of 1,3-dioxan-4-one Derivatives as 
Intermediates for Beta-Hydroxy-Alpha-Amino Acids 1989. 
(353)  Lowe, J. R.; Martello, M. T.; Tolman, W. B.; Hillmyer, M. A. Polymer Chemistry 
2011, 2, 702–708. 
(354)  Tsuruta, T.; Matsuura, K.; Inoue, S. Die Makromolekulare Chemie 1964, 75, 211–
214. 
(355)  Le Hellaye, M.; Fortin, N.; Guilloteau, J.; Soum, A.; Lecommandoux, S.; 
Guillaume, S. M. Biomacromolecules 2008, 9, 1924–1933. 
(356)  Zhang, D.; Hillmyer, M. A.; Tolman, W. B. Macromolecules 2004, 37, 8198–
8200. 
(357)  Kricheldorf, H. R. Polypeptides and 100 Years of Chemistry of α‐Amino Acid N‐
Carboxyanhydrides. Angewandte Chemie International Edition 2006, 45, 5752–
5784. 
(358)  Deming, T. J. Journal of Polymer Science Part A: Polymer Chemistry 2000, 38, 
3011–3018. 
(359)  Kricheldorf, H. R.; Berl, M.; Scharnagl, N. Macromolecules 1988, 21, 286–293. 
(360)  Barakat, I.; Dubois, P.; Jerome, R.; Teyssie, P. Macromolecules 1991, 24, 6542–
6545. 
(361)  Cao, A.; Kasuya, K.; Abe, H.; Doi, Y.; Inoue, Y. Polymer 1998, 39, 4801–4816. 
(362)  Nanba, T.; Ito, H.; Kobayashi, H.; Hayashi, T. No Title 1994. 
(363)  Andreeßen, B.; Steinbüchel, A. Applied and Environmental Microbiology 76 , 
4919–4925. 
(364)  Doi, Y. Macromolecular Symposia 1995, 98, 585–599. 
(365)  Gresham, T. L.; Jansen, J. E.; Shaver, F. W. Journal of the American Chemical 
Society 1948, 70, 998–999. 
(366)  Ouhadi, T.; Heuschen, J. M. Journal of Macromolecular Science: Part A - 
Chemistry 1975, 9, 1183–1193. 
(367)  Yamashita, M.; Takemoto, Y.; Ihara, E.; Yasuda, H. Macromolecules 1996, 29, 
1798–1806. 
   204 
 
(368)  Jedliński, Z.; Kurcok, P.; Kowalczuk, M. Polymer International 1995, 37, 187–
190. 
(369)  Miyake, A.; Stockmayer, W. H. Die Makromolekulare Chemie 1965, 88, 90–116. 
(370)  Greer, S. C. Annual Review of Physical Chemistry 2002, 53, 173–200. 
(371)  Das, S. S.; Andrews, A. P.; Greer Journal of Chemical Physics1 1995, 102, 2951. 
(372)  Zhuang, J.; Das, S. S.; Nowakowski, M. D.; Greer, S. C. Physica A 1997, 244, 
522–535. 
(373)  Poland, D. Journal of Chemical Physics 1999, 111, 8214. 
(374)  Save, M.; Schappacher, M.; Soum, A. Macromolecular Chemistry and Physics 
2002, 203, 889–899. 
(375)  Martello, M. T.; Burns, A.; Hillmyer, M. ACS Macro Letters 2011, 1, 131–135. 
(376)  Wanamaker, C. L.; Tolman, W. B.; Hillmyer, M. A. Biomacromolecules 2009, 10, 
443–448. 
(377)  Zhang, D.; Hillmyer, M. A.; Tolman, W. B. Biomacromolecules 2005, 6, 2091–
2095. 
(378)  Lowe, J. R.; Tolman, W. B.; Hillmyer, M. A. Biomacromolecules 2009, 10, 2003–
2008.  
 
